id	sid	tid	token	lemma	pos
admet-437	1	1	preclinical	preclinical	ADJ
admet-437	1	2	assessment	assessment	NOUN
admet-437	1	3	of	of	ADP
admet-437	1	4	ulixertinib	ulixertinib	NOUN
admet-437	1	5	,	,	PUNCT
admet-437	1	6	a	a	DET
admet-437	1	7	novel	novel	NOUN
admet-437	1	8	erk1/2	erk1/2	PROPN
admet-437	1	9	inhibitor	inhibitor	NOUN
admet-437	1	10	doi	doi	NOUN
admet-437	1	11	:	:	PUNCT
admet-437	1	12	10.5599	10.5599	NUM
admet-437	1	13	/	/	SYM
admet-437	1	14	admet.5.4.437	admet.5.4.437	NUM
admet-437	1	15	212	212	NUM
admet-437	1	16	admet	admet	X
admet-437	1	17	&	&	CCONJ
admet-437	1	18	dmpk	dmpk	PROPN
admet-437	1	19	5(4	5(4	NOUN
admet-437	1	20	)	)	PUNCT
admet-437	1	21	(	(	PUNCT
admet-437	1	22	2017	2017	NUM
admet-437	1	23	)	)	PUNCT
admet-437	1	24	212	212	NUM
admet-437	1	25	-	-	SYM
admet-437	1	26	223	223	NUM
admet-437	1	27	;	;	PUNCT
admet-437	1	28	doi	doi	NOUN
admet-437	1	29	:	:	PUNCT
admet-437	1	30	http://dx.doi.org/10.5599/admet.5.4.437	http://dx.doi.org/10.5599/admet.5.4.437	NUM
admet-437	1	31	open	open	ADJ
admet-437	1	32	access	access	NOUN
admet-437	1	33	:	:	PUNCT
admet-437	1	34	issn	issn	PROPN
admet-437	1	35	:	:	PUNCT
admet-437	1	36	1848	1848	NUM
admet-437	1	37	-	-	SYM
admet-437	1	38	7718	7718	NUM
admet-437	1	39	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-437	1	40	original	original	ADJ
admet-437	1	41	scientific	scientific	ADJ
admet-437	1	42	paper	paper	NOUN
admet-437	1	43	preclinical	preclinical	ADJ
admet-437	1	44	assessment	assessment	NOUN
admet-437	1	45	of	of	ADP
admet-437	1	46	ulixertinib	ulixertinib	NOUN
admet-437	1	47	,	,	PUNCT
admet-437	1	48	a	a	DET
admet-437	1	49	novel	novel	NOUN
admet-437	1	50	erk1/2	erk1/2	NUM
admet-437	1	51	inhibitor	inhibitor	NOUN
admet-437	1	52	vinod	vinod	PROPN
admet-437	1	53	a	a	DET
admet-437	1	54	balakrishna1	balakrishna1	PROPN
admet-437	1	55	,	,	PUNCT
admet-437	1	56	anitha	anitha	NOUN
admet-437	1	57	police1	police1	PROPN
admet-437	1	58	,	,	PUNCT
admet-437	1	59	rakesh	rakesh	PROPN
admet-437	1	60	a	a	DET
admet-437	1	61	hiremath2	hiremath2	PROPN
admet-437	1	62	,	,	PUNCT
admet-437	1	63	anusha	anusha	PROPN
admet-437	1	64	raj2	raj2	PROPN
admet-437	1	65	,	,	PUNCT
admet-437	1	66	suresh	suresh	PROPN
admet-437	1	67	p	p	PROPN
admet-437	1	68	sulochana1	sulochana1	PROPN
admet-437	1	69	,	,	PUNCT
admet-437	1	70	devaraj	devaraj	VERB
admet-437	1	71	v	v	ADP
admet-437	1	72	chandrasekhar1	chandrasekhar1	PROPN
admet-437	1	73	,	,	PUNCT
admet-437	1	74	mohd	mohd	PROPN
admet-437	1	75	zainuddin1	zainuddin1	PROPN
admet-437	1	76	,	,	PUNCT
admet-437	1	77	ravi	ravi	NOUN
admet-437	1	78	kanth	kanth	ADJ
admet-437	1	79	bhamidipati1	bhamidipati1	NOUN
admet-437	1	80	and	and	CCONJ
admet-437	1	81	ramesh	ramesh	PROPN
admet-437	1	82	mullangi1	mullangi1	PROPN
admet-437	1	83	*	*	PROPN
admet-437	1	84	1	1	NUM
admet-437	1	85	drug	drug	NOUN
admet-437	1	86	metabolism	metabolism	NOUN
admet-437	1	87	and	and	CCONJ
admet-437	1	88	pharmacokinetics	pharmacokinetic	NOUN
admet-437	1	89	,	,	PUNCT
admet-437	1	90	jubilant	jubilant	ADJ
admet-437	1	91	biosys	biosy	NOUN
admet-437	1	92	,	,	PUNCT
admet-437	1	93	industrial	industrial	ADJ
admet-437	1	94	suburb	suburb	NOUN
admet-437	1	95	,	,	PUNCT
admet-437	1	96	yeshwanthpur	yeshwanthpur	PROPN
admet-437	1	97	,	,	PUNCT
admet-437	1	98	bangalore-560	bangalore-560	PROPN
admet-437	1	99	022	022	NUM
admet-437	1	100	,	,	PUNCT
admet-437	1	101	india	india	PROPN
admet-437	1	102	2	2	NUM
admet-437	1	103	j.s.s	j.s.s	PROPN
admet-437	1	104	college	college	NOUN
admet-437	1	105	of	of	ADP
admet-437	1	106	pharmacy	pharmacy	NOUN
admet-437	1	107	,	,	PUNCT
admet-437	1	108	mysore	mysore	PROPN
admet-437	1	109	,	,	PUNCT
admet-437	1	110	india	india	PROPN
admet-437	1	111	*	*	PUNCT
admet-437	1	112	corresponding	correspond	VERB
admet-437	1	113	author	author	NOUN
admet-437	1	114	:	:	PUNCT
admet-437	1	115	e	e	NOUN
admet-437	1	116	-	-	NOUN
admet-437	1	117	mail	mail	NOUN
admet-437	1	118	:	:	PUNCT
admet-437	1	119	mullangi.ramesh@jubilantinnovation.com	mullangi.ramesh@jubilantinnovation.com	X
admet-437	1	120	;	;	PUNCT
admet-437	2	1	tel	tel	PROPN
admet-437	2	2	.	.	PROPN
admet-437	2	3	:	:	PUNCT
admet-437	2	4	9611333488	9611333488	NUM
admet-437	2	5	received	receive	VERB
admet-437	2	6	:	:	PUNCT
admet-437	2	7	september	september	PROPN
admet-437	2	8	08	08	NUM
admet-437	2	9	,	,	PUNCT
admet-437	2	10	2017	2017	NUM
admet-437	2	11	;	;	PUNCT
admet-437	2	12	revised	revise	VERB
admet-437	2	13	:	:	PUNCT
admet-437	2	14	october	october	PROPN
admet-437	2	15	03	03	NUM
admet-437	2	16	,	,	PUNCT
admet-437	2	17	2017	2017	NUM
admet-437	2	18	;	;	PUNCT
admet-437	2	19	published	publish	VERB
admet-437	2	20	:	:	PUNCT
admet-437	2	21	december	december	PROPN
admet-437	2	22	24	24	NUM
admet-437	2	23	,	,	PUNCT
admet-437	2	24	2017	2017	NUM
admet-437	2	25	abstract	abstract	ADJ
admet-437	2	26	ulixertinib	ulixertinib	NOUN
admet-437	2	27	(	(	PUNCT
admet-437	2	28	bvd-523	bvd-523	NOUN
admet-437	2	29	)	)	PUNCT
admet-437	2	30	is	be	AUX
admet-437	2	31	a	a	DET
admet-437	2	32	novel	novel	ADJ
admet-437	2	33	and	and	CCONJ
admet-437	2	34	selective	selective	ADJ
admet-437	2	35	reversible	reversible	ADJ
admet-437	2	36	inhibitor	inhibitor	NOUN
admet-437	2	37	of	of	ADP
admet-437	2	38	erk1	erk1	PROPN
admet-437	2	39	/	/	SYM
admet-437	2	40	erk2	erk2	PROPN
admet-437	2	41	.	.	PUNCT
admet-437	3	1	in	in	ADP
admet-437	3	2	xenograft	xenograft	NOUN
admet-437	3	3	studies	study	NOUN
admet-437	3	4	it	it	PRON
admet-437	3	5	inhibited	inhibit	VERB
admet-437	3	6	tumor	tumor	NOUN
admet-437	3	7	growth	growth	NOUN
admet-437	3	8	in	in	ADP
admet-437	3	9	braf	braf	NOUN
admet-437	3	10	-	-	PUNCT
admet-437	3	11	mutant	mutant	ADJ
admet-437	3	12	melanoma	melanoma	NOUN
admet-437	3	13	and	and	CCONJ
admet-437	3	14	colorectal	colorectal	ADJ
admet-437	3	15	xenografts	xenograft	NOUN
admet-437	3	16	as	as	ADV
admet-437	3	17	well	well	ADV
admet-437	3	18	as	as	ADP
admet-437	3	19	kras	kra	NOUN
admet-437	3	20	-	-	PUNCT
admet-437	3	21	mutant	mutant	ADJ
admet-437	3	22	colorectal	colorectal	ADJ
admet-437	3	23	and	and	CCONJ
admet-437	3	24	pancreatic	pancreatic	ADJ
admet-437	3	25	models	model	NOUN
admet-437	3	26	.	.	PUNCT
admet-437	4	1	ulixertinib	ulixertinib	PROPN
admet-437	4	2	is	be	AUX
admet-437	4	3	currently	currently	ADV
admet-437	4	4	in	in	ADP
admet-437	4	5	phase	phase	NOUN
admet-437	4	6	i	i	PRON
admet-437	4	7	clinical	clinical	ADJ
admet-437	4	8	development	development	NOUN
admet-437	4	9	for	for	ADP
admet-437	4	10	the	the	DET
admet-437	4	11	treatment	treatment	NOUN
admet-437	4	12	of	of	ADP
admet-437	4	13	advance	advance	NOUN
admet-437	4	14	solid	solid	ADJ
admet-437	4	15	tumors	tumor	NOUN
admet-437	4	16	.	.	PUNCT
admet-437	5	1	the	the	DET
admet-437	5	2	objective	objective	NOUN
admet-437	5	3	of	of	ADP
admet-437	5	4	the	the	DET
admet-437	5	5	study	study	NOUN
admet-437	5	6	is	be	AUX
admet-437	5	7	to	to	PART
admet-437	5	8	assess	assess	VERB
admet-437	5	9	the	the	DET
admet-437	5	10	metabolic	metabolic	NOUN
admet-437	5	11	stability	stability	NOUN
admet-437	5	12	(	(	PUNCT
admet-437	5	13	in	in	ADP
admet-437	5	14	various	various	ADJ
admet-437	5	15	preclinical	preclinical	ADJ
admet-437	5	16	and	and	CCONJ
admet-437	5	17	human	human	ADJ
admet-437	5	18	liver	liver	NOUN
admet-437	5	19	microsomes	microsome	NOUN
admet-437	5	20	/	/	SYM
admet-437	5	21	hepatocytes	hepatocyte	NOUN
admet-437	5	22	)	)	PUNCT
admet-437	5	23	,	,	PUNCT
admet-437	5	24	permeability	permeability	NOUN
admet-437	5	25	,	,	PUNCT
admet-437	5	26	protein	protein	NOUN
admet-437	5	27	binding	bind	VERB
admet-437	5	28	,	,	PUNCT
admet-437	5	29	cyp	cyp	ADJ
admet-437	5	30	inhibition	inhibition	NOUN
admet-437	5	31	,	,	PUNCT
admet-437	5	32	cyp	cyp	ADJ
admet-437	5	33	induction	induction	NOUN
admet-437	5	34	and	and	CCONJ
admet-437	5	35	cyp	cyp	ADJ
admet-437	5	36	phenotyping	phenotyping	NOUN
admet-437	5	37	of	of	ADP
admet-437	5	38	ulixertinib	ulixertinib	NOUN
admet-437	5	39	.	.	PUNCT
admet-437	6	1	we	we	PRON
admet-437	6	2	have	have	AUX
admet-437	6	3	also	also	ADV
admet-437	6	4	studied	study	VERB
admet-437	6	5	the	the	DET
admet-437	6	6	oral	oral	ADJ
admet-437	6	7	and	and	CCONJ
admet-437	6	8	intravenous	intravenous	ADJ
admet-437	6	9	pharmacokinetics	pharmacokinetic	NOUN
admet-437	6	10	of	of	ADP
admet-437	6	11	ulixertinib	ulixertinib	NOUN
admet-437	6	12	in	in	ADP
admet-437	6	13	mice	mouse	NOUN
admet-437	6	14	,	,	PUNCT
admet-437	6	15	rats	rat	NOUN
admet-437	6	16	and	and	CCONJ
admet-437	6	17	dogs	dog	NOUN
admet-437	6	18	.	.	PUNCT
admet-437	7	1	ulixertinib	ulixertinib	PROPN
admet-437	7	2	was	be	AUX
admet-437	7	3	found	find	VERB
admet-437	7	4	to	to	PART
admet-437	7	5	be	be	AUX
admet-437	7	6	moderately	moderately	ADV
admet-437	7	7	to	to	PART
admet-437	7	8	highly	highly	ADV
admet-437	7	9	stable	stable	ADJ
admet-437	7	10	in	in	ADP
admet-437	7	11	various	various	ADJ
admet-437	7	12	liver	liver	NOUN
admet-437	7	13	microsomes	microsome	NOUN
admet-437	7	14	/	/	SYM
admet-437	7	15	hepatocytes	hepatocyte	NOUN
admet-437	7	16	tested	test	VERB
admet-437	7	17	.	.	PUNCT
admet-437	8	1	it	it	PRON
admet-437	8	2	is	be	AUX
admet-437	8	3	a	a	DET
admet-437	8	4	medium	medium	ADJ
admet-437	8	5	permeable	permeable	ADJ
admet-437	8	6	(	(	PUNCT
admet-437	8	7	2.67	2.67	NUM
admet-437	8	8	x	x	SYM
admet-437	8	9	10	10	NUM
admet-437	8	10	-6	-6	NOUN
admet-437	8	11	cm	cm	NOUN
admet-437	8	12	/sec	/sec	ADV
admet-437	8	13	)	)	PUNCT
admet-437	8	14	drug	drug	NOUN
admet-437	8	15	and	and	CCONJ
admet-437	8	16	a	a	DET
admet-437	8	17	substrate	substrate	NOUN
admet-437	8	18	for	for	ADP
admet-437	8	19	efflux	efflux	NOUN
admet-437	8	20	(	(	PUNCT
admet-437	8	21	efflux	efflux	NOUN
admet-437	8	22	ratio	ratio	NOUN
admet-437	8	23	:	:	PUNCT
admet-437	8	24	3.02	3.02	NUM
admet-437	8	25	)	)	PUNCT
admet-437	8	26	in	in	ADP
admet-437	8	27	caco-2	caco-2	NUM
admet-437	8	28	model	model	NOUN
admet-437	8	29	.	.	PUNCT
admet-437	9	1	ulixertinib	ulixertinib	PROPN
admet-437	9	2	was	be	AUX
admet-437	9	3	highly	highly	ADV
admet-437	9	4	bound	bind	VERB
admet-437	9	5	to	to	ADP
admet-437	9	6	plasma	plasma	NOUN
admet-437	9	7	proteins	protein	NOUN
admet-437	9	8	.	.	PUNCT
admet-437	10	1	cyps	cyps	PROPN
admet-437	10	2	involved	involve	VERB
admet-437	10	3	in	in	ADP
admet-437	10	4	its	its	PRON
admet-437	10	5	limited	limited	ADJ
admet-437	10	6	metabolism	metabolism	NOUN
admet-437	11	1	and	and	CCONJ
admet-437	11	2	it	it	PRON
admet-437	11	3	is	be	AUX
admet-437	11	4	cyp	cyp	ADJ
admet-437	11	5	inhibition	inhibition	NOUN
admet-437	11	6	ic50	ic50	PROPN
admet-437	11	7	ranged	range	VERB
admet-437	11	8	between	between	ADP
admet-437	11	9	10	10	NUM
admet-437	11	10	-	-	SYM
admet-437	11	11	20	20	NUM
admet-437	11	12	µm	µm	NOUN
admet-437	11	13	.	.	PUNCT
admet-437	12	1	post	post	PROPN
admet-437	12	2	oral	oral	PROPN
admet-437	12	3	administration	administration	PROPN
admet-437	12	4	ulixertinib	ulixertinib	PROPN
admet-437	12	5	exhibited	exhibit	VERB
admet-437	12	6	early	early	ADJ
admet-437	12	7	tmax	tmax	ADP
admet-437	12	8	(	(	PUNCT
admet-437	12	9	0.50	0.50	NUM
admet-437	12	10	-	-	SYM
admet-437	12	11	0.75	0.75	NUM
admet-437	12	12	h	h	NOUN
admet-437	12	13	)	)	PUNCT
admet-437	12	14	in	in	ADP
admet-437	12	15	mice	mouse	NOUN
admet-437	12	16	and	and	CCONJ
admet-437	12	17	rats	rat	NOUN
admet-437	12	18	indicating	indicate	VERB
admet-437	12	19	absorption	absorption	NOUN
admet-437	12	20	was	be	AUX
admet-437	12	21	rapid	rapid	ADJ
admet-437	12	22	,	,	PUNCT
admet-437	12	23	however	however	ADV
admet-437	12	24	in	in	ADP
admet-437	12	25	dogs	dog	NOUN
admet-437	12	26	tmax	tmax	VERB
admet-437	12	27	attained	attain	VERB
admet-437	12	28	at	at	ADP
admet-437	12	29	2	2	NUM
admet-437	12	30	h.	h.	NOUN
admet-437	12	31	the	the	DET
admet-437	12	32	half	half	ADJ
admet-437	12	33	-	-	PUNCT
admet-437	12	34	life	life	NOUN
admet-437	12	35	(	(	PUNCT
admet-437	12	36	t½	t½	NOUN
admet-437	12	37	)	)	PUNCT
admet-437	12	38	of	of	ADP
admet-437	12	39	ulixertinib	ulixertinib	NOUN
admet-437	12	40	by	by	ADP
admet-437	12	41	intravenous	intravenous	ADJ
admet-437	12	42	and	and	CCONJ
admet-437	12	43	oral	oral	ADJ
admet-437	12	44	routes	route	NOUN
admet-437	12	45	ranged	range	VERB
admet-437	12	46	between	between	ADP
admet-437	12	47	1.0	1.0	NUM
admet-437	12	48	-	-	SYM
admet-437	12	49	2.5	2.5	NUM
admet-437	12	50	h	h	NOUN
admet-437	12	51	across	across	ADP
admet-437	12	52	the	the	DET
admet-437	12	53	species	specie	NOUN
admet-437	12	54	.	.	PUNCT
admet-437	13	1	clearance	clearance	NOUN
admet-437	13	2	and	and	CCONJ
admet-437	13	3	volume	volume	NOUN
admet-437	13	4	of	of	ADP
admet-437	13	5	distribution	distribution	NOUN
admet-437	13	6	by	by	ADP
admet-437	13	7	intravenous	intravenous	ADJ
admet-437	13	8	route	route	NOUN
admet-437	13	9	for	for	ADP
admet-437	13	10	ulixertinib	ulixertinib	NOUN
admet-437	13	11	were	be	AUX
admet-437	13	12	found	find	VERB
admet-437	13	13	to	to	PART
admet-437	13	14	be	be	AUX
admet-437	13	15	6.24	6.24	NUM
admet-437	13	16	ml	ml	NOUN
admet-437	13	17	/	/	SYM
admet-437	13	18	min	min	NOUN
admet-437	13	19	/	/	SYM
admet-437	13	20	kg	kg	PROPN
admet-437	13	21	and	and	CCONJ
admet-437	13	22	0.56	0.56	NUM
admet-437	13	23	l	l	NOUN
admet-437	13	24	/	/	SYM
admet-437	13	25	kg	kg	PROPN
admet-437	13	26	;	;	PUNCT
admet-437	13	27	1.67	1.67	NUM
admet-437	13	28	ml	ml	NOUN
admet-437	13	29	/	/	SYM
admet-437	13	30	min	min	NOUN
admet-437	13	31	/	/	SYM
admet-437	13	32	kg	kg	PROPN
admet-437	13	33	and	and	CCONJ
admet-437	13	34	0.36	0.36	NUM
admet-437	13	35	l	l	NOUN
admet-437	13	36	/	/	SYM
admet-437	13	37	kg	kg	PROPN
admet-437	13	38	and	and	CCONJ
admet-437	13	39	15.5	15.5	NUM
admet-437	13	40	ml	ml	NOUN
admet-437	13	41	/	/	SYM
admet-437	13	42	min	min	NOUN
admet-437	13	43	/	/	SYM
admet-437	13	44	kg	kg	PROPN
admet-437	13	45	and	and	CCONJ
admet-437	13	46	1.61	1.61	NUM
admet-437	13	47	l	l	NOUN
admet-437	13	48	/	/	SYM
admet-437	13	49	kg	kg	PROPN
admet-437	13	50	in	in	ADP
admet-437	13	51	mice	mouse	NOUN
admet-437	13	52	,	,	PUNCT
admet-437	13	53	rats	rat	NOUN
admet-437	13	54	and	and	CCONJ
admet-437	13	55	dogs	dog	NOUN
admet-437	13	56	,	,	PUNCT
admet-437	13	57	respectively	respectively	ADV
admet-437	13	58	.	.	PUNCT
admet-437	14	1	absolute	absolute	ADJ
admet-437	14	2	oral	oral	ADJ
admet-437	14	3	bioavailability	bioavailability	NOUN
admet-437	14	4	in	in	ADP
admet-437	14	5	mice	mouse	NOUN
admet-437	14	6	and	and	CCONJ
admet-437	14	7	rats	rat	NOUN
admet-437	14	8	was	be	AUX
admet-437	14	9	>	>	X
admet-437	14	10	92	92	NUM
admet-437	14	11	%	%	NOUN
admet-437	14	12	,	,	PUNCT
admet-437	14	13	however	however	ADV
admet-437	14	14	in	in	ADP
admet-437	14	15	dogs	dog	NOUN
admet-437	14	16	it	it	PRON
admet-437	14	17	was	be	AUX
admet-437	14	18	34	34	NUM
admet-437	14	19	%	%	NOUN
admet-437	14	20	.	.	PUNCT
admet-437	15	1	keywords	keyword	NOUN
admet-437	15	2	ulixertinib	ulixertinib	VERB
admet-437	15	3	;	;	PUNCT
admet-437	15	4	erk	erk	NOUN
admet-437	15	5	inhibitor	inhibitor	NOUN
admet-437	15	6	;	;	PUNCT
admet-437	15	7	in	in	ADP
admet-437	15	8	vitro	vitro	X
admet-437	15	9	studies	study	NOUN
admet-437	15	10	;	;	PUNCT
admet-437	15	11	pharmacokinetics	pharmacokinetic	NOUN
admet-437	15	12	;	;	PUNCT
admet-437	15	13	mice	mouse	NOUN
admet-437	15	14	;	;	PUNCT
admet-437	15	15	rats	rat	NOUN
admet-437	15	16	;	;	PUNCT
admet-437	15	17	dogs	dog	NOUN
admet-437	15	18	introduction	introduction	VERB
admet-437	15	19	the	the	DET
admet-437	15	20	extracellular	extracellular	ADJ
admet-437	15	21	-	-	PUNCT
admet-437	15	22	signal	signal	NOUN
admet-437	15	23	-	-	PUNCT
admet-437	15	24	regulated	regulate	VERB
admet-437	15	25	kinases	kinase	NOUN
admet-437	15	26	,	,	PUNCT
admet-437	15	27	erk1	erk1	PROPN
admet-437	15	28	and	and	CCONJ
admet-437	15	29	erk2	erk2	PROPN
admet-437	15	30	(	(	PUNCT
admet-437	15	31	erk1/2	erk1/2	PROPN
admet-437	15	32	)	)	PUNCT
admet-437	15	33	,	,	PUNCT
admet-437	15	34	play	play	VERB
admet-437	15	35	a	a	DET
admet-437	15	36	critical	critical	ADJ
admet-437	15	37	role	role	NOUN
admet-437	15	38	in	in	ADP
admet-437	15	39	the	the	DET
admet-437	15	40	ras	ras	PROPN
admet-437	15	41	/	/	SYM
admet-437	15	42	raf	raf	PROPN
admet-437	15	43	/	/	SYM
admet-437	15	44	mek	mek	PROPN
admet-437	15	45	signaling	signal	VERB
admet-437	15	46	pathway	pathway	NOUN
admet-437	15	47	,	,	PUNCT
admet-437	15	48	that	that	PRON
admet-437	15	49	controls	control	VERB
admet-437	15	50	several	several	ADJ
admet-437	15	51	fundamental	fundamental	ADJ
admet-437	15	52	cellular	cellular	ADJ
admet-437	15	53	processes	process	NOUN
admet-437	15	54	,	,	PUNCT
admet-437	15	55	driving	drive	VERB
admet-437	15	56	proliferation	proliferation	NOUN
admet-437	15	57	,	,	PUNCT
admet-437	15	58	differentiation	differentiation	NOUN
admet-437	15	59	and	and	CCONJ
admet-437	15	60	cell	cell	NOUN
admet-437	15	61	survival	survival	NOUN
admet-437	16	1	[	[	X
admet-437	16	2	1	1	NUM
admet-437	16	3	]	]	PUNCT
admet-437	16	4	.	.	PUNCT
admet-437	17	1	ras	ras	PROPN
admet-437	17	2	/	/	SYM
admet-437	17	3	raf	raf	PROPN
admet-437	17	4	/	/	SYM
admet-437	17	5	mek	mek	PROPN
admet-437	17	6	signaling	signal	VERB
admet-437	17	7	pathway	pathway	NOUN
admet-437	17	8	is	be	AUX
admet-437	17	9	frequently	frequently	ADV
admet-437	17	10	activated	activate	VERB
admet-437	17	11	by	by	ADP
admet-437	17	12	mutations	mutation	NOUN
admet-437	17	13	in	in	ADP
admet-437	17	14	upstream	upstream	ADJ
admet-437	17	15	targets	target	NOUN
admet-437	17	16	such	such	ADJ
admet-437	17	17	as	as	ADP
admet-437	17	18	braf	braf	NOUN
admet-437	17	19	,	,	PUNCT
admet-437	17	20	ras	ras	NOUN
admet-437	17	21	and	and	CCONJ
admet-437	17	22	receptor	receptor	NOUN
admet-437	17	23	tyrosine	tyrosine	NOUN
admet-437	17	24	kinases	kinase	NOUN
admet-437	18	1	[	[	X
admet-437	18	2	2	2	NUM
admet-437	18	3	]	]	PUNCT
admet-437	18	4	.	.	PUNCT
admet-437	19	1	most	most	ADJ
admet-437	19	2	of	of	ADP
admet-437	19	3	the	the	DET
admet-437	19	4	resistance	resistance	NOUN
admet-437	19	5	mechanisms	mechanism	NOUN
admet-437	19	6	to	to	ADP
admet-437	19	7	braf	braf	NOUN
admet-437	19	8	and	and	CCONJ
admet-437	19	9	mek	mek	PROPN
admet-437	19	10	inhibitors	inhibitor	NOUN
admet-437	19	11	ultimately	ultimately	ADV
admet-437	19	12	lead	lead	VERB
admet-437	19	13	to	to	PART
admet-437	19	14	increase	increase	VERB
admet-437	19	15	in	in	ADP
admet-437	19	16	phosphorylation	phosphorylation	NOUN
admet-437	19	17	of	of	ADP
admet-437	19	18	erk1/2	erk1/2	PROPN
admet-437	19	19	suggesting	suggest	VERB
admet-437	19	20	the	the	DET
admet-437	19	21	importance	importance	NOUN
admet-437	19	22	of	of	ADP
admet-437	19	23	this	this	DET
admet-437	19	24	node	node	NOUN
admet-437	19	25	in	in	ADP
admet-437	19	26	the	the	DET
admet-437	19	27	ras	ras	PROPN
admet-437	19	28	/	/	SYM
admet-437	19	29	raf	raf	PROPN
admet-437	19	30	/	/	SYM
admet-437	19	31	mek	mek	PROPN
admet-437	19	32	pathway	pathway	NOUN
admet-437	19	33	even	even	ADV
admet-437	19	34	in	in	ADP
admet-437	19	35	the	the	DET
admet-437	19	36	resistance	resistance	NOUN
admet-437	19	37	setting	set	VERB
admet-437	19	38	[	[	X
admet-437	19	39	3	3	NUM
admet-437	19	40	]	]	PUNCT
admet-437	19	41	.	.	PUNCT
admet-437	20	1	ras	ra	VERB
admet-437	20	2	activating	activate	VERB
admet-437	20	3	mutations	mutation	NOUN
admet-437	20	4	have	have	AUX
admet-437	20	5	been	be	AUX
admet-437	20	6	reported	report	VERB
admet-437	20	7	in	in	ADP
admet-437	20	8	about	about	ADV
admet-437	20	9	90	90	NUM
admet-437	20	10	%	%	NOUN
admet-437	20	11	of	of	ADP
admet-437	20	12	pancreatic	pancreatic	ADJ
admet-437	20	13	carcinomas	carcinoma	NOUN
admet-437	20	14	,	,	PUNCT
admet-437	20	15	followed	follow	VERB
admet-437	20	16	by	by	ADP
admet-437	20	17	colon	colon	NOUN
admet-437	20	18	carcinomas	carcinoma	NOUN
admet-437	20	19	(	(	PUNCT
admet-437	20	20	50	50	NUM
admet-437	20	21	%	%	NOUN
admet-437	20	22	)	)	PUNCT
admet-437	20	23	,	,	PUNCT
admet-437	20	24	lung	lung	NOUN
admet-437	20	25	cancers	cancer	NOUN
admet-437	20	26	and	and	CCONJ
admet-437	20	27	myeloid	myeloid	NOUN
admet-437	20	28	leukemia	leukemia	NOUN
admet-437	20	29	cases	case	NOUN
admet-437	20	30	(	(	PUNCT
admet-437	20	31	30	30	NUM
admet-437	20	32	%	%	NOUN
admet-437	20	33	each	each	PRON
admet-437	20	34	)	)	PUNCT
admet-437	21	1	[	[	X
admet-437	21	2	4	4	NUM
admet-437	21	3	]	]	PUNCT
admet-437	21	4	.	.	PUNCT
admet-437	22	1	therefore	therefore	ADV
admet-437	22	2	,	,	PUNCT
admet-437	22	3	inhibition	inhibition	NOUN
admet-437	22	4	of	of	ADP
admet-437	22	5	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-437	22	6	mailto:mullangi.ramesh@jubilantinnovation.com	mailto:mullangi.ramesh@jubilantinnovation.com	PROPN
admet-437	22	7	admet	admet	PROPN
admet-437	22	8	&	&	CCONJ
admet-437	22	9	dmpk	dmpk	PROPN
admet-437	22	10	5(4	5(4	NOUN
admet-437	22	11	)	)	PUNCT
admet-437	22	12	(	(	PUNCT
admet-437	22	13	2017	2017	NUM
admet-437	22	14	)	)	PUNCT
admet-437	22	15	212	212	NUM
admet-437	22	16	-	-	SYM
admet-437	22	17	223	223	NUM
admet-437	22	18	preclinical	preclinical	ADJ
admet-437	22	19	assessment	assessment	NOUN
admet-437	22	20	of	of	ADP
admet-437	22	21	ulixertinib	ulixertinib	PROPN
admet-437	22	22	doi	doi	PROPN
admet-437	22	23	:	:	PUNCT
admet-437	22	24	10.5599	10.5599	NUM
admet-437	22	25	/	/	SYM
admet-437	22	26	admet.5.4.437	admet.5.4.437	NUM
admet-437	22	27	213	213	NUM
admet-437	22	28	erk1/2	erk1/2	PROPN
admet-437	22	29	offers	offer	VERB
admet-437	22	30	a	a	DET
admet-437	22	31	promising	promising	ADJ
admet-437	22	32	strategy	strategy	NOUN
admet-437	22	33	to	to	PART
admet-437	22	34	address	address	VERB
admet-437	22	35	both	both	PRON
admet-437	22	36	innate	innate	ADJ
admet-437	22	37	and	and	CCONJ
admet-437	22	38	acquired	acquire	VERB
admet-437	22	39	resistance	resistance	NOUN
admet-437	22	40	to	to	ADP
admet-437	22	41	braf	braf	NOUN
admet-437	22	42	and	and	CCONJ
admet-437	22	43	mek	mek	PROPN
admet-437	22	44	inhibitors	inhibitor	NOUN
admet-437	22	45	in	in	ADP
admet-437	22	46	various	various	ADJ
admet-437	22	47	solid	solid	ADJ
admet-437	22	48	tumors	tumor	NOUN
admet-437	22	49	.	.	PUNCT
admet-437	23	1	ulixertinib	ulixertinib	PROPN
admet-437	23	2	(	(	PUNCT
admet-437	23	3	bvd-523	bvd-523	NOUN
admet-437	23	4	,	,	PUNCT
admet-437	23	5	vrt752271	vrt752271	NOUN
admet-437	23	6	;	;	PUNCT
admet-437	23	7	figure	figure	NOUN
admet-437	23	8	1	1	NUM
admet-437	23	9	)	)	PUNCT
admet-437	23	10	is	be	AUX
admet-437	23	11	a	a	DET
admet-437	23	12	first	first	ADJ
admet-437	23	13	-	-	PUNCT
admet-437	23	14	in	in	ADP
admet-437	23	15	-	-	PUNCT
admet-437	23	16	class	class	NOUN
admet-437	23	17	novel	novel	ADJ
admet-437	23	18	small	small	ADJ
admet-437	23	19	molecule	molecule	NOUN
admet-437	23	20	,	,	PUNCT
admet-437	23	21	which	which	PRON
admet-437	23	22	potently	potently	ADV
admet-437	23	23	and	and	CCONJ
admet-437	23	24	selectively	selectively	ADV
admet-437	23	25	inhibits	inhibit	VERB
admet-437	23	26	erk1/2	erk1/2	PROPN
admet-437	23	27	kinases	kinase	NOUN
admet-437	23	28	in	in	ADP
admet-437	23	29	a	a	DET
admet-437	23	30	reversible	reversible	ADJ
admet-437	23	31	,	,	PUNCT
admet-437	23	32	atp	atp	NOUN
admet-437	23	33	-	-	PUNCT
admet-437	23	34	competitive	competitive	ADJ
admet-437	23	35	fashion	fashion	NOUN
admet-437	23	36	.	.	PUNCT
admet-437	24	1	inhibition	inhibition	NOUN
admet-437	24	2	of	of	ADP
admet-437	24	3	erk1/2	erk1/2	PROPN
admet-437	24	4	leads	lead	VERB
admet-437	24	5	to	to	ADP
admet-437	24	6	proliferation	proliferation	NOUN
admet-437	24	7	inhibition	inhibition	NOUN
admet-437	24	8	(	(	PUNCT
admet-437	24	9	by	by	ADP
admet-437	24	10	decreasing	decrease	VERB
admet-437	24	11	the	the	DET
admet-437	24	12	expression	expression	NOUN
admet-437	24	13	of	of	ADP
admet-437	24	14	vegfa	vegfa	PROPN
admet-437	24	15	and	and	CCONJ
admet-437	24	16	vegfr2	vegfr2	NOUN
admet-437	24	17	at	at	ADP
admet-437	24	18	mrna	mrna	PROPN
admet-437	24	19	and	and	CCONJ
admet-437	24	20	protein	protein	NOUN
admet-437	24	21	level	level	NOUN
admet-437	24	22	)	)	PUNCT
admet-437	24	23	,	,	PUNCT
admet-437	24	24	cell	cell	NOUN
admet-437	24	25	cycle	cycle	NOUN
admet-437	24	26	arrest	arrest	NOUN
admet-437	24	27	and	and	CCONJ
admet-437	24	28	apoptosis	apoptosis	NOUN
admet-437	24	29	in	in	ADP
admet-437	24	30	lymphoma	lymphoma	NOUN
admet-437	24	31	cell	cell	NOUN
admet-437	24	32	lines	line	NOUN
admet-437	25	1	[	[	X
admet-437	25	2	5	5	NUM
admet-437	25	3	]	]	PUNCT
admet-437	25	4	.	.	PUNCT
admet-437	26	1	ulixertinib	ulixertinib	PROPN
admet-437	26	2	inhibits	inhibit	VERB
admet-437	26	3	tumor	tumor	NOUN
admet-437	26	4	growth	growth	NOUN
admet-437	26	5	in	in	ADP
admet-437	26	6	vivo	vivo	NOUN
admet-437	26	7	in	in	ADP
admet-437	26	8	braf	braf	NOUN
admet-437	26	9	-	-	PUNCT
admet-437	26	10	mutant	mutant	ADJ
admet-437	26	11	melanoma	melanoma	NOUN
admet-437	26	12	and	and	CCONJ
admet-437	26	13	colorectal	colorectal	ADJ
admet-437	26	14	xenografts	xenograft	NOUN
admet-437	26	15	as	as	ADV
admet-437	26	16	well	well	ADV
admet-437	26	17	as	as	ADP
admet-437	26	18	in	in	ADP
admet-437	26	19	kras	kra	NOUN
admet-437	26	20	-	-	PUNCT
admet-437	26	21	mutant	mutant	ADJ
admet-437	26	22	colorectal	colorectal	ADJ
admet-437	26	23	and	and	CCONJ
admet-437	26	24	pancreatic	pancreatic	ADJ
admet-437	26	25	models	model	NOUN
admet-437	26	26	[	[	X
admet-437	26	27	6	6	NUM
admet-437	26	28	]	]	PUNCT
admet-437	26	29	.	.	PUNCT
admet-437	27	1	in	in	ADP
admet-437	27	2	clinical	clinical	ADJ
admet-437	27	3	studies	study	NOUN
admet-437	27	4	,	,	PUNCT
admet-437	27	5	ulixertinib	ulixertinib	PROPN
admet-437	27	6	was	be	AUX
admet-437	27	7	well	well	ADV
admet-437	27	8	tolerated	tolerate	VERB
admet-437	27	9	by	by	ADP
admet-437	27	10	patients	patient	NOUN
admet-437	27	11	with	with	ADP
admet-437	27	12	advanced	advanced	ADJ
admet-437	27	13	solid	solid	ADJ
admet-437	27	14	tumors	tumor	NOUN
admet-437	27	15	.	.	PUNCT
admet-437	28	1	in	in	ADP
admet-437	28	2	an	an	DET
admet-437	28	3	oral	oral	ADJ
admet-437	28	4	phase	phase	NOUN
admet-437	28	5	-	-	PUNCT
admet-437	28	6	i	i	PRON
admet-437	28	7	dose	dose	VERB
admet-437	28	8	escalation	escalation	NOUN
admet-437	28	9	study	study	NOUN
admet-437	28	10	(	(	PUNCT
admet-437	28	11	having	have	VERB
admet-437	28	12	9	9	NUM
admet-437	28	13	doses	dose	NOUN
admet-437	28	14	)	)	PUNCT
admet-437	28	15	with	with	ADP
admet-437	28	16	an	an	DET
admet-437	28	17	end	end	NOUN
admet-437	28	18	point	point	NOUN
admet-437	28	19	to	to	PART
admet-437	28	20	determine	determine	VERB
admet-437	28	21	the	the	DET
admet-437	28	22	dose	dose	NOUN
admet-437	28	23	limited	limit	VERB
admet-437	28	24	toxicities	toxicity	NOUN
admet-437	28	25	(	(	PUNCT
admet-437	28	26	dlt	dlt	PROPN
admet-437	28	27	)	)	PUNCT
admet-437	28	28	,	,	PUNCT
admet-437	28	29	maximum	maximum	ADJ
admet-437	28	30	tolerated	tolerate	VERB
admet-437	28	31	dose	dose	PROPN
admet-437	28	32	(	(	PUNCT
admet-437	28	33	mtd	mtd	PROPN
admet-437	28	34	)	)	PUNCT
admet-437	28	35	along	along	ADP
admet-437	28	36	with	with	ADP
admet-437	28	37	pharmacokinetic	pharmacokinetic	ADJ
admet-437	28	38	profile	profile	NOUN
admet-437	28	39	and	and	CCONJ
admet-437	28	40	preliminary	preliminary	ADJ
admet-437	28	41	efficacy	efficacy	NOUN
admet-437	28	42	assessment	assessment	NOUN
admet-437	28	43	it	it	PRON
admet-437	28	44	was	be	AUX
admet-437	28	45	administered	administer	VERB
admet-437	28	46	in	in	ADP
admet-437	28	47	a	a	DET
admet-437	28	48	dose	dose	ADJ
admet-437	28	49	range	range	NOUN
admet-437	28	50	of	of	ADP
admet-437	28	51	10	10	NUM
admet-437	28	52	-	-	SYM
admet-437	28	53	900	900	NUM
admet-437	28	54	mg	mg	NOUN
admet-437	28	55	in	in	ADP
admet-437	28	56	a	a	DET
admet-437	28	57	b.i.d	b.i.d	PROPN
admet-437	28	58	regimen	regimen	PROPN
admet-437	28	59	.	.	PUNCT
admet-437	29	1	ulixertinib	ulixertinib	PROPN
admet-437	29	2	showed	show	VERB
admet-437	29	3	linear	linear	ADJ
admet-437	29	4	pharmacokinetics	pharmacokinetic	NOUN
admet-437	29	5	up	up	ADP
admet-437	29	6	to	to	ADP
admet-437	29	7	600	600	NUM
admet-437	29	8	mg	mg	NOUN
admet-437	29	9	(	(	PUNCT
admet-437	29	10	b.i.d	b.i.d	PROPN
admet-437	29	11	)	)	PUNCT
admet-437	29	12	,	,	PUNCT
admet-437	29	13	this	this	PRON
admet-437	29	14	was	be	AUX
admet-437	29	15	found	find	VERB
admet-437	29	16	to	to	PART
admet-437	29	17	be	be	AUX
admet-437	29	18	mtd	mtd	PROPN
admet-437	30	1	[	[	X
admet-437	30	2	7	7	NUM
admet-437	30	3	]	]	PUNCT
admet-437	30	4	.	.	PUNCT
admet-437	31	1	figure	figure	NOUN
admet-437	31	2	1	1	NUM
admet-437	31	3	.	.	PUNCT
admet-437	31	4	structural	structural	ADJ
admet-437	31	5	representation	representation	NOUN
admet-437	31	6	of	of	ADP
admet-437	31	7	ulixertinib	ulixertinib	NOUN
admet-437	31	8	to	to	ADP
admet-437	31	9	date	date	NOUN
admet-437	31	10	there	there	PRON
admet-437	31	11	is	be	VERB
admet-437	31	12	no	no	DET
admet-437	31	13	publication	publication	NOUN
admet-437	31	14	on	on	ADP
admet-437	31	15	preclinical	preclinical	ADJ
admet-437	31	16	pharmacokinetics	pharmacokinetic	NOUN
admet-437	31	17	of	of	ADP
admet-437	31	18	erk1/2	erk1/2	PROPN
admet-437	31	19	inhibitors	inhibitor	NOUN
admet-437	31	20	,	,	PUNCT
admet-437	31	21	hence	hence	ADV
admet-437	31	22	we	we	PRON
admet-437	31	23	felt	feel	VERB
admet-437	31	24	that	that	SCONJ
admet-437	31	25	preliminary	preliminary	ADJ
admet-437	31	26	data	datum	NOUN
admet-437	31	27	on	on	ADP
admet-437	31	28	various	various	ADJ
admet-437	31	29	in	in	ADP
admet-437	31	30	vitro	vitro	X
admet-437	31	31	adme	adme	NOUN
admet-437	31	32	studies	study	NOUN
admet-437	31	33	and	and	CCONJ
admet-437	31	34	in	in	ADP
admet-437	31	35	vivo	vivo	ADJ
admet-437	31	36	pharmacokinetics	pharmacokinetic	NOUN
admet-437	31	37	in	in	ADP
admet-437	31	38	mice	mouse	NOUN
admet-437	31	39	,	,	PUNCT
admet-437	31	40	rats	rat	NOUN
admet-437	31	41	and	and	CCONJ
admet-437	31	42	dogs	dog	NOUN
admet-437	31	43	of	of	ADP
admet-437	31	44	ulixertinib	ulixertinib	NOUN
admet-437	31	45	will	will	AUX
admet-437	31	46	help	help	VERB
admet-437	31	47	researchers	researcher	NOUN
admet-437	31	48	in	in	ADP
admet-437	31	49	this	this	DET
admet-437	31	50	field	field	NOUN
admet-437	31	51	to	to	PART
admet-437	31	52	provide	provide	VERB
admet-437	31	53	the	the	DET
admet-437	31	54	differentiating	differentiate	VERB
admet-437	31	55	features	feature	NOUN
admet-437	31	56	in	in	ADP
admet-437	31	57	this	this	DET
admet-437	31	58	class	class	NOUN
admet-437	31	59	.	.	PUNCT
admet-437	32	1	this	this	DET
admet-437	32	2	paper	paper	NOUN
admet-437	32	3	describes	describe	VERB
admet-437	32	4	various	various	ADJ
admet-437	32	5	in	in	ADP
admet-437	32	6	vitro	vitro	X
admet-437	32	7	experiments	experiment	NOUN
admet-437	32	8	done	do	VERB
admet-437	32	9	to	to	ADP
admet-437	32	10	(	(	PUNCT
admet-437	32	11	a	a	PRON
admet-437	32	12	)	)	PUNCT
admet-437	32	13	assess	assess	VERB
admet-437	32	14	the	the	DET
admet-437	32	15	metabolic	metabolic	NOUN
admet-437	32	16	stability	stability	NOUN
admet-437	32	17	of	of	ADP
admet-437	32	18	ulixertinib	ulixertinib	NOUN
admet-437	32	19	in	in	ADP
admet-437	32	20	various	various	ADJ
admet-437	32	21	preclinical	preclinical	ADJ
admet-437	32	22	species	specie	NOUN
admet-437	32	23	and	and	CCONJ
admet-437	32	24	human	human	ADJ
admet-437	32	25	liver	liver	NOUN
admet-437	32	26	microsomes	microsome	NOUN
admet-437	32	27	and	and	CCONJ
admet-437	32	28	hepatocytes	hepatocyte	NOUN
admet-437	32	29	(	(	PUNCT
admet-437	32	30	b	b	X
admet-437	32	31	)	)	PUNCT
admet-437	32	32	determine	determine	VERB
admet-437	32	33	the	the	DET
admet-437	32	34	permeability	permeability	NOUN
admet-437	32	35	in	in	ADP
admet-437	32	36	caco-2	caco-2	NUM
admet-437	32	37	cells	cell	NOUN
admet-437	32	38	(	(	PUNCT
admet-437	32	39	c	c	NOUN
admet-437	32	40	)	)	PUNCT
admet-437	32	41	determine	determine	VERB
admet-437	32	42	the	the	DET
admet-437	32	43	unbound	unbound	NOUN
admet-437	32	44	fraction	fraction	NOUN
admet-437	32	45	in	in	ADP
admet-437	32	46	preclinical	preclinical	ADJ
admet-437	32	47	species	specie	NOUN
admet-437	32	48	and	and	CCONJ
admet-437	32	49	human	human	ADJ
admet-437	32	50	plasma	plasma	NOUN
admet-437	32	51	(	(	PUNCT
admet-437	32	52	d	d	X
admet-437	32	53	)	)	PUNCT
admet-437	32	54	cyp	cyp	ADJ
admet-437	32	55	inhibition	inhibition	NOUN
admet-437	32	56	(	(	PUNCT
admet-437	32	57	e	e	NOUN
admet-437	32	58	)	)	PUNCT
admet-437	32	59	cyp	cyp	ADJ
admet-437	32	60	induction	induction	NOUN
admet-437	32	61	and	and	CCONJ
admet-437	32	62	(	(	PUNCT
admet-437	32	63	f	f	X
admet-437	32	64	)	)	PUNCT
admet-437	32	65	cyp	cyp	ADJ
admet-437	32	66	phenotyping	phenotyping	NOUN
admet-437	32	67	of	of	ADP
admet-437	32	68	ulixertinib	ulixertinib	NOUN
admet-437	32	69	.	.	PUNCT
admet-437	33	1	moreover	moreover	ADV
admet-437	33	2	,	,	PUNCT
admet-437	33	3	a	a	DET
admet-437	33	4	series	series	NOUN
admet-437	33	5	of	of	ADP
admet-437	33	6	in	in	ADP
admet-437	33	7	vivo	vivo	ADJ
admet-437	33	8	experiments	experiment	NOUN
admet-437	33	9	in	in	ADP
admet-437	33	10	balb	balb	ADJ
admet-437	33	11	/	/	SYM
admet-437	33	12	c	c	NOUN
admet-437	33	13	mice	mouse	NOUN
admet-437	33	14	,	,	PUNCT
admet-437	33	15	sprague	sprague	NOUN
admet-437	33	16	dawley	dawley	NOUN
admet-437	33	17	rats	rat	NOUN
admet-437	33	18	and	and	CCONJ
admet-437	33	19	beagle	beagle	NOUN
admet-437	33	20	dogs	dog	NOUN
admet-437	33	21	were	be	AUX
admet-437	33	22	performed	perform	VERB
admet-437	33	23	to	to	PART
admet-437	33	24	characterize	characterize	VERB
admet-437	33	25	and	and	CCONJ
admet-437	33	26	understand	understand	VERB
admet-437	33	27	pharmacokinetic	pharmacokinetic	ADJ
admet-437	33	28	parameters	parameter	NOUN
admet-437	33	29	and	and	CCONJ
admet-437	33	30	absolute	absolute	ADJ
admet-437	33	31	oral	oral	ADJ
admet-437	33	32	bioavailability	bioavailability	NOUN
admet-437	33	33	of	of	ADP
admet-437	33	34	ulixertinib	ulixertinib	NOUN
admet-437	33	35	across	across	ADP
admet-437	33	36	the	the	DET
admet-437	33	37	species	specie	NOUN
admet-437	33	38	.	.	PUNCT
admet-437	34	1	materials	material	NOUN
admet-437	34	2	and	and	CCONJ
admet-437	34	3	methods	method	NOUN
admet-437	34	4	materials	material	NOUN
admet-437	34	5	ulixertinib	ulixertinib	NOUN
admet-437	34	6	(	(	PUNCT
admet-437	34	7	purity	purity	NOUN
admet-437	34	8	>	>	X
admet-437	34	9	99	99	NUM
admet-437	34	10	%	%	NOUN
admet-437	34	11	)	)	PUNCT
admet-437	34	12	was	be	AUX
admet-437	34	13	purchased	purchase	VERB
admet-437	34	14	from	from	ADP
admet-437	34	15	medkoo	medkoo	NOUN
admet-437	34	16	biosciences	bioscience	NOUN
admet-437	34	17	,	,	PUNCT
admet-437	34	18	inc	inc	PROPN
admet-437	34	19	.	.	PROPN
admet-437	34	20	,	,	PUNCT
admet-437	34	21	nc	nc	PROPN
admet-437	34	22	,	,	PUNCT
admet-437	34	23	usa	usa	PROPN
admet-437	34	24	.	.	PROPN
admet-437	34	25	hplc	hplc	PROPN
admet-437	34	26	grade	grade	PROPN
admet-437	34	27	acetonitrile	acetonitrile	NOUN
admet-437	34	28	,	,	PUNCT
admet-437	34	29	formic	formic	ADJ
admet-437	34	30	acid	acid	NOUN
admet-437	34	31	and	and	CCONJ
admet-437	34	32	methanol	methanol	NOUN
admet-437	34	33	were	be	AUX
admet-437	34	34	purchased	purchase	VERB
admet-437	34	35	from	from	ADP
admet-437	34	36	rankem	rankem	PROPN
admet-437	34	37	,	,	PUNCT
admet-437	34	38	ranbaxy	ranbaxy	PROPN
admet-437	34	39	fine	fine	ADJ
admet-437	34	40	chemicals	chemical	NOUN
admet-437	34	41	limited	limit	VERB
admet-437	34	42	,	,	PUNCT
admet-437	34	43	new	new	ADJ
admet-437	34	44	delhi	delhi	PROPN
admet-437	34	45	,	,	PUNCT
admet-437	34	46	india	india	PROPN
admet-437	34	47	.	.	PUNCT
admet-437	35	1	preclinical	preclinical	ADJ
admet-437	35	2	species	specie	NOUN
admet-437	35	3	and	and	CCONJ
admet-437	35	4	human	human	ADJ
admet-437	35	5	liver	liver	NOUN
admet-437	35	6	microsomes	microsome	NOUN
admet-437	35	7	and	and	CCONJ
admet-437	35	8	hepatocytes	hepatocyte	NOUN
admet-437	35	9	were	be	AUX
admet-437	35	10	purchased	purchase	VERB
admet-437	35	11	from	from	ADP
admet-437	35	12	life	life	NOUN
admet-437	35	13	technologies	technology	NOUN
admet-437	35	14	(	(	PUNCT
admet-437	35	15	gibco	gibco	NOUN
admet-437	35	16	®	®	NOUN
admet-437	35	17	)	)	PUNCT
admet-437	35	18	,	,	PUNCT
admet-437	35	19	inchinnan	inchinnan	PROPN
admet-437	35	20	,	,	PUNCT
admet-437	35	21	uk	uk	PROPN
admet-437	35	22	.	.	PROPN
admet-437	35	23	substrates	substrate	NOUN
admet-437	35	24	and	and	CCONJ
admet-437	35	25	inhibitors	inhibitor	NOUN
admet-437	35	26	of	of	ADP
admet-437	35	27	cyp	cyp	ADJ
admet-437	35	28	isoforms	isoform	NOUN
admet-437	35	29	like	like	ADP
admet-437	35	30	midazolam	midazolam	PROPN
admet-437	35	31	,	,	PUNCT
admet-437	35	32	quinidine	quinidine	ADJ
admet-437	35	33	,	,	PUNCT
admet-437	35	34	diclofenac	diclofenac	NOUN
admet-437	35	35	,	,	PUNCT
admet-437	35	36	bufuralol	bufuralol	NOUN
admet-437	35	37	,	,	PUNCT
admet-437	35	38	omeprazole	omeprazole	NOUN
admet-437	35	39	,	,	PUNCT
admet-437	35	40	verapamil	verapamil	NOUN
admet-437	35	41	,	,	PUNCT
admet-437	35	42	rifampicin	rifampicin	VERB
admet-437	35	43	,	,	PUNCT
admet-437	35	44	warfarin	warfarin	NOUN
admet-437	35	45	,	,	PUNCT
admet-437	35	46	tolbutamide	tolbutamide	NOUN
admet-437	35	47	,	,	PUNCT
admet-437	35	48	phenacetin	phenacetin	NOUN
admet-437	35	49	,	,	PUNCT
admet-437	35	50	ketoconazole	ketoconazole	NOUN
admet-437	35	51	,	,	PUNCT
admet-437	35	52	sulfaphenazole	sulfaphenazole	NOUN
admet-437	35	53	,	,	PUNCT
admet-437	35	54	nootkatone	nootkatone	NOUN
admet-437	35	55	,	,	PUNCT
admet-437	35	56	furafylline	furafylline	NOUN
admet-437	35	57	and	and	CCONJ
admet-437	35	58	digoxin	digoxin	PROPN
admet-437	35	59	were	be	AUX
admet-437	35	60	purchased	purchase	VERB
admet-437	35	61	from	from	ADP
admet-437	35	62	sigma	sigma	PROPN
admet-437	35	63	-	-	PUNCT
admet-437	35	64	aldrich	aldrich	PROPN
admet-437	35	65	chemie	chemie	PROPN
admet-437	35	66	gmbh	gmbh	PROPN
admet-437	35	67	,	,	PUNCT
admet-437	35	68	steinheim	steinheim	PROPN
admet-437	35	69	,	,	PUNCT
admet-437	35	70	germany	germany	PROPN
admet-437	35	71	.	.	PUNCT
admet-437	36	1	all	all	DET
admet-437	36	2	other	other	ADJ
admet-437	36	3	chemicals	chemical	NOUN
admet-437	36	4	/	/	SYM
admet-437	36	5	reagents	reagent	NOUN
admet-437	36	6	were	be	AUX
admet-437	36	7	of	of	ADP
admet-437	36	8	research	research	NOUN
admet-437	36	9	grade	grade	NOUN
admet-437	36	10	and	and	CCONJ
admet-437	36	11	used	use	VERB
admet-437	36	12	without	without	ADP
admet-437	36	13	further	further	ADJ
admet-437	36	14	purification	purification	NOUN
admet-437	36	15	.	.	PUNCT
admet-437	37	1	r.	r.	PROPN
admet-437	37	2	mullangi	mullangi	VERB
admet-437	37	3	et	et	PROPN
admet-437	37	4	al	al	PROPN
admet-437	37	5	.	.	PROPN
admet-437	37	6	admet	admet	PROPN
admet-437	37	7	&	&	CCONJ
admet-437	37	8	dmpk	dmpk	PROPN
admet-437	37	9	5(4	5(4	NOUN
admet-437	37	10	)	)	PUNCT
admet-437	37	11	(	(	PUNCT
admet-437	37	12	2017	2017	NUM
admet-437	37	13	)	)	PUNCT
admet-437	38	1	212	212	NUM
admet-437	38	2	-	-	SYM
admet-437	38	3	223	223	NUM
admet-437	38	4	214	214	NUM
admet-437	38	5	in	in	ADP
admet-437	38	6	vitro	vitro	X
admet-437	38	7	studies	study	NOUN
admet-437	38	8	metabolic	metabolic	NOUN
admet-437	38	9	stability	stability	NOUN
admet-437	38	10	in	in	ADP
admet-437	38	11	liver	liver	NOUN
admet-437	38	12	microsomes	microsome	NOUN
admet-437	38	13	metabolic	metabolic	NOUN
admet-437	38	14	stability	stability	NOUN
admet-437	38	15	is	be	AUX
admet-437	38	16	defined	define	VERB
admet-437	38	17	as	as	ADP
admet-437	38	18	the	the	DET
admet-437	38	19	percentage	percentage	NOUN
admet-437	38	20	of	of	ADP
admet-437	38	21	parent	parent	NOUN
admet-437	38	22	compound	compound	NOUN
admet-437	38	23	lost	lose	VERB
admet-437	38	24	over	over	ADP
admet-437	38	25	time	time	NOUN
admet-437	38	26	in	in	ADP
admet-437	38	27	the	the	DET
admet-437	38	28	presence	presence	NOUN
admet-437	38	29	of	of	ADP
admet-437	38	30	a	a	DET
admet-437	38	31	metabolically	metabolically	ADV
admet-437	38	32	active	active	ADJ
admet-437	38	33	test	test	NOUN
admet-437	38	34	system	system	NOUN
admet-437	38	35	.	.	PUNCT
admet-437	39	1	the	the	DET
admet-437	39	2	incubation	incubation	NOUN
admet-437	39	3	mixtures	mixture	NOUN
admet-437	39	4	consisted	consist	VERB
admet-437	39	5	of	of	ADP
admet-437	39	6	liver	liver	NOUN
admet-437	39	7	microsomes	microsome	NOUN
admet-437	39	8	(	(	PUNCT
admet-437	39	9	0.5	0.5	NUM
admet-437	39	10	mg	mg	PROPN
admet-437	39	11	microsomal	microsomal	ADJ
admet-437	39	12	protein	protein	NOUN
admet-437	39	13	/	/	SYM
admet-437	39	14	ml	ml	NOUN
admet-437	39	15	)	)	PUNCT
admet-437	39	16	,	,	PUNCT
admet-437	39	17	ulixertinib	ulixertinib	NOUN
admet-437	39	18	(	(	PUNCT
admet-437	39	19	1	1	NUM
admet-437	39	20	μm	μm	NUM
admet-437	39	21	)	)	PUNCT
admet-437	39	22	or	or	CCONJ
admet-437	39	23	positive	positive	ADJ
admet-437	39	24	control	control	NOUN
admet-437	39	25	(	(	PUNCT
admet-437	39	26	verapamil	verapamil	NOUN
admet-437	39	27	,	,	PUNCT
admet-437	39	28	1	1	NUM
admet-437	39	29	μm	μm	NUM
admet-437	39	30	)	)	PUNCT
admet-437	39	31	.	.	PUNCT
admet-437	40	1	the	the	DET
admet-437	40	2	reactions	reaction	NOUN
admet-437	40	3	were	be	AUX
admet-437	40	4	initiated	initiate	VERB
admet-437	40	5	by	by	ADP
admet-437	40	6	adding	add	VERB
admet-437	40	7	20	20	NUM
admet-437	40	8	μl	μl	ADP
admet-437	40	9	of	of	ADP
admet-437	40	10	10	10	NUM
admet-437	40	11	mm	mm	NOUN
admet-437	40	12	nadph	nadph	ADJ
admet-437	40	13	[	[	X
admet-437	40	14	8	8	NUM
admet-437	40	15	]	]	PUNCT
admet-437	40	16	.	.	PUNCT
admet-437	41	1	reactions	reaction	NOUN
admet-437	41	2	without	without	ADP
admet-437	41	3	nadph	nadph	PROPN
admet-437	41	4	(	(	PUNCT
admet-437	41	5	0	0	NUM
admet-437	41	6	and	and	CCONJ
admet-437	41	7	30	30	NUM
admet-437	41	8	min	min	NOUN
admet-437	41	9	)	)	PUNCT
admet-437	41	10	were	be	AUX
admet-437	41	11	also	also	ADV
admet-437	41	12	incubated	incubate	VERB
admet-437	41	13	to	to	PART
admet-437	41	14	rule	rule	VERB
admet-437	41	15	out	out	ADP
admet-437	41	16	non	non	ADJ
admet-437	41	17	-	-	ADJ
admet-437	41	18	nadph	nadph	ADJ
admet-437	41	19	metabolism	metabolism	NOUN
admet-437	41	20	or	or	CCONJ
admet-437	41	21	chemical	chemical	NOUN
admet-437	41	22	instability	instability	NOUN
admet-437	41	23	in	in	ADP
admet-437	41	24	the	the	DET
admet-437	41	25	incubation	incubation	NOUN
admet-437	41	26	buffer	buffer	NOUN
admet-437	41	27	[	[	X
admet-437	41	28	8	8	NUM
admet-437	41	29	]	]	PUNCT
admet-437	41	30	.	.	PUNCT
admet-437	42	1	all	all	DET
admet-437	42	2	reactions	reaction	NOUN
admet-437	42	3	were	be	AUX
admet-437	42	4	terminated	terminate	VERB
admet-437	42	5	using	use	VERB
admet-437	42	6	200	200	NUM
admet-437	42	7	μl	μl	ADP
admet-437	42	8	of	of	ADP
admet-437	42	9	ice	ice	NOUN
admet-437	42	10	-	-	PUNCT
admet-437	42	11	cold	cold	ADJ
admet-437	42	12	acetonitrile	acetonitrile	NOUN
admet-437	42	13	containing	contain	VERB
admet-437	42	14	internal	internal	ADJ
admet-437	42	15	standard	standard	NOUN
admet-437	42	16	(	(	PUNCT
admet-437	42	17	200	200	NUM
admet-437	42	18	ng	ng	PROPN
admet-437	42	19	/	/	SYM
admet-437	42	20	ml	ml	PROPN
admet-437	42	21	of	of	ADP
admet-437	42	22	phenacetin	phenacetin	NOUN
admet-437	42	23	)	)	PUNCT
admet-437	42	24	at	at	ADP
admet-437	42	25	0	0	NUM
admet-437	42	26	,	,	PUNCT
admet-437	42	27	5	5	NUM
admet-437	42	28	,	,	PUNCT
admet-437	42	29	15	15	NUM
admet-437	42	30	and	and	CCONJ
admet-437	42	31	30	30	NUM
admet-437	42	32	min	min	NOUN
admet-437	42	33	.	.	PUNCT
admet-437	43	1	the	the	DET
admet-437	43	2	vials	vial	NOUN
admet-437	43	3	were	be	AUX
admet-437	43	4	centrifuged	centrifuge	VERB
admet-437	43	5	at	at	ADP
admet-437	43	6	3000	3000	NUM
admet-437	43	7	rpm	rpm	NOUN
admet-437	43	8	(	(	PUNCT
admet-437	43	9	eppendorf	eppendorf	PROPN
admet-437	43	10	5424r	5424r	NUM
admet-437	43	11	,	,	PUNCT
admet-437	43	12	germany	germany	PROPN
admet-437	43	13	)	)	PUNCT
admet-437	43	14	for	for	ADP
admet-437	43	15	15	15	NUM
admet-437	43	16	min	min	NOUN
admet-437	43	17	.	.	PUNCT
admet-437	44	1	the	the	DET
admet-437	44	2	supernatants	supernatant	NOUN
admet-437	44	3	thus	thus	ADV
admet-437	44	4	obtained	obtain	VERB
admet-437	44	5	were	be	AUX
admet-437	44	6	analyzed	analyze	VERB
admet-437	44	7	on	on	ADP
admet-437	44	8	lc	lc	PROPN
admet-437	44	9	-	-	PUNCT
admet-437	44	10	ms	ms	PROPN
admet-437	44	11	/	/	PROPN
admet-437	44	12	ms	ms	NOUN
admet-437	44	13	to	to	PART
admet-437	44	14	monitor	monitor	VERB
admet-437	44	15	the	the	DET
admet-437	44	16	disappearance	disappearance	NOUN
admet-437	44	17	of	of	ADP
admet-437	44	18	ulixertinib	ulixertinib	NOUN
admet-437	44	19	.	.	PUNCT
admet-437	45	1	metabolic	metabolic	NOUN
admet-437	45	2	stability	stability	NOUN
admet-437	45	3	in	in	ADP
admet-437	45	4	hepatocytes	hepatocyte	NOUN
admet-437	45	5	after	after	ADP
admet-437	45	6	checking	check	VERB
admet-437	45	7	the	the	DET
admet-437	45	8	viability	viability	NOUN
admet-437	45	9	of	of	ADP
admet-437	45	10	cryopreserved	cryopreserved	ADJ
admet-437	45	11	hepatocytes	hepatocyte	NOUN
admet-437	45	12	,	,	PUNCT
admet-437	45	13	they	they	PRON
admet-437	45	14	were	be	AUX
admet-437	45	15	distributed	distribute	VERB
admet-437	45	16	1	1	NUM
admet-437	45	17	million	million	NUM
admet-437	45	18	viable	viable	ADJ
admet-437	45	19	cells	cell	NOUN
admet-437	45	20	per	per	ADP
admet-437	45	21	ml	ml	NOUN
admet-437	45	22	.	.	PUNCT
admet-437	46	1	an	an	DET
admet-437	46	2	aliquot	aliquot	NOUN
admet-437	46	3	of	of	ADP
admet-437	46	4	100	100	NUM
admet-437	46	5	µl	µl	NOUN
admet-437	46	6	of	of	ADP
admet-437	46	7	thawed	thaw	VERB
admet-437	46	8	hepatocytes	hepatocyte	NOUN
admet-437	46	9	cell	cell	NOUN
admet-437	46	10	suspension	suspension	NOUN
admet-437	46	11	was	be	AUX
admet-437	46	12	aliquoted	aliquote	VERB
admet-437	46	13	into	into	ADP
admet-437	46	14	different	different	ADJ
admet-437	46	15	vials	vial	NOUN
admet-437	46	16	labeled	label	VERB
admet-437	46	17	as	as	ADP
admet-437	46	18	0	0	NUM
admet-437	46	19	,	,	PUNCT
admet-437	46	20	30	30	NUM
admet-437	46	21	,	,	PUNCT
admet-437	46	22	60	60	NUM
admet-437	46	23	,	,	PUNCT
admet-437	46	24	120	120	NUM
admet-437	46	25	and	and	CCONJ
admet-437	46	26	180	180	NUM
admet-437	46	27	min	min	NOUN
admet-437	46	28	(	(	PUNCT
admet-437	46	29	mouse	mouse	NOUN
admet-437	46	30	,	,	PUNCT
admet-437	46	31	rat	rat	NOUN
admet-437	46	32	,	,	PUNCT
admet-437	46	33	dog	dog	NOUN
admet-437	46	34	or	or	CCONJ
admet-437	46	35	human	human	ADJ
admet-437	46	36	hepatocytes	hepatocyte	NOUN
admet-437	46	37	)	)	PUNCT
admet-437	46	38	and	and	CCONJ
admet-437	46	39	ulixertinib	ulixertinib	NOUN
admet-437	46	40	(	(	PUNCT
admet-437	46	41	3	3	NUM
admet-437	46	42	μm	μm	NUM
admet-437	46	43	)	)	PUNCT
admet-437	46	44	.	.	PUNCT
admet-437	47	1	imipramine	imipramine	PROPN
admet-437	47	2	or	or	CCONJ
admet-437	47	3	naloxone	naloxone	NOUN
admet-437	47	4	(	(	PUNCT
admet-437	47	5	3	3	NUM
admet-437	47	6	μm	μm	NOUN
admet-437	47	7	)	)	PUNCT
admet-437	47	8	was	be	AUX
admet-437	47	9	used	use	VERB
admet-437	47	10	as	as	ADP
admet-437	47	11	a	a	DET
admet-437	47	12	positive	positive	ADJ
admet-437	47	13	control	control	NOUN
admet-437	47	14	[	[	X
admet-437	47	15	9	9	NUM
admet-437	47	16	]	]	PUNCT
admet-437	47	17	.	.	PUNCT
admet-437	48	1	the	the	DET
admet-437	48	2	vials	vial	NOUN
admet-437	48	3	were	be	AUX
admet-437	48	4	pre	pre	ADJ
admet-437	48	5	-	-	VERB
admet-437	48	6	incubated	incubate	VERB
admet-437	48	7	in	in	ADP
admet-437	48	8	a	a	DET
admet-437	48	9	37	37	NUM
admet-437	48	10	°	°	NOUN
admet-437	48	11	c	c	NOUN
admet-437	48	12	water	water	NOUN
admet-437	48	13	bath	bath	NOUN
admet-437	48	14	for	for	ADP
admet-437	48	15	5	5	NUM
admet-437	48	16	min	min	NOUN
admet-437	48	17	.	.	PUNCT
admet-437	49	1	all	all	DET
admet-437	49	2	reactions	reaction	NOUN
admet-437	49	3	were	be	AUX
admet-437	49	4	terminated	terminate	VERB
admet-437	49	5	using	use	VERB
admet-437	49	6	200	200	NUM
admet-437	49	7	μl	μl	ADP
admet-437	49	8	of	of	ADP
admet-437	49	9	ice	ice	NOUN
admet-437	49	10	-	-	PUNCT
admet-437	49	11	cold	cold	ADJ
admet-437	49	12	acetonitrile	acetonitrile	NOUN
admet-437	49	13	containing	contain	VERB
admet-437	49	14	internal	internal	ADJ
admet-437	49	15	standard	standard	NOUN
admet-437	49	16	(	(	PUNCT
admet-437	49	17	200	200	NUM
admet-437	49	18	ng	ng	PROPN
admet-437	49	19	/	/	SYM
admet-437	49	20	ml	ml	PROPN
admet-437	49	21	of	of	ADP
admet-437	49	22	phenacetin	phenacetin	NOUN
admet-437	49	23	)	)	PUNCT
admet-437	49	24	at	at	ADP
admet-437	49	25	specified	specify	VERB
admet-437	49	26	time	time	NOUN
admet-437	49	27	points	point	NOUN
admet-437	49	28	.	.	PUNCT
admet-437	50	1	the	the	DET
admet-437	50	2	vials	vial	NOUN
admet-437	50	3	(	(	PUNCT
admet-437	50	4	having	have	VERB
admet-437	50	5	reaction	reaction	NOUN
admet-437	50	6	mixture	mixture	NOUN
admet-437	50	7	terminated	terminate	VERB
admet-437	50	8	contents	content	NOUN
admet-437	50	9	)	)	PUNCT
admet-437	50	10	were	be	AUX
admet-437	50	11	centrifuged	centrifuge	VERB
admet-437	50	12	at	at	ADP
admet-437	50	13	3000	3000	NUM
admet-437	50	14	rpm	rpm	NOUN
admet-437	50	15	(	(	PUNCT
admet-437	50	16	eppendorf	eppendorf	PROPN
admet-437	50	17	5424r	5424r	NUM
admet-437	50	18	,	,	PUNCT
admet-437	50	19	germany	germany	PROPN
admet-437	50	20	)	)	PUNCT
admet-437	50	21	for	for	ADP
admet-437	50	22	15	15	NUM
admet-437	50	23	min	min	NOUN
admet-437	50	24	.	.	PUNCT
admet-437	51	1	the	the	DET
admet-437	51	2	supernatants	supernatant	NOUN
admet-437	51	3	thus	thus	ADV
admet-437	51	4	obtained	obtain	VERB
admet-437	51	5	were	be	AUX
admet-437	51	6	analyzed	analyze	VERB
admet-437	51	7	on	on	ADP
admet-437	51	8	lc	lc	PROPN
admet-437	51	9	-	-	PUNCT
admet-437	51	10	ms	ms	PROPN
admet-437	51	11	/	/	PROPN
admet-437	51	12	ms	ms	NOUN
admet-437	51	13	to	to	PART
admet-437	51	14	monitor	monitor	VERB
admet-437	51	15	the	the	DET
admet-437	51	16	disappearance	disappearance	NOUN
admet-437	51	17	of	of	ADP
admet-437	51	18	ulixertinib	ulixertinib	NOUN
admet-437	51	19	.	.	PUNCT
admet-437	52	1	clearance	clearance	NOUN
admet-437	52	2	rate	rate	NOUN
admet-437	52	3	and	and	CCONJ
admet-437	52	4	halflife	halflife	NOUN
admet-437	52	5	were	be	AUX
admet-437	52	6	calculated	calculate	VERB
admet-437	52	7	using	use	VERB
admet-437	52	8	the	the	DET
admet-437	52	9	obtained	obtain	VERB
admet-437	52	10	data	datum	NOUN
admet-437	52	11	.	.	PUNCT
admet-437	53	1	caco-2	caco-2	NUM
admet-437	53	2	permeability	permeability	NOUN
admet-437	53	3	caco-2	caco-2	NUM
admet-437	53	4	human	human	ADJ
admet-437	53	5	intestinal	intestinal	ADJ
admet-437	53	6	epithelial	epithelial	ADJ
admet-437	53	7	cells	cell	NOUN
admet-437	53	8	were	be	AUX
admet-437	53	9	plated	plate	VERB
admet-437	53	10	in	in	ADP
admet-437	53	11	24	24	NUM
admet-437	53	12	-	-	PUNCT
admet-437	53	13	transwell	transwell	NOUN
admet-437	53	14	®	®	NOUN
admet-437	53	15	dual	dual	ADJ
admet-437	53	16	chamber	chamber	NOUN
admet-437	53	17	plates	plate	NOUN
admet-437	53	18	(	(	PUNCT
admet-437	53	19	millipore	millipore	PROPN
admet-437	53	20	,	,	PUNCT
admet-437	53	21	billerica	billerica	PROPN
admet-437	53	22	,	,	PUNCT
admet-437	53	23	ma	ma	PROPN
admet-437	53	24	,	,	PUNCT
admet-437	53	25	usa	usa	PROPN
admet-437	53	26	)	)	PUNCT
admet-437	53	27	(	(	PUNCT
admet-437	53	28	cell	cell	NOUN
admet-437	53	29	density	density	NOUN
admet-437	53	30	of	of	ADP
admet-437	53	31	80,000	80,000	NUM
admet-437	53	32	cells	cell	NOUN
admet-437	53	33	/	/	SYM
admet-437	53	34	cm2	cm2	NOUN
admet-437	53	35	on	on	ADP
admet-437	53	36	day-1	day-1	NUM
admet-437	53	37	)	)	PUNCT
admet-437	53	38	.	.	PUNCT
admet-437	54	1	the	the	DET
admet-437	54	2	permeability	permeability	NOUN
admet-437	54	3	studies	study	NOUN
admet-437	54	4	were	be	AUX
admet-437	54	5	conducted	conduct	VERB
admet-437	54	6	with	with	ADP
admet-437	54	7	the	the	DET
admet-437	54	8	monolayers	monolayer	NOUN
admet-437	54	9	cultured	cultured	ADJ
admet-437	54	10	for	for	ADP
admet-437	54	11	21	21	NUM
admet-437	54	12	to	to	PART
admet-437	54	13	22	22	NUM
admet-437	54	14	days	day	NOUN
admet-437	54	15	.	.	PUNCT
admet-437	55	1	the	the	DET
admet-437	55	2	integrity	integrity	NOUN
admet-437	55	3	of	of	ADP
admet-437	55	4	each	each	DET
admet-437	55	5	caco-2	caco-2	NUM
admet-437	55	6	cell	cell	NOUN
admet-437	55	7	monolayer	monolayer	NOUN
admet-437	55	8	was	be	AUX
admet-437	55	9	certified	certify	VERB
admet-437	55	10	by	by	ADP
admet-437	55	11	trans	tran	NOUN
admet-437	55	12	epithelial	epithelial	ADJ
admet-437	55	13	electrical	electrical	ADJ
admet-437	55	14	resistance	resistance	NOUN
admet-437	55	15	(	(	PUNCT
admet-437	55	16	teer	teer	NOUN
admet-437	55	17	)	)	PUNCT
admet-437	55	18	test	test	NOUN
admet-437	55	19	(	(	PUNCT
admet-437	55	20	pre	pre	ADJ
admet-437	55	21	-	-	NOUN
admet-437	55	22	experiment	experiment	NOUN
admet-437	55	23	)	)	PUNCT
admet-437	55	24	and	and	CCONJ
admet-437	55	25	by	by	ADP
admet-437	55	26	determining	determine	VERB
admet-437	55	27	the	the	DET
admet-437	55	28	permeability	permeability	NOUN
admet-437	55	29	of	of	ADP
admet-437	55	30	reference	reference	NOUN
admet-437	55	31	compound	compound	NOUN
admet-437	55	32	i.e.	i.e.	ADV
admet-437	55	33	,	,	PUNCT
admet-437	55	34	lucifer	lucifer	PROPN
admet-437	55	35	yellow	yellow	ADJ
admet-437	55	36	.	.	PUNCT
admet-437	56	1	caco-2	caco-2	NUM
admet-437	56	2	cell	cell	NOUN
admet-437	56	3	monolayers	monolayer	NOUN
admet-437	56	4	with	with	ADP
admet-437	56	5	teer	teer	NOUN
admet-437	56	6	values	value	NOUN
admet-437	56	7	greater	great	ADJ
admet-437	56	8	than	than	ADP
admet-437	56	9	500	500	NUM
admet-437	56	10	ω	ω	NOUN
admet-437	56	11	cm2	cm2	NOUN
admet-437	56	12	were	be	AUX
admet-437	56	13	considered	consider	VERB
admet-437	56	14	for	for	ADP
admet-437	56	15	experimentation	experimentation	NOUN
admet-437	56	16	.	.	PUNCT
admet-437	57	1	digoxin	digoxin	NOUN
admet-437	57	2	(	(	PUNCT
admet-437	57	3	5	5	NUM
admet-437	57	4	µm	µm	NOUN
admet-437	57	5	)	)	PUNCT
admet-437	57	6	was	be	AUX
admet-437	57	7	used	use	VERB
admet-437	57	8	as	as	ADP
admet-437	57	9	a	a	DET
admet-437	57	10	positive	positive	ADJ
admet-437	57	11	control	control	NOUN
admet-437	57	12	for	for	ADP
admet-437	57	13	p	p	NOUN
admet-437	57	14	-	-	PUNCT
admet-437	57	15	gp	gp	NOUN
admet-437	57	16	substrate	substrate	NOUN
admet-437	57	17	[	[	X
admet-437	57	18	10	10	NUM
admet-437	57	19	]	]	PUNCT
admet-437	57	20	.	.	PUNCT
admet-437	58	1	the	the	DET
admet-437	58	2	concentration	concentration	NOUN
admet-437	58	3	of	of	ADP
admet-437	58	4	ulixertinib	ulixertinib	NOUN
admet-437	58	5	used	use	VERB
admet-437	58	6	in	in	ADP
admet-437	58	7	the	the	DET
admet-437	58	8	assay	assay	NOUN
admet-437	58	9	was	be	AUX
admet-437	58	10	10	10	NUM
admet-437	58	11	µm	µm	NOUN
admet-437	58	12	.	.	PUNCT
admet-437	58	13	hbss	hbss	NOUN
admet-437	58	14	buffer	buffer	NOUN
admet-437	58	15	was	be	AUX
admet-437	58	16	used	use	VERB
admet-437	58	17	as	as	ADP
admet-437	58	18	the	the	DET
admet-437	58	19	medium	medium	NOUN
admet-437	58	20	for	for	ADP
admet-437	58	21	the	the	DET
admet-437	58	22	transport	transport	NOUN
admet-437	58	23	assay	assay	VERB
admet-437	58	24	and	and	CCONJ
admet-437	58	25	the	the	DET
admet-437	58	26	final	final	ADJ
admet-437	58	27	concentration	concentration	NOUN
admet-437	58	28	of	of	ADP
admet-437	58	29	dmso	dmso	NOUN
admet-437	58	30	in	in	ADP
admet-437	58	31	spiking	spike	VERB
admet-437	58	32	solution	solution	NOUN
admet-437	58	33	was	be	AUX
admet-437	58	34	0.05	0.05	NUM
admet-437	58	35	%	%	NOUN
admet-437	58	36	.	.	PUNCT
admet-437	59	1	the	the	DET
admet-437	59	2	bidirectional	bidirectional	ADJ
admet-437	59	3	permeability	permeability	NOUN
admet-437	59	4	study	study	NOUN
admet-437	59	5	was	be	AUX
admet-437	59	6	initiated	initiate	VERB
admet-437	59	7	by	by	ADP
admet-437	59	8	adding	add	VERB
admet-437	59	9	an	an	DET
admet-437	59	10	appropriate	appropriate	ADJ
admet-437	59	11	volume	volume	NOUN
admet-437	59	12	of	of	ADP
admet-437	59	13	hbss	hbss	NOUN
admet-437	59	14	buffer	buffer	NOUN
admet-437	59	15	containing	contain	VERB
admet-437	59	16	ulixertinib	ulixertinib	NOUN
admet-437	59	17	to	to	ADP
admet-437	59	18	respective	respective	ADJ
admet-437	59	19	apical	apical	ADJ
admet-437	59	20	and	and	CCONJ
admet-437	59	21	basolateral	basolateral	ADJ
admet-437	59	22	chambers	chamber	NOUN
admet-437	59	23	(	(	PUNCT
admet-437	59	24	n=2	n=2	ADV
admet-437	59	25	)	)	PUNCT
admet-437	60	1	[	[	X
admet-437	60	2	11	11	NUM
admet-437	60	3	]	]	PUNCT
admet-437	60	4	.	.	PUNCT
admet-437	61	1	an	an	DET
admet-437	61	2	aliquot	aliquot	NOUN
admet-437	61	3	of	of	ADP
admet-437	61	4	sample	sample	NOUN
admet-437	61	5	(	(	PUNCT
admet-437	61	6	100	100	NUM
admet-437	61	7	µl	µl	NOUN
admet-437	61	8	)	)	PUNCT
admet-437	61	9	was	be	AUX
admet-437	61	10	taken	take	VERB
admet-437	61	11	from	from	ADP
admet-437	61	12	both	both	DET
admet-437	61	13	chambers	chamber	NOUN
admet-437	61	14	at	at	ADP
admet-437	61	15	0	0	NUM
admet-437	61	16	and	and	CCONJ
admet-437	61	17	60	60	NUM
admet-437	61	18	min	min	NOUN
admet-437	61	19	of	of	ADP
admet-437	61	20	the	the	DET
admet-437	61	21	incubation	incubation	NOUN
admet-437	61	22	period	period	NOUN
admet-437	61	23	and	and	CCONJ
admet-437	61	24	to	to	ADP
admet-437	61	25	this	this	DET
admet-437	61	26	equal	equal	ADJ
admet-437	61	27	volume	volume	NOUN
admet-437	61	28	of	of	ADP
admet-437	61	29	acetonitrile	acetonitrile	NOUN
admet-437	61	30	with	with	ADP
admet-437	61	31	internal	internal	ADJ
admet-437	61	32	standard	standard	NOUN
admet-437	61	33	(	(	PUNCT
admet-437	61	34	200	200	NUM
admet-437	61	35	ng	ng	PROPN
admet-437	61	36	/	/	SYM
admet-437	61	37	ml	ml	PROPN
admet-437	61	38	of	of	ADP
admet-437	61	39	phenacetin	phenacetin	NOUN
admet-437	61	40	)	)	PUNCT
admet-437	61	41	was	be	AUX
admet-437	61	42	added	add	VERB
admet-437	61	43	,	,	PUNCT
admet-437	61	44	mixed	mix	VERB
admet-437	61	45	gently	gently	ADV
admet-437	61	46	and	and	CCONJ
admet-437	61	47	centrifuged	centrifuge	VERB
admet-437	61	48	at	at	ADP
admet-437	61	49	4000	4000	NUM
admet-437	61	50	rpm	rpm	NOUN
admet-437	61	51	(	(	PUNCT
admet-437	61	52	eppendorf	eppendorf	PROPN
admet-437	61	53	5424r	5424r	NUM
admet-437	61	54	,	,	PUNCT
admet-437	61	55	germany	germany	PROPN
admet-437	61	56	)	)	PUNCT
admet-437	61	57	for	for	ADP
admet-437	61	58	10	10	NUM
admet-437	61	59	min	min	NOUN
admet-437	61	60	.	.	PUNCT
admet-437	62	1	an	an	DET
admet-437	62	2	aliquot	aliquot	NOUN
admet-437	62	3	of	of	ADP
admet-437	62	4	100	100	NUM
admet-437	62	5	µl	µl	NOUN
admet-437	62	6	was	be	AUX
admet-437	62	7	subsequently	subsequently	ADV
admet-437	62	8	transferred	transfer	VERB
admet-437	62	9	to	to	ADP
admet-437	62	10	the	the	DET
admet-437	62	11	auto	auto	NOUN
admet-437	62	12	-	-	PUNCT
admet-437	62	13	sampler	sampler	NOUN
admet-437	62	14	and	and	CCONJ
admet-437	62	15	injected	inject	VERB
admet-437	62	16	for	for	ADP
admet-437	62	17	analysis	analysis	NOUN
admet-437	62	18	on	on	ADP
admet-437	62	19	lc	lc	PROPN
admet-437	62	20	-	-	PUNCT
admet-437	62	21	ms	ms	PROPN
admet-437	62	22	/	/	SYM
admet-437	62	23	ms	ms	PROPN
admet-437	62	24	.	.	PROPN
admet-437	62	25	plasma	plasma	NOUN
admet-437	62	26	protein	protein	NOUN
admet-437	62	27	binding	bind	VERB
admet-437	62	28	to	to	PART
admet-437	62	29	evaluate	evaluate	VERB
admet-437	62	30	the	the	DET
admet-437	62	31	ability	ability	NOUN
admet-437	62	32	of	of	ADP
admet-437	62	33	ulixertinib	ulixertinib	NOUN
admet-437	62	34	to	to	PART
admet-437	62	35	bind	bind	VERB
admet-437	62	36	the	the	DET
admet-437	62	37	plasma	plasma	NOUN
admet-437	62	38	proteins	protein	NOUN
admet-437	62	39	,	,	PUNCT
admet-437	62	40	the	the	DET
admet-437	62	41	most	most	ADV
admet-437	62	42	common	common	ADJ
admet-437	62	43	approach	approach	NOUN
admet-437	62	44	of	of	ADP
admet-437	62	45	plasma	plasma	NOUN
admet-437	62	46	protein	protein	NOUN
admet-437	62	47	binding	bind	VERB
admet-437	62	48	using	use	VERB
admet-437	62	49	equilibrium	equilibrium	NOUN
admet-437	62	50	dialysis	dialysis	NOUN
admet-437	62	51	was	be	AUX
admet-437	62	52	used	use	VERB
admet-437	62	53	[	[	X
admet-437	62	54	12	12	NUM
admet-437	62	55	]	]	PUNCT
admet-437	62	56	.	.	PUNCT
admet-437	63	1	ulixertinib	ulixertinib	PROPN
admet-437	63	2	was	be	AUX
admet-437	63	3	tested	test	VERB
admet-437	63	4	at	at	ADP
admet-437	63	5	a	a	DET
admet-437	63	6	final	final	ADJ
admet-437	63	7	concentration	concentration	NOUN
admet-437	63	8	of	of	ADP
admet-437	63	9	3	3	NUM
admet-437	63	10	µm	µm	NOUN
admet-437	63	11	in	in	ADP
admet-437	63	12	mouse	mouse	NOUN
admet-437	63	13	,	,	PUNCT
admet-437	63	14	rat	rat	NOUN
admet-437	63	15	and	and	CCONJ
admet-437	63	16	dog	dog	NOUN
admet-437	63	17	plasma	plasma	NOUN
admet-437	63	18	.	.	PUNCT
admet-437	64	1	an	an	DET
admet-437	64	2	aliquot	aliquot	NOUN
admet-437	64	3	of	of	ADP
admet-437	64	4	150	150	NUM
admet-437	64	5	μl	μl	ADP
admet-437	64	6	plasma	plasma	NOUN
admet-437	64	7	containing	contain	VERB
admet-437	64	8	ulixertinib	ulixertinib	NOUN
admet-437	64	9	was	be	AUX
admet-437	64	10	added	add	VERB
admet-437	64	11	in	in	ADP
admet-437	64	12	first	first	ADJ
admet-437	64	13	half	half	NOUN
admet-437	64	14	(	(	PUNCT
admet-437	64	15	plasma	plasma	NOUN
admet-437	64	16	side	side	NOUN
admet-437	64	17	)	)	PUNCT
admet-437	64	18	of	of	ADP
admet-437	64	19	the	the	DET
admet-437	64	20	well	well	NOUN
admet-437	64	21	of	of	ADP
admet-437	64	22	96	96	NUM
admet-437	64	23	-	-	PUNCT
admet-437	64	24	well	well	NOUN
admet-437	64	25	micro	micro	ADJ
admet-437	64	26	-	-	NOUN
admet-437	64	27	equilibrium	equilibrium	NOUN
admet-437	64	28	dialysis	dialysis	NOUN
admet-437	64	29	device	device	NOUN
admet-437	64	30	.	.	PUNCT
admet-437	65	1	an	an	DET
admet-437	65	2	aliquot	aliquot	NOUN
admet-437	65	3	of	of	ADP
admet-437	65	4	150	150	NUM
admet-437	65	5	μl	μl	ADP
admet-437	65	6	of	of	ADP
admet-437	65	7	100	100	NUM
admet-437	65	8	mm	mm	PROPN
admet-437	65	9	admet	admet	PROPN
admet-437	65	10	&	&	CCONJ
admet-437	65	11	dmpk	dmpk	PROPN
admet-437	65	12	5(4	5(4	NOUN
admet-437	65	13	)	)	PUNCT
admet-437	65	14	(	(	PUNCT
admet-437	65	15	2017	2017	NUM
admet-437	65	16	)	)	PUNCT
admet-437	65	17	212	212	NUM
admet-437	65	18	-	-	SYM
admet-437	65	19	223	223	NUM
admet-437	65	20	preclinical	preclinical	ADJ
admet-437	65	21	assessment	assessment	NOUN
admet-437	65	22	of	of	ADP
admet-437	65	23	ulixertinib	ulixertinib	PROPN
admet-437	65	24	doi	doi	PROPN
admet-437	65	25	:	:	PUNCT
admet-437	65	26	10.5599	10.5599	NUM
admet-437	65	27	/	/	SYM
admet-437	65	28	admet.5.4.437	admet.5.4.437	NUM
admet-437	65	29	215	215	NUM
admet-437	65	30	sodium	sodium	NOUN
admet-437	65	31	phosphate	phosphate	NOUN
admet-437	65	32	buffer	buffer	NOUN
admet-437	65	33	ph	ph	X
admet-437	65	34	7.4	7.4	NUM
admet-437	65	35	was	be	AUX
admet-437	65	36	added	add	VERB
admet-437	65	37	in	in	ADP
admet-437	65	38	the	the	DET
admet-437	65	39	second	second	ADJ
admet-437	65	40	half	half	NOUN
admet-437	65	41	(	(	PUNCT
admet-437	65	42	buffer	buffer	NOUN
admet-437	65	43	side	side	NOUN
admet-437	65	44	)	)	PUNCT
admet-437	65	45	of	of	ADP
admet-437	65	46	the	the	DET
admet-437	65	47	well	well	NOUN
admet-437	65	48	of	of	ADP
admet-437	65	49	96	96	NUM
admet-437	65	50	-	-	PUNCT
admet-437	65	51	well	well	NOUN
admet-437	65	52	ht	ht	PROPN
admet-437	65	53	equilibrium	equilibrium	NOUN
admet-437	65	54	dialysis	dialysis	NOUN
admet-437	65	55	device	device	NOUN
admet-437	65	56	.	.	PUNCT
admet-437	66	1	the	the	DET
admet-437	66	2	plate	plate	NOUN
admet-437	66	3	containing	contain	VERB
admet-437	66	4	plasma	plasma	NOUN
admet-437	66	5	and	and	CCONJ
admet-437	66	6	buffer	buffer	NOUN
admet-437	66	7	was	be	AUX
admet-437	66	8	equilibrated	equilibrate	VERB
admet-437	66	9	at	at	ADP
admet-437	66	10	37	37	NUM
admet-437	66	11	±	±	NUM
admet-437	66	12	1	1	NUM
admet-437	66	13	°	°	ADP
admet-437	66	14	c	c	NOUN
admet-437	66	15	for	for	ADP
admet-437	66	16	4.5	4.5	NUM
admet-437	66	17	h	h	NOUN
admet-437	66	18	,	,	PUNCT
admet-437	66	19	with	with	ADP
admet-437	66	20	constant	constant	ADJ
admet-437	66	21	shaking	shaking	NOUN
admet-437	66	22	at	at	ADP
admet-437	66	23	120	120	NUM
admet-437	66	24	rpm	rpm	NOUN
admet-437	66	25	on	on	ADP
admet-437	66	26	an	an	DET
admet-437	66	27	orbital	orbital	ADJ
admet-437	66	28	shaker	shaker	NOUN
admet-437	66	29	.	.	PUNCT
admet-437	67	1	samples	sample	NOUN
admet-437	67	2	were	be	AUX
admet-437	67	3	collected	collect	VERB
admet-437	67	4	from	from	ADP
admet-437	67	5	respective	respective	ADJ
admet-437	67	6	halves	half	NOUN
admet-437	67	7	after	after	ADP
admet-437	67	8	the	the	DET
admet-437	67	9	completion	completion	NOUN
admet-437	67	10	of	of	ADP
admet-437	67	11	incubation	incubation	NOUN
admet-437	67	12	time	time	NOUN
admet-437	67	13	.	.	PUNCT
admet-437	68	1	the	the	DET
admet-437	68	2	proteins	protein	NOUN
admet-437	68	3	were	be	AUX
admet-437	68	4	precipitated	precipitate	VERB
admet-437	68	5	using	use	VERB
admet-437	68	6	organic	organic	ADJ
admet-437	68	7	solvents	solvent	NOUN
admet-437	68	8	.	.	PUNCT
admet-437	69	1	the	the	DET
admet-437	69	2	samples	sample	NOUN
admet-437	69	3	were	be	AUX
admet-437	69	4	subjected	subject	VERB
admet-437	69	5	to	to	ADP
admet-437	69	6	centrifugation	centrifugation	NOUN
admet-437	69	7	and	and	CCONJ
admet-437	69	8	the	the	DET
admet-437	69	9	supernatants	supernatant	NOUN
admet-437	69	10	were	be	AUX
admet-437	69	11	analyzed	analyze	VERB
admet-437	69	12	analysis	analysis	NOUN
admet-437	69	13	on	on	ADP
admet-437	69	14	lc	lc	PROPN
admet-437	69	15	-	-	PUNCT
admet-437	69	16	ms	ms	PROPN
admet-437	69	17	/	/	SYM
admet-437	69	18	ms	ms	PROPN
admet-437	69	19	.	.	PROPN
admet-437	69	20	cyp	cyp	ADJ
admet-437	69	21	inhibition	inhibition	NOUN
admet-437	69	22	cyp	cyp	ADJ
admet-437	69	23	inhibition	inhibition	NOUN
admet-437	69	24	potential	potential	NOUN
admet-437	69	25	of	of	ADP
admet-437	69	26	ulixertinib	ulixertinib	NOUN
admet-437	69	27	was	be	AUX
admet-437	69	28	assessed	assess	VERB
admet-437	69	29	in	in	ADP
admet-437	70	1	human	human	ADJ
admet-437	70	2	liver	liver	NOUN
admet-437	70	3	microsomes	microsome	NOUN
admet-437	71	1	[	[	X
admet-437	71	2	life	life	NOUN
admet-437	71	3	technologies	technology	NOUN
admet-437	71	4	(	(	PUNCT
admet-437	71	5	gibco	gibco	NOUN
admet-437	71	6	®	®	NOUN
admet-437	71	7	)	)	PUNCT
admet-437	71	8	,	,	PUNCT
admet-437	71	9	inchinnan	inchinnan	PROPN
admet-437	71	10	,	,	PUNCT
admet-437	71	11	uk	uk	PROPN
admet-437	71	12	]	]	PUNCT
admet-437	71	13	against	against	ADP
admet-437	71	14	cyp3a4	cyp3a4	NOUN
admet-437	71	15	,	,	PUNCT
admet-437	71	16	2d6	2d6	NUM
admet-437	71	17	,	,	PUNCT
admet-437	71	18	1a2	1a2	NUM
admet-437	71	19	,	,	PUNCT
admet-437	71	20	2c9	2c9	NUM
admet-437	71	21	and	and	CCONJ
admet-437	71	22	2c19	2c19	NOUN
admet-437	71	23	in	in	ADP
admet-437	71	24	the	the	DET
admet-437	71	25	following	follow	VERB
admet-437	71	26	sequential	sequential	ADJ
admet-437	71	27	steps	step	NOUN
admet-437	71	28	.	.	PUNCT
admet-437	72	1	standard	standard	ADJ
admet-437	72	2	reaction	reaction	NOUN
admet-437	72	3	mixture	mixture	NOUN
admet-437	72	4	(	(	PUNCT
admet-437	72	5	final	final	ADJ
admet-437	72	6	volume	volume	NOUN
admet-437	72	7	300	300	NUM
admet-437	72	8	μl	μl	PRON
admet-437	72	9	)	)	PUNCT
admet-437	72	10	contained	contain	VERB
admet-437	72	11	66.7	66.7	NUM
admet-437	72	12	m	m	NOUN
admet-437	72	13	potassium	potassium	NOUN
admet-437	72	14	phosphate	phosphate	NOUN
admet-437	72	15	buffer	buffer	NOUN
admet-437	72	16	(	(	PUNCT
admet-437	72	17	ph	ph	NOUN
admet-437	72	18	7.4	7.4	NUM
admet-437	72	19	)	)	PUNCT
admet-437	72	20	,	,	PUNCT
admet-437	72	21	protein	protein	NOUN
admet-437	73	1	[	[	X
admet-437	73	2	0.1	0.1	NUM
admet-437	73	3	(	(	PUNCT
admet-437	73	4	for	for	ADP
admet-437	73	5	cyp3a4	cyp3a4	NOUN
admet-437	73	6	)	)	PUNCT
admet-437	73	7	,	,	PUNCT
admet-437	73	8	0.25	0.25	NUM
admet-437	73	9	(	(	PUNCT
admet-437	73	10	for	for	ADP
admet-437	73	11	cyp2d6	cyp2d6	NOUN
admet-437	73	12	)	)	PUNCT
admet-437	73	13	,	,	PUNCT
admet-437	73	14	0.5	0.5	NUM
admet-437	73	15	mg	mg	NUM
admet-437	73	16	/	/	SYM
admet-437	73	17	ml	ml	PROPN
admet-437	73	18	(	(	PUNCT
admet-437	73	19	for	for	ADP
admet-437	73	20	cyp1a2	cyp1a2	NOUN
admet-437	73	21	,	,	PUNCT
admet-437	73	22	2c9	2c9	NUM
admet-437	73	23	and	and	CCONJ
admet-437	73	24	2c19	2c19	NUM
admet-437	73	25	)	)	PUNCT
admet-437	73	26	]	]	PUNCT
admet-437	73	27	and	and	CCONJ
admet-437	73	28	ulixertinib	ulixertinib	PROPN
admet-437	73	29	(	(	PUNCT
admet-437	73	30	at	at	ADP
admet-437	73	31	2.0	2.0	NUM
admet-437	73	32	,	,	PUNCT
admet-437	73	33	10	10	NUM
admet-437	73	34	and	and	CCONJ
admet-437	73	35	20	20	NUM
admet-437	73	36	µm	µm	NOUN
admet-437	73	37	,	,	PUNCT
admet-437	73	38	added	add	VERB
admet-437	73	39	as	as	ADP
admet-437	73	40	0.9	0.9	NUM
admet-437	73	41	µl	µl	ADP
admet-437	73	42	dmso	dmso	ADJ
admet-437	73	43	solution	solution	NOUN
admet-437	73	44	with	with	ADP
admet-437	73	45	a	a	DET
admet-437	73	46	final	final	ADJ
admet-437	73	47	dmso	dmso	NOUN
admet-437	73	48	concentration	concentration	NOUN
admet-437	73	49	of	of	ADP
admet-437	73	50	0.1	0.1	NUM
admet-437	73	51	%	%	NOUN
admet-437	73	52	)	)	PUNCT
admet-437	73	53	.	.	PUNCT
admet-437	74	1	the	the	DET
admet-437	74	2	mixtures	mixture	NOUN
admet-437	74	3	were	be	AUX
admet-437	74	4	pre	pre	ADJ
admet-437	74	5	-	-	VERB
admet-437	74	6	incubated	incubate	VERB
admet-437	74	7	at	at	ADP
admet-437	74	8	37	37	NUM
admet-437	74	9	±	±	NUM
admet-437	74	10	1	1	NUM
admet-437	74	11	°	°	ADP
admet-437	74	12	c	c	NOUN
admet-437	74	13	for	for	ADP
admet-437	74	14	5	5	NUM
admet-437	74	15	min	min	NOUN
admet-437	74	16	.	.	PUNCT
admet-437	75	1	the	the	DET
admet-437	75	2	reaction	reaction	NOUN
admet-437	75	3	(	(	PUNCT
admet-437	75	4	in	in	ADP
admet-437	75	5	duplicate	duplicate	NOUN
admet-437	75	6	)	)	PUNCT
admet-437	75	7	was	be	AUX
admet-437	75	8	initiated	initiate	VERB
admet-437	75	9	by	by	ADP
admet-437	75	10	addition	addition	NOUN
admet-437	75	11	of	of	ADP
admet-437	75	12	30	30	NUM
admet-437	75	13	µl	µl	NOUN
admet-437	75	14	of	of	ADP
admet-437	75	15	nadph	nadph	ADJ
admet-437	75	16	(	(	PUNCT
admet-437	75	17	10	10	NUM
admet-437	75	18	mm	mm	NOUN
admet-437	75	19	)	)	PUNCT
admet-437	76	1	[	[	X
admet-437	76	2	13	13	NUM
admet-437	76	3	]	]	PUNCT
admet-437	76	4	.	.	PUNCT
admet-437	77	1	reaction	reaction	NOUN
admet-437	77	2	was	be	AUX
admet-437	77	3	terminated	terminate	VERB
admet-437	77	4	at	at	ADP
admet-437	77	5	10	10	NUM
admet-437	77	6	min	min	NOUN
admet-437	77	7	by	by	ADP
admet-437	77	8	adding	add	VERB
admet-437	77	9	300	300	NUM
admet-437	77	10	µl	µl	NOUN
admet-437	77	11	of	of	ADP
admet-437	77	12	ice	ice	NOUN
admet-437	77	13	cold	cold	ADJ
admet-437	77	14	acetonitrile	acetonitrile	NOUN
admet-437	77	15	with	with	ADP
admet-437	77	16	internal	internal	ADJ
admet-437	77	17	standard	standard	NOUN
admet-437	77	18	.	.	PUNCT
admet-437	78	1	the	the	DET
admet-437	78	2	activity	activity	NOUN
admet-437	78	3	of	of	ADP
admet-437	78	4	liver	liver	NOUN
admet-437	78	5	microsomes	microsome	NOUN
admet-437	78	6	was	be	AUX
admet-437	78	7	confirmed	confirm	VERB
admet-437	78	8	with	with	ADP
admet-437	78	9	positive	positive	ADJ
admet-437	78	10	controls	control	NOUN
admet-437	78	11	i.e.	i.e.	ADV
admet-437	78	12	,	,	PUNCT
admet-437	78	13	monitoring	monitor	VERB
admet-437	78	14	the	the	DET
admet-437	78	15	hydroxylation	hydroxylation	NOUN
admet-437	78	16	of	of	ADP
admet-437	78	17	midazolam	midazolam	PROPN
admet-437	78	18	,	,	PUNCT
admet-437	78	19	bufuralol	bufuralol	NOUN
admet-437	78	20	,	,	PUNCT
admet-437	78	21	diclofenac	diclofenac	NOUN
admet-437	78	22	and	and	CCONJ
admet-437	78	23	omeprazole	omeprazole	NOUN
admet-437	78	24	for	for	ADP
admet-437	78	25	cyp3a4	cyp3a4	NOUN
admet-437	78	26	,	,	PUNCT
admet-437	78	27	2d6	2d6	NUM
admet-437	78	28	,	,	PUNCT
admet-437	78	29	2c9	2c9	NUM
admet-437	78	30	and	and	CCONJ
admet-437	78	31	2c19	2c19	NOUN
admet-437	78	32	,	,	PUNCT
admet-437	78	33	respectively	respectively	ADV
admet-437	78	34	and	and	CCONJ
admet-437	78	35	deethylation	deethylation	NOUN
admet-437	78	36	of	of	ADP
admet-437	78	37	phenacetin	phenacetin	NOUN
admet-437	78	38	for	for	ADP
admet-437	78	39	cyp1a2	cyp1a2	NOUN
admet-437	78	40	(	(	PUNCT
admet-437	78	41	data	datum	NOUN
admet-437	78	42	not	not	PART
admet-437	78	43	shown	show	VERB
admet-437	78	44	)	)	PUNCT
admet-437	78	45	.	.	PUNCT
admet-437	79	1	the	the	DET
admet-437	79	2	reaction	reaction	NOUN
admet-437	79	3	mixtures	mixture	NOUN
admet-437	79	4	(	(	PUNCT
admet-437	79	5	obtained	obtain	VERB
admet-437	79	6	from	from	ADP
admet-437	79	7	the	the	DET
admet-437	79	8	above	above	ADJ
admet-437	79	9	studies	study	NOUN
admet-437	79	10	)	)	PUNCT
admet-437	79	11	were	be	AUX
admet-437	79	12	extracted	extract	VERB
admet-437	79	13	,	,	PUNCT
admet-437	79	14	processed	process	VERB
admet-437	79	15	,	,	PUNCT
admet-437	79	16	analyzed	analyze	VERB
admet-437	79	17	on	on	ADP
admet-437	79	18	lc	lc	PROPN
admet-437	79	19	-	-	PUNCT
admet-437	79	20	ms	ms	PROPN
admet-437	79	21	/	/	SYM
admet-437	79	22	ms	ms	PROPN
admet-437	79	23	.	.	PROPN
admet-437	79	24	rhcyp	rhcyp	PROPN
admet-437	79	25	metabolism	metabolism	NOUN
admet-437	79	26	to	to	PART
admet-437	79	27	evaluate	evaluate	VERB
admet-437	79	28	the	the	DET
admet-437	79	29	metabolism	metabolism	NOUN
admet-437	79	30	of	of	ADP
admet-437	79	31	ulixertinib	ulixertinib	NOUN
admet-437	79	32	,	,	PUNCT
admet-437	79	33	the	the	DET
admet-437	79	34	most	most	ADV
admet-437	79	35	common	common	ADJ
admet-437	79	36	approach	approach	NOUN
admet-437	79	37	of	of	ADP
admet-437	79	38	reaction	reaction	NOUN
admet-437	79	39	phenotyping	phenotype	VERB
admet-437	79	40	by	by	ADP
admet-437	79	41	using	use	VERB
admet-437	79	42	cdna	cdna	PROPN
admet-437	79	43	expressed	express	VERB
admet-437	79	44	enzyme	enzyme	NOUN
admet-437	79	45	system	system	NOUN
admet-437	79	46	was	be	AUX
admet-437	79	47	used	use	VERB
admet-437	79	48	.	.	PUNCT
admet-437	80	1	ulixertinib	ulixertinib	PROPN
admet-437	80	2	was	be	AUX
admet-437	80	3	incubated	incubate	VERB
admet-437	80	4	with	with	ADP
admet-437	80	5	a	a	DET
admet-437	80	6	panel	panel	NOUN
admet-437	80	7	of	of	ADP
admet-437	80	8	individually	individually	ADV
admet-437	80	9	-	-	PUNCT
admet-437	80	10	expressed	express	VERB
admet-437	80	11	recombinant	recombinant	ADJ
admet-437	80	12	human	human	ADJ
admet-437	80	13	cyp	cyp	ADJ
admet-437	80	14	enzymes	enzyme	NOUN
admet-437	80	15	(	(	PUNCT
admet-437	80	16	cyp1a2	cyp1a2	PROPN
admet-437	80	17	,	,	PUNCT
admet-437	80	18	2b6	2b6	NUM
admet-437	80	19	,	,	PUNCT
admet-437	80	20	2c8	2c8	NUM
admet-437	80	21	,	,	PUNCT
admet-437	80	22	2c9	2c9	NUM
admet-437	80	23	,	,	PUNCT
admet-437	80	24	2c19	2c19	NOUN
admet-437	80	25	,	,	PUNCT
admet-437	80	26	2d6	2d6	NUM
admet-437	80	27	and	and	CCONJ
admet-437	80	28	3a4	3a4	NUM
admet-437	80	29	,	,	PUNCT
admet-437	80	30	purchased	purchase	VERB
admet-437	80	31	from	from	ADP
admet-437	80	32	life	life	NOUN
admet-437	80	33	technologies	technology	NOUN
admet-437	80	34	(	(	PUNCT
admet-437	80	35	gibco	gibco	NOUN
admet-437	80	36	®	®	NOUN
admet-437	80	37	)	)	PUNCT
admet-437	80	38	,	,	PUNCT
admet-437	80	39	inchinnan	inchinnan	PROPN
admet-437	80	40	,	,	PUNCT
admet-437	80	41	uk	uk	PROPN
admet-437	80	42	expressed	express	VERB
admet-437	80	43	in	in	ADP
admet-437	80	44	baculovirus	baculovirus	NOUN
admet-437	80	45	-	-	PUNCT
admet-437	80	46	infected	infect	VERB
admet-437	80	47	insect	insect	NOUN
admet-437	80	48	cell	cell	NOUN
admet-437	80	49	membranes	membrane	NOUN
admet-437	80	50	.	.	PUNCT
admet-437	81	1	the	the	DET
admet-437	81	2	incubation	incubation	NOUN
admet-437	81	3	mixture	mixture	NOUN
admet-437	81	4	contained	contain	VERB
admet-437	81	5	ulixertinib	ulixertinib	NOUN
admet-437	81	6	at	at	ADP
admet-437	81	7	a	a	DET
admet-437	81	8	final	final	ADJ
admet-437	81	9	concentration	concentration	NOUN
admet-437	81	10	of	of	ADP
admet-437	81	11	0.1	0.1	NUM
admet-437	81	12	μm	μm	NUM
admet-437	81	13	,	,	PUNCT
admet-437	81	14	expressed	express	VERB
admet-437	81	15	cyp	cyp	ADJ
admet-437	81	16	enzyme	enzyme	NOUN
admet-437	81	17	(	(	PUNCT
admet-437	81	18	50	50	NUM
admet-437	81	19	pmol	pmol	NOUN
admet-437	81	20	/	/	SYM
admet-437	81	21	ml	ml	NOUN
admet-437	81	22	)	)	PUNCT
admet-437	81	23	,	,	PUNCT
admet-437	81	24	phosphate	phosphate	NOUN
admet-437	81	25	buffer	buffer	NOUN
admet-437	81	26	(	(	PUNCT
admet-437	81	27	66.7	66.7	NUM
admet-437	81	28	mm	mm	NOUN
admet-437	81	29	,	,	PUNCT
admet-437	81	30	ph	ph	NOUN
admet-437	81	31	7.4	7.4	NUM
admet-437	81	32	)	)	PUNCT
admet-437	81	33	in	in	ADP
admet-437	81	34	a	a	DET
admet-437	81	35	total	total	ADJ
admet-437	81	36	volume	volume	NOUN
admet-437	81	37	of	of	ADP
admet-437	81	38	1	1	NUM
admet-437	81	39	ml	ml	NOUN
admet-437	81	40	.	.	PUNCT
admet-437	82	1	the	the	DET
admet-437	82	2	reaction	reaction	NOUN
admet-437	82	3	was	be	AUX
admet-437	82	4	initiated	initiate	VERB
admet-437	82	5	by	by	ADP
admet-437	82	6	the	the	DET
admet-437	82	7	addition	addition	NOUN
admet-437	82	8	of	of	ADP
admet-437	82	9	20	20	NUM
admet-437	82	10	µl	µl	NOUN
admet-437	82	11	of	of	ADP
admet-437	82	12	nadph	nadph	ADJ
admet-437	82	13	after	after	ADP
admet-437	82	14	pre	pre	NOUN
admet-437	82	15	-	-	NOUN
admet-437	82	16	incubation	incubation	NOUN
admet-437	82	17	of	of	ADP
admet-437	82	18	the	the	DET
admet-437	82	19	aliquots	aliquot	NOUN
admet-437	82	20	(	(	PUNCT
admet-437	82	21	180	180	NUM
admet-437	82	22	µl	µl	NOUN
admet-437	82	23	)	)	PUNCT
admet-437	82	24	marked	mark	VERB
admet-437	82	25	0	0	NUM
admet-437	82	26	,	,	PUNCT
admet-437	82	27	5	5	NUM
admet-437	82	28	,	,	PUNCT
admet-437	82	29	15	15	NUM
admet-437	82	30	,	,	PUNCT
admet-437	82	31	30	30	NUM
admet-437	82	32	and	and	CCONJ
admet-437	82	33	60	60	NUM
admet-437	82	34	min	min	NOUN
admet-437	82	35	followed	follow	VERB
admet-437	82	36	by	by	ADP
admet-437	82	37	incubation	incubation	NOUN
admet-437	82	38	at	at	ADP
admet-437	82	39	37	37	NUM
admet-437	82	40	±	±	NUM
admet-437	82	41	1	1	NUM
admet-437	82	42	°	°	SYM
admet-437	82	43	c	c	NOUN
admet-437	82	44	.	.	PUNCT
admet-437	83	1	the	the	DET
admet-437	83	2	reaction	reaction	NOUN
admet-437	83	3	was	be	AUX
admet-437	83	4	terminated	terminate	VERB
admet-437	83	5	by	by	ADP
admet-437	83	6	the	the	DET
admet-437	83	7	addition	addition	NOUN
admet-437	83	8	of	of	ADP
admet-437	83	9	equal	equal	ADJ
admet-437	83	10	volumes	volume	NOUN
admet-437	83	11	of	of	ADP
admet-437	83	12	ice	ice	NOUN
admet-437	83	13	cold	cold	ADJ
admet-437	83	14	acetonitrile	acetonitrile	NOUN
admet-437	83	15	with	with	ADP
admet-437	83	16	internal	internal	ADJ
admet-437	83	17	standard	standard	NOUN
admet-437	83	18	(	(	PUNCT
admet-437	83	19	200	200	NUM
admet-437	83	20	ng	ng	PROPN
admet-437	83	21	/	/	SYM
admet-437	83	22	ml	ml	PROPN
admet-437	83	23	of	of	ADP
admet-437	83	24	phenacetin	phenacetin	NOUN
admet-437	83	25	)	)	PUNCT
admet-437	83	26	.	.	PUNCT
admet-437	84	1	the	the	DET
admet-437	84	2	samples	sample	NOUN
admet-437	84	3	were	be	AUX
admet-437	84	4	centrifuged	centrifuge	VERB
admet-437	84	5	at	at	ADP
admet-437	84	6	3000	3000	NUM
admet-437	84	7	rpm	rpm	NOUN
admet-437	84	8	(	(	PUNCT
admet-437	84	9	eppendorf	eppendorf	PROPN
admet-437	84	10	5424r	5424r	NUM
admet-437	84	11	,	,	PUNCT
admet-437	84	12	germany	germany	PROPN
admet-437	84	13	)	)	PUNCT
admet-437	84	14	at	at	ADP
admet-437	84	15	4	4	NUM
admet-437	84	16	°	°	ADP
admet-437	84	17	c	c	NOUN
admet-437	84	18	for	for	SCONJ
admet-437	84	19	20	20	NUM
admet-437	84	20	min	min	NOUN
admet-437	84	21	to	to	PART
admet-437	84	22	precipitate	precipitate	VERB
admet-437	84	23	proteins	protein	NOUN
admet-437	84	24	.	.	PUNCT
admet-437	85	1	supernatants	supernatant	NOUN
admet-437	85	2	were	be	AUX
admet-437	85	3	then	then	ADV
admet-437	85	4	transferred	transfer	VERB
admet-437	85	5	to	to	ADP
admet-437	85	6	clean	clean	ADJ
admet-437	85	7	vials	vial	NOUN
admet-437	85	8	and	and	CCONJ
admet-437	85	9	stored	store	VERB
admet-437	85	10	at	at	ADP
admet-437	85	11	-20	-20	NUM
admet-437	85	12	°	°	ADP
admet-437	85	13	c	c	NOUN
admet-437	85	14	until	until	ADP
admet-437	85	15	analysis	analysis	NOUN
admet-437	85	16	.	.	PUNCT
admet-437	86	1	incubations	incubation	NOUN
admet-437	86	2	without	without	ADP
admet-437	86	3	nadph	nadph	PROPN
admet-437	86	4	were	be	AUX
admet-437	86	5	used	use	VERB
admet-437	86	6	as	as	ADP
admet-437	86	7	negative	negative	ADJ
admet-437	86	8	controls	control	NOUN
admet-437	86	9	.	.	PUNCT
admet-437	87	1	control	control	NOUN
admet-437	87	2	incubations	incubation	NOUN
admet-437	87	3	using	use	VERB
admet-437	87	4	probe	probe	NOUN
admet-437	87	5	substrates	substrate	NOUN
admet-437	87	6	for	for	ADP
admet-437	87	7	individual	individual	ADJ
admet-437	87	8	recombinant	recombinant	ADJ
admet-437	87	9	humans	human	NOUN
admet-437	87	10	cyps	cyp	NOUN
admet-437	87	11	were	be	AUX
admet-437	87	12	included	include	VERB
admet-437	87	13	to	to	PART
admet-437	87	14	check	check	VERB
admet-437	87	15	for	for	ADP
admet-437	87	16	appropriate	appropriate	ADJ
admet-437	87	17	incubation	incubation	NOUN
admet-437	87	18	conditions	condition	NOUN
admet-437	87	19	and	and	CCONJ
admet-437	87	20	as	as	ADP
admet-437	87	21	positive	positive	ADJ
admet-437	87	22	control	control	NOUN
admet-437	87	23	for	for	ADP
admet-437	87	24	activity	activity	NOUN
admet-437	87	25	[	[	X
admet-437	87	26	15	15	NUM
admet-437	87	27	]	]	PUNCT
admet-437	87	28	.	.	PUNCT
admet-437	88	1	the	the	DET
admet-437	88	2	samples	sample	NOUN
admet-437	88	3	were	be	AUX
admet-437	88	4	analyzed	analyze	VERB
admet-437	88	5	on	on	ADP
admet-437	88	6	lc	lc	PROPN
admet-437	88	7	-	-	PUNCT
admet-437	88	8	ms	ms	PROPN
admet-437	88	9	/	/	SYM
admet-437	88	10	ms	ms	PROPN
admet-437	88	11	.	.	PROPN
admet-437	88	12	disappearance	disappearance	NOUN
admet-437	88	13	of	of	ADP
admet-437	88	14	ulixertinib	ulixertinib	NOUN
admet-437	88	15	was	be	AUX
admet-437	88	16	compared	compare	VERB
admet-437	88	17	to	to	ADP
admet-437	88	18	that	that	PRON
admet-437	88	19	of	of	ADP
admet-437	88	20	control	control	NOUN
admet-437	88	21	treatment	treatment	NOUN
admet-437	88	22	(	(	PUNCT
admet-437	88	23	no	no	DET
admet-437	88	24	cyp	cyp	ADJ
admet-437	88	25	enzymes	enzyme	NOUN
admet-437	88	26	present	present	ADJ
admet-437	88	27	)	)	PUNCT
admet-437	88	28	in	in	ADP
admet-437	88	29	order	order	NOUN
admet-437	88	30	to	to	PART
admet-437	88	31	assess	assess	VERB
admet-437	88	32	the	the	DET
admet-437	88	33	contribution	contribution	NOUN
admet-437	88	34	of	of	ADP
admet-437	88	35	a	a	DET
admet-437	88	36	given	give	VERB
admet-437	88	37	cyp	cyp	NOUN
admet-437	88	38	in	in	ADP
admet-437	88	39	ulixertinib	ulixertinib	ADJ
admet-437	88	40	metabolism	metabolism	NOUN
admet-437	88	41	.	.	PUNCT
admet-437	89	1	in	in	ADP
admet-437	89	2	vivo	vivo	ADJ
admet-437	89	3	studies	study	NOUN
admet-437	89	4	formulations	formulation	NOUN
admet-437	89	5	for	for	ADP
admet-437	89	6	oral	oral	ADJ
admet-437	89	7	administration	administration	NOUN
admet-437	89	8	a	a	DET
admet-437	89	9	suspension	suspension	NOUN
admet-437	89	10	formulation	formulation	NOUN
admet-437	89	11	was	be	AUX
admet-437	89	12	prepared	prepare	VERB
admet-437	89	13	using	use	VERB
admet-437	89	14	tween-80	tween-80	NUM
admet-437	89	15	and	and	CCONJ
admet-437	89	16	0.5	0.5	NUM
admet-437	89	17	%	%	NOUN
admet-437	89	18	methyl	methyl	NOUN
admet-437	89	19	cellulose	cellulose	NOUN
admet-437	89	20	.	.	PUNCT
admet-437	90	1	weighed	weigh	VERB
admet-437	90	2	amount	amount	NOUN
admet-437	90	3	of	of	ADP
admet-437	90	4	ulixertinib	ulixertinib	NOUN
admet-437	90	5	was	be	AUX
admet-437	90	6	taken	take	VERB
admet-437	90	7	into	into	ADP
admet-437	90	8	a	a	DET
admet-437	90	9	mortar	mortar	NOUN
admet-437	90	10	and	and	CCONJ
admet-437	90	11	grinded	grind	VERB
admet-437	90	12	into	into	ADP
admet-437	90	13	a	a	DET
admet-437	90	14	fine	fine	ADJ
admet-437	90	15	powder	powder	NOUN
admet-437	90	16	with	with	ADP
admet-437	90	17	the	the	DET
admet-437	90	18	help	help	NOUN
admet-437	90	19	of	of	ADP
admet-437	90	20	a	a	DET
admet-437	90	21	pestle	pestle	NOUN
admet-437	90	22	.	.	PUNCT
admet-437	91	1	to	to	ADP
admet-437	91	2	this	this	DET
admet-437	91	3	tween-80	tween-80	NUM
admet-437	91	4	was	be	AUX
admet-437	91	5	added	add	VERB
admet-437	91	6	drop	drop	NOUN
admet-437	91	7	wise	wise	ADJ
admet-437	91	8	to	to	PART
admet-437	91	9	wet	wet	VERB
admet-437	91	10	the	the	DET
admet-437	91	11	entire	entire	ADJ
admet-437	91	12	powder	powder	NOUN
admet-437	91	13	.	.	PUNCT
admet-437	92	1	then	then	ADV
admet-437	92	2	slowly	slowly	ADV
admet-437	92	3	0.5	0.5	NUM
admet-437	92	4	%	%	NOUN
admet-437	92	5	methyl	methyl	NOUN
admet-437	92	6	cellulose	cellulose	NOUN
admet-437	92	7	was	be	AUX
admet-437	92	8	added	add	VERB
admet-437	92	9	with	with	ADP
admet-437	92	10	constant	constant	ADJ
admet-437	92	11	stirring	stirring	NOUN
admet-437	92	12	to	to	PART
admet-437	92	13	get	get	VERB
admet-437	92	14	a	a	DET
admet-437	92	15	uniform	uniform	ADJ
admet-437	92	16	suspension	suspension	NOUN
admet-437	92	17	.	.	PUNCT
admet-437	93	1	the	the	DET
admet-437	93	2	final	final	ADJ
admet-437	93	3	strength	strength	NOUN
admet-437	93	4	of	of	ADP
admet-437	93	5	the	the	DET
admet-437	93	6	suspension	suspension	NOUN
admet-437	93	7	formulation	formulation	NOUN
admet-437	93	8	was	be	AUX
admet-437	93	9	10	10	NUM
admet-437	93	10	mg	mg	NUM
admet-437	93	11	/	/	SYM
admet-437	93	12	ml	ml	NOUN
admet-437	94	1	and	and	CCONJ
admet-437	94	2	it	it	PRON
admet-437	94	3	was	be	AUX
admet-437	94	4	administered	administer	VERB
admet-437	94	5	to	to	AUX
admet-437	94	6	animal	animal	NOUN
admet-437	94	7	species	specie	NOUN
admet-437	94	8	at	at	ADP
admet-437	94	9	10	10	NUM
admet-437	94	10	ml	ml	NOUN
admet-437	94	11	/	/	SYM
admet-437	94	12	kg	kg	PROPN
admet-437	94	13	body	body	NOUN
admet-437	94	14	weight	weight	NOUN
admet-437	94	15	.	.	PUNCT
admet-437	95	1	for	for	ADP
admet-437	95	2	intravenous	intravenous	ADJ
admet-437	95	3	(	(	PUNCT
admet-437	95	4	i.v	i.v	PROPN
admet-437	95	5	.	.	PUNCT
admet-437	95	6	)	)	PUNCT
admet-437	96	1	administration	administration	NOUN
admet-437	96	2	a	a	DET
admet-437	96	3	solution	solution	NOUN
admet-437	96	4	formulation	formulation	NOUN
admet-437	96	5	was	be	AUX
admet-437	96	6	used	use	VERB
admet-437	96	7	(	(	PUNCT
admet-437	96	8	prepared	prepare	VERB
admet-437	96	9	using	use	VERB
admet-437	96	10	10	10	NUM
admet-437	96	11	%	%	NOUN
admet-437	96	12	dmso	dmso	NOUN
admet-437	96	13	,	,	PUNCT
admet-437	96	14	10	10	NUM
admet-437	96	15	%	%	NOUN
admet-437	96	16	r.	r.	PROPN
admet-437	96	17	mullangi	mullangi	PROPN
admet-437	96	18	et	et	PROPN
admet-437	96	19	al	al	PROPN
admet-437	96	20	.	.	PROPN
admet-437	96	21	admet	admet	PROPN
admet-437	96	22	&	&	CCONJ
admet-437	96	23	dmpk	dmpk	PROPN
admet-437	96	24	5(4	5(4	NOUN
admet-437	96	25	)	)	PUNCT
admet-437	96	26	(	(	PUNCT
admet-437	96	27	2017	2017	NUM
admet-437	96	28	)	)	PUNCT
admet-437	97	1	212	212	NUM
admet-437	97	2	-	-	SYM
admet-437	97	3	223	223	NUM
admet-437	97	4	216	216	NUM
admet-437	97	5	solutol	solutol	NOUN
admet-437	97	6	:	:	PUNCT
admet-437	97	7	absolute	absolute	ADJ
admet-437	97	8	ethyl	ethyl	PROPN
admet-437	97	9	alcohol	alcohol	NOUN
admet-437	97	10	(	(	PUNCT
admet-437	97	11	1:1	1:1	NUM
admet-437	97	12	,	,	PUNCT
admet-437	97	13	v	v	NOUN
admet-437	97	14	/	/	SYM
admet-437	97	15	v	v	NOUN
admet-437	97	16	)	)	PUNCT
admet-437	97	17	and	and	CCONJ
admet-437	97	18	80	80	NUM
admet-437	97	19	%	%	NOUN
admet-437	97	20	normal	normal	ADJ
admet-437	97	21	saline	saline	NOUN
admet-437	97	22	)	)	PUNCT
admet-437	97	23	.	.	PUNCT
admet-437	98	1	the	the	DET
admet-437	98	2	volume	volume	NOUN
admet-437	98	3	of	of	ADP
admet-437	98	4	administration	administration	NOUN
admet-437	98	5	for	for	ADP
admet-437	98	6	intravenous	intravenous	ADJ
admet-437	98	7	was	be	AUX
admet-437	98	8	10	10	NUM
admet-437	98	9	ml	ml	NOUN
admet-437	98	10	/	/	SYM
admet-437	98	11	kg	kg	NOUN
admet-437	98	12	for	for	ADP
admet-437	98	13	mice	mouse	NOUN
admet-437	98	14	and	and	CCONJ
admet-437	98	15	2	2	NUM
admet-437	98	16	ml	ml	NOUN
admet-437	98	17	/	/	SYM
admet-437	98	18	kg	kg	NOUN
admet-437	98	19	for	for	ADP
admet-437	98	20	rats	rat	NOUN
admet-437	98	21	and	and	CCONJ
admet-437	98	22	dogs	dog	NOUN
admet-437	98	23	.	.	PUNCT
admet-437	99	1	animal	animal	NOUN
admet-437	99	2	experiments	experiment	NOUN
admet-437	99	3	details	detail	NOUN
admet-437	99	4	institutional	institutional	ADJ
admet-437	99	5	animal	animal	NOUN
admet-437	99	6	ethical	ethical	PROPN
admet-437	99	7	committee	committee	NOUN
admet-437	99	8	(	(	PUNCT
admet-437	99	9	iaec	iaec	NOUN
admet-437	99	10	)	)	PUNCT
admet-437	99	11	of	of	ADP
admet-437	99	12	jubilant	jubilant	ADJ
admet-437	99	13	biosys	biosys	NOUN
admet-437	99	14	(	(	PUNCT
admet-437	99	15	iaec	iaec	NOUN
admet-437	99	16	/	/	SYM
admet-437	99	17	jdc/2017/121	jdc/2017/121	NOUN
admet-437	99	18	)	)	PUNCT
admet-437	99	19	nominated	nominate	VERB
admet-437	99	20	by	by	ADP
admet-437	99	21	cpcsea	cpcsea	PROPN
admet-437	99	22	(	(	PUNCT
admet-437	99	23	committee	committee	NOUN
admet-437	99	24	for	for	ADP
admet-437	99	25	the	the	DET
admet-437	99	26	purpose	purpose	NOUN
admet-437	99	27	of	of	ADP
admet-437	99	28	control	control	NOUN
admet-437	99	29	and	and	CCONJ
admet-437	99	30	supervision	supervision	NOUN
admet-437	99	31	of	of	ADP
admet-437	99	32	experiments	experiment	NOUN
admet-437	99	33	on	on	ADP
admet-437	99	34	animals	animal	NOUN
admet-437	99	35	)	)	PUNCT
admet-437	99	36	approved	approve	VERB
admet-437	99	37	the	the	DET
admet-437	99	38	rodents	rodent	NOUN
admet-437	99	39	pharmacokinetic	pharmacokinetic	ADJ
admet-437	99	40	experiments	experiment	NOUN
admet-437	99	41	.	.	PUNCT
admet-437	100	1	male	male	ADJ
admet-437	100	2	sprague	sprague	PROPN
admet-437	100	3	dawley	dawley	NOUN
admet-437	100	4	rats	rat	NOUN
admet-437	100	5	(	(	PUNCT
admet-437	100	6	~7	~7	NOUN
admet-437	100	7	-	-	PUNCT
admet-437	100	8	8	8	NUM
admet-437	100	9	weeks	week	NOUN
admet-437	100	10	old	old	ADJ
admet-437	100	11	)	)	PUNCT
admet-437	100	12	and	and	CCONJ
admet-437	100	13	balbc	balbc	PROPN
admet-437	100	14	mice	mouse	NOUN
admet-437	100	15	(	(	PUNCT
admet-437	100	16	~6	~6	ADJ
admet-437	100	17	-	-	PUNCT
admet-437	100	18	10	10	NUM
admet-437	100	19	weeks	week	NOUN
admet-437	100	20	old	old	ADJ
admet-437	100	21	)	)	PUNCT
admet-437	100	22	were	be	AUX
admet-437	100	23	purchased	purchase	VERB
admet-437	100	24	from	from	ADP
admet-437	100	25	vivo	vivo	ADJ
admet-437	100	26	biotech	biotech	NOUN
admet-437	100	27	,	,	PUNCT
admet-437	100	28	hyderabad	hyderabad	PROPN
admet-437	100	29	,	,	PUNCT
admet-437	100	30	india	india	PROPN
admet-437	100	31	.	.	PUNCT
admet-437	101	1	animals	animal	NOUN
admet-437	101	2	were	be	AUX
admet-437	101	3	quarantined	quarantine	VERB
admet-437	101	4	in	in	ADP
admet-437	101	5	jubilant	jubilant	ADJ
admet-437	101	6	biosys	biosys	NOUN
admet-437	101	7	animal	animal	NOUN
admet-437	101	8	house	house	NOUN
admet-437	101	9	for	for	ADP
admet-437	101	10	a	a	DET
admet-437	101	11	period	period	NOUN
admet-437	101	12	of	of	ADP
admet-437	101	13	7	7	NUM
admet-437	101	14	days	day	NOUN
admet-437	101	15	with	with	ADP
admet-437	101	16	a	a	DET
admet-437	101	17	12:12	12:12	NUM
admet-437	101	18	h	h	NOUN
admet-437	101	19	light	light	NOUN
admet-437	101	20	:	:	PUNCT
admet-437	101	21	dark	dark	ADJ
admet-437	101	22	cycles	cycle	NOUN
admet-437	101	23	,	,	PUNCT
admet-437	101	24	had	have	VERB
admet-437	101	25	free	free	ADJ
admet-437	101	26	access	access	NOUN
admet-437	101	27	to	to	ADP
admet-437	101	28	rodent	rodent	VERB
admet-437	101	29	food	food	NOUN
admet-437	101	30	(	(	PUNCT
admet-437	101	31	altromin	altromin	PROPN
admet-437	101	32	spezialfutter	spezialfutter	PROPN
admet-437	101	33	gmbh	gmbh	PROPN
admet-437	101	34	&	&	CCONJ
admet-437	101	35	co.	co.	PROPN
admet-437	102	1	kg	kg	PROPN
admet-437	102	2	.	.	PROPN
admet-437	102	3	,	,	PUNCT
admet-437	103	1	i	i	PRON
admet-437	103	2	m	m	VERB
admet-437	103	3	seelenkamp	seelenkamp	ADJ
admet-437	103	4	20	20	NUM
admet-437	103	5	,	,	PUNCT
admet-437	103	6	d-32791	d-32791	PROPN
admet-437	103	7	,	,	PUNCT
admet-437	103	8	lage	lage	NOUN
admet-437	103	9	,	,	PUNCT
admet-437	103	10	germany	germany	PROPN
admet-437	103	11	)	)	PUNCT
admet-437	103	12	and	and	CCONJ
admet-437	103	13	water	water	NOUN
admet-437	103	14	ad	ad	NOUN
admet-437	103	15	libitum	libitum	PROPN
admet-437	103	16	.	.	PUNCT
admet-437	104	1	for	for	ADP
admet-437	104	2	all	all	DET
admet-437	104	3	the	the	DET
admet-437	104	4	experimental	experimental	ADJ
admet-437	104	5	work	work	NOUN
admet-437	104	6	animals	animal	NOUN
admet-437	104	7	were	be	AUX
admet-437	104	8	kept	keep	VERB
admet-437	104	9	for	for	ADP
admet-437	104	10	fasting	fast	VERB
admet-437	104	11	(	(	PUNCT
admet-437	104	12	4	4	NUM
admet-437	104	13	h	h	NOUN
admet-437	104	14	for	for	ADP
admet-437	104	15	balbc	balbc	NOUN
admet-437	104	16	mice	mouse	NOUN
admet-437	104	17	and	and	CCONJ
admet-437	104	18	12	12	NUM
admet-437	104	19	h	h	NOUN
admet-437	104	20	for	for	ADP
admet-437	104	21	sprague	sprague	NOUN
admet-437	104	22	dawley	dawley	NOUN
admet-437	104	23	rats	rat	NOUN
admet-437	104	24	)	)	PUNCT
admet-437	104	25	and	and	CCONJ
admet-437	104	26	during	during	ADP
admet-437	104	27	this	this	DET
admet-437	104	28	time	time	NOUN
admet-437	104	29	they	they	PRON
admet-437	104	30	were	be	AUX
admet-437	104	31	allowed	allow	VERB
admet-437	104	32	to	to	PART
admet-437	104	33	take	take	VERB
admet-437	104	34	water	water	NOUN
admet-437	104	35	ad	ad	NOUN
admet-437	104	36	libitum	libitum	X
admet-437	104	37	.	.	PUNCT
admet-437	105	1	food	food	NOUN
admet-437	105	2	was	be	AUX
admet-437	105	3	provided	provide	VERB
admet-437	105	4	2	2	NUM
admet-437	105	5	h	h	NOUN
admet-437	105	6	post	post	ADJ
admet-437	105	7	-	-	ADJ
admet-437	105	8	dose	dose	ADJ
admet-437	105	9	and	and	CCONJ
admet-437	105	10	water	water	NOUN
admet-437	105	11	was	be	AUX
admet-437	105	12	allowed	allow	VERB
admet-437	105	13	ad	ad	NOUN
admet-437	105	14	libitum	libitum	X
admet-437	105	15	.	.	PUNCT
admet-437	106	1	iaec	iaec	NOUN
admet-437	106	2	of	of	ADP
admet-437	106	3	palamur	palamur	NOUN
admet-437	106	4	biosciences	bioscience	NOUN
admet-437	106	5	,	,	PUNCT
admet-437	106	6	telangana	telangana	PROPN
admet-437	106	7	,	,	PUNCT
admet-437	106	8	india	india	PROPN
admet-437	106	9	(	(	PUNCT
admet-437	106	10	1312	1312	NUM
admet-437	106	11	/	/	SYM
admet-437	106	12	po	po	NOUN
admet-437	106	13	/	/	SYM
admet-437	106	14	rcbibt	rcbibt	NOUN
admet-437	106	15	/	/	SYM
admet-437	106	16	s	s	NOUN
admet-437	106	17	/	/	SYM
admet-437	106	18	l/09	l/09	ADJ
admet-437	106	19	/	/	SYM
admet-437	106	20	cpcsea	cpcsea	NOUN
admet-437	106	21	)	)	PUNCT
admet-437	106	22	approved	approve	VERB
admet-437	106	23	studies	study	NOUN
admet-437	106	24	conducted	conduct	VERB
admet-437	106	25	in	in	ADP
admet-437	106	26	dogs	dog	NOUN
admet-437	106	27	.	.	PUNCT
admet-437	107	1	male	male	ADJ
admet-437	107	2	beagle	beagle	NOUN
admet-437	107	3	dogs	dog	NOUN
admet-437	107	4	(	(	PUNCT
admet-437	107	5	~1.0	~1.0	NOUN
admet-437	107	6	-	-	SYM
admet-437	107	7	1.5	1.5	NUM
admet-437	107	8	year	year	NOUN
admet-437	107	9	old	old	ADJ
admet-437	107	10	)	)	PUNCT
admet-437	107	11	were	be	AUX
admet-437	107	12	housed	house	VERB
admet-437	107	13	in	in	ADP
admet-437	107	14	palamur	palamur	NOUN
admet-437	107	15	biosciences	bioscience	NOUN
admet-437	107	16	private	private	ADJ
admet-437	107	17	limited	limited	ADJ
admet-437	107	18	animal	animal	NOUN
admet-437	107	19	house	house	NOUN
admet-437	107	20	facility	facility	NOUN
admet-437	107	21	in	in	ADP
admet-437	107	22	a	a	DET
admet-437	107	23	temperature	temperature	NOUN
admet-437	107	24	(	(	PUNCT
admet-437	107	25	18	18	NUM
admet-437	107	26	-	-	SYM
admet-437	107	27	28	28	NUM
admet-437	107	28	°	°	NOUN
admet-437	107	29	c	c	NOUN
admet-437	107	30	)	)	PUNCT
admet-437	107	31	and	and	CCONJ
admet-437	107	32	humidity	humidity	NOUN
admet-437	107	33	(	(	PUNCT
admet-437	107	34	30	30	NUM
admet-437	107	35	-	-	SYM
admet-437	107	36	70	70	NUM
admet-437	107	37	%	%	NOUN
admet-437	107	38	)	)	PUNCT
admet-437	107	39	controlled	control	VERB
admet-437	107	40	room	room	NOUN
admet-437	107	41	and	and	CCONJ
admet-437	107	42	fed	feed	VERB
admet-437	107	43	with	with	ADP
admet-437	107	44	pedigree	pedigree	ADJ
admet-437	107	45	standard	standard	ADJ
admet-437	107	46	pellet	pellet	NOUN
admet-437	107	47	food	food	NOUN
admet-437	107	48	and	and	CCONJ
admet-437	107	49	water	water	NOUN
admet-437	107	50	ad	ad	NOUN
admet-437	107	51	libitum	libitum	NOUN
admet-437	107	52	for	for	ADP
admet-437	107	53	one	one	NUM
admet-437	107	54	week	week	NOUN
admet-437	107	55	before	before	ADP
admet-437	107	56	using	use	VERB
admet-437	107	57	for	for	ADP
admet-437	107	58	experimental	experimental	ADJ
admet-437	107	59	purpose	purpose	NOUN
admet-437	107	60	.	.	PUNCT
admet-437	108	1	for	for	ADP
admet-437	108	2	all	all	DET
admet-437	108	3	the	the	DET
admet-437	108	4	experimental	experimental	ADJ
admet-437	108	5	work	work	NOUN
admet-437	108	6	animals	animal	NOUN
admet-437	108	7	were	be	AUX
admet-437	108	8	kept	keep	VERB
admet-437	108	9	for	for	ADP
admet-437	108	10	12	12	NUM
admet-437	108	11	h	h	NOUN
admet-437	108	12	overnight	overnight	ADV
admet-437	108	13	fasting	fasting	NOUN
admet-437	108	14	and	and	CCONJ
admet-437	108	15	during	during	ADP
admet-437	108	16	this	this	DET
admet-437	108	17	time	time	NOUN
admet-437	108	18	they	they	PRON
admet-437	108	19	were	be	AUX
admet-437	108	20	allowed	allow	VERB
admet-437	108	21	to	to	PART
admet-437	108	22	take	take	VERB
admet-437	108	23	water	water	NOUN
admet-437	108	24	ad	ad	NOUN
admet-437	108	25	libitum	libitum	X
admet-437	108	26	.	.	PUNCT
admet-437	109	1	food	food	NOUN
admet-437	109	2	was	be	AUX
admet-437	109	3	provided	provide	VERB
admet-437	109	4	4	4	NUM
admet-437	109	5	h	h	NOUN
admet-437	109	6	post	post	ADJ
admet-437	109	7	-	-	ADJ
admet-437	109	8	dose	dose	ADJ
admet-437	109	9	and	and	CCONJ
admet-437	109	10	water	water	NOUN
admet-437	109	11	was	be	AUX
admet-437	109	12	allowed	allow	VERB
admet-437	109	13	ad	ad	NOUN
admet-437	109	14	libitum	libitum	X
admet-437	109	15	.	.	PUNCT
admet-437	110	1	pharmacokinetic	pharmacokinetic	ADJ
admet-437	110	2	studies	study	NOUN
admet-437	110	3	oral	oral	ADJ
admet-437	110	4	bioavailability	bioavailability	NOUN
admet-437	110	5	of	of	ADP
admet-437	110	6	ulixertinib	ulixertinib	NOUN
admet-437	110	7	was	be	AUX
admet-437	110	8	evaluated	evaluate	VERB
admet-437	110	9	in	in	ADP
admet-437	110	10	male	male	ADJ
admet-437	110	11	balb	balb	ADJ
admet-437	110	12	/	/	SYM
admet-437	110	13	c	c	NOUN
admet-437	110	14	mice	mouse	NOUN
admet-437	110	15	,	,	PUNCT
admet-437	110	16	sprague	sprague	NOUN
admet-437	110	17	dawley	dawley	NOUN
admet-437	110	18	rats	rat	NOUN
admet-437	110	19	and	and	CCONJ
admet-437	110	20	beagle	beagle	NOUN
admet-437	110	21	dogs	dog	NOUN
admet-437	110	22	.	.	PUNCT
admet-437	111	1	fasted	fast	VERB
admet-437	111	2	mice	mice	NOUN
admet-437	111	3	(	(	PUNCT
admet-437	111	4	~4	~4	NOUN
admet-437	111	5	h	h	NOUN
admet-437	111	6	)	)	PUNCT
admet-437	111	7	and	and	CCONJ
admet-437	111	8	rats	rat	NOUN
admet-437	111	9	(	(	PUNCT
admet-437	111	10	overnight	overnight	ADV
admet-437	111	11	~12	~12	VERB
admet-437	111	12	h	h	NOUN
admet-437	111	13	)	)	PUNCT
admet-437	111	14	were	be	AUX
admet-437	111	15	divided	divide	VERB
admet-437	111	16	into	into	ADP
admet-437	111	17	two	two	NUM
admet-437	111	18	groups	group	NOUN
admet-437	111	19	(	(	PUNCT
admet-437	111	20	mice	mouse	NOUN
admet-437	111	21	:	:	PUNCT
admet-437	111	22	12	12	NUM
admet-437	111	23	/	/	SYM
admet-437	111	24	group	group	NOUN
admet-437	111	25	;	;	PUNCT
admet-437	111	26	rats	rat	NOUN
admet-437	111	27	:	:	PUNCT
admet-437	111	28	4	4	NUM
admet-437	111	29	/	/	SYM
admet-437	111	30	group	group	NOUN
admet-437	111	31	)	)	PUNCT
admet-437	111	32	,	,	PUNCT
admet-437	111	33	however	however	ADV
admet-437	111	34	in	in	ADP
admet-437	111	35	cases	case	NOUN
admet-437	111	36	of	of	ADP
admet-437	111	37	dogs	dog	NOUN
admet-437	111	38	(	(	PUNCT
admet-437	111	39	n=2	n=2	ADV
admet-437	111	40	;	;	PUNCT
admet-437	111	41	fasted	fast	VERB
admet-437	111	42	for	for	ADP
admet-437	111	43	~12	~12	NUM
admet-437	111	44	h	h	NOUN
admet-437	111	45	overnight	overnight	ADV
admet-437	111	46	)	)	PUNCT
admet-437	111	47	same	same	ADJ
admet-437	111	48	dogs	dog	NOUN
admet-437	111	49	were	be	AUX
admet-437	111	50	dose	dose	VERB
admet-437	111	51	after	after	ADP
admet-437	111	52	one	one	NUM
admet-437	111	53	week	week	NOUN
admet-437	111	54	wash	wash	NOUN
admet-437	111	55	-	-	PUNCT
admet-437	111	56	out	out	NOUN
admet-437	111	57	period	period	NOUN
admet-437	111	58	(	(	PUNCT
admet-437	111	59	cross	cross	VERB
admet-437	111	60	over	over	ADP
admet-437	111	61	design	design	NOUN
admet-437	111	62	)	)	PUNCT
admet-437	111	63	.	.	PUNCT
admet-437	112	1	in	in	ADP
admet-437	112	2	each	each	DET
admet-437	112	3	species	specie	NOUN
admet-437	112	4	group-1	group-1	NOUN
admet-437	112	5	animals	animal	NOUN
admet-437	112	6	received	receive	VERB
admet-437	112	7	ulixertinib	ulixertinib	NOUN
admet-437	112	8	through	through	ADP
admet-437	112	9	intravenous	intravenous	ADJ
admet-437	112	10	route	route	NOUN
admet-437	112	11	at	at	ADP
admet-437	112	12	a	a	DET
admet-437	112	13	dose	dose	NOUN
admet-437	112	14	of	of	ADP
admet-437	112	15	1	1	NUM
admet-437	112	16	mg	mg	PROPN
admet-437	112	17	/	/	SYM
admet-437	112	18	kg	kg	PROPN
admet-437	112	19	;	;	PUNCT
admet-437	112	20	whereas	whereas	SCONJ
admet-437	112	21	group	group	NOUN
admet-437	112	22	2	2	NUM
admet-437	112	23	received	receive	VERB
admet-437	112	24	ulixertinib	ulixertinib	NOUN
admet-437	112	25	through	through	ADP
admet-437	112	26	oral	oral	ADJ
admet-437	112	27	gavage	gavage	NOUN
admet-437	112	28	at	at	ADP
admet-437	112	29	10	10	NUM
admet-437	112	30	mg	mg	NUM
admet-437	112	31	/	/	SYM
admet-437	112	32	kg	kg	PROPN
admet-437	112	33	dose	dose	NOUN
admet-437	112	34	.	.	PUNCT
admet-437	113	1	serial	serial	ADJ
admet-437	113	2	blood	blood	NOUN
admet-437	113	3	samples	sample	NOUN
admet-437	113	4	[	[	X
admet-437	113	5	100	100	NUM
admet-437	113	6	µl	µl	ADP
admet-437	113	7	in	in	ADP
admet-437	113	8	case	case	NOUN
admet-437	113	9	of	of	ADP
admet-437	113	10	mice	mouse	NOUN
admet-437	113	11	(	(	PUNCT
admet-437	113	12	sparse	sparse	ADJ
admet-437	113	13	sampling	sampling	NOUN
admet-437	113	14	;	;	PUNCT
admet-437	113	15	n=3	n=3	PUNCT
admet-437	113	16	at	at	ADP
admet-437	113	17	each	each	DET
admet-437	113	18	time	time	NOUN
admet-437	113	19	point	point	NOUN
admet-437	113	20	)	)	PUNCT
admet-437	113	21	and	and	CCONJ
admet-437	113	22	rats	rat	NOUN
admet-437	113	23	;	;	PUNCT
admet-437	113	24	500	500	NUM
admet-437	113	25	µl	µl	NOUN
admet-437	113	26	in	in	ADP
admet-437	113	27	dogs	dog	NOUN
admet-437	113	28	)	)	PUNCT
admet-437	113	29	]	]	PUNCT
admet-437	113	30	were	be	AUX
admet-437	113	31	collected	collect	VERB
admet-437	113	32	from	from	ADP
admet-437	113	33	retro	retro	ADJ
admet-437	113	34	-	-	PUNCT
admet-437	113	35	orbital	orbital	ADJ
admet-437	113	36	plexus	plexus	NOUN
admet-437	113	37	at	at	ADP
admet-437	113	38	0.12	0.12	NUM
admet-437	113	39	,	,	PUNCT
admet-437	113	40	0.25	0.25	NUM
admet-437	113	41	,	,	PUNCT
admet-437	113	42	0.5	0.5	NUM
admet-437	113	43	,	,	PUNCT
admet-437	113	44	1	1	NUM
admet-437	113	45	,	,	PUNCT
admet-437	113	46	2	2	NUM
admet-437	113	47	,	,	PUNCT
admet-437	113	48	4	4	NUM
admet-437	113	49	,	,	PUNCT
admet-437	113	50	8	8	NUM
admet-437	113	51	,	,	PUNCT
admet-437	113	52	and	and	CCONJ
admet-437	113	53	24	24	NUM
admet-437	113	54	h	h	NOUN
admet-437	113	55	(	(	PUNCT
admet-437	113	56	intravenous	intravenous	ADJ
admet-437	113	57	administration	administration	NOUN
admet-437	113	58	)	)	PUNCT
admet-437	113	59	or	or	CCONJ
admet-437	113	60	at	at	ADP
admet-437	113	61	0.25	0.25	NUM
admet-437	113	62	,	,	PUNCT
admet-437	113	63	0.5	0.5	NUM
admet-437	113	64	,	,	PUNCT
admet-437	113	65	1	1	NUM
admet-437	113	66	,	,	PUNCT
admet-437	113	67	2	2	NUM
admet-437	113	68	,	,	PUNCT
admet-437	113	69	4	4	NUM
admet-437	113	70	,	,	PUNCT
admet-437	113	71	8	8	NUM
admet-437	113	72	,	,	PUNCT
admet-437	113	73	10	10	NUM
admet-437	113	74	and	and	CCONJ
admet-437	113	75	24	24	NUM
admet-437	113	76	h	h	NOUN
admet-437	113	77	(	(	PUNCT
admet-437	113	78	oral	oral	ADJ
admet-437	113	79	administration	administration	NOUN
admet-437	113	80	)	)	PUNCT
admet-437	113	81	after	after	ADP
admet-437	113	82	drug	drug	NOUN
admet-437	113	83	administration	administration	NOUN
admet-437	113	84	.	.	PUNCT
admet-437	114	1	blood	blood	NOUN
admet-437	114	2	samples	sample	NOUN
admet-437	114	3	were	be	AUX
admet-437	114	4	collected	collect	VERB
admet-437	114	5	in	in	ADP
admet-437	114	6	tubes	tube	NOUN
admet-437	114	7	containing	contain	VERB
admet-437	114	8	k2.edta	k2.edta	NOUN
admet-437	114	9	as	as	ADP
admet-437	114	10	the	the	DET
admet-437	114	11	anticoagulant	anticoagulant	NOUN
admet-437	114	12	and	and	CCONJ
admet-437	114	13	centrifuged	centrifuge	VERB
admet-437	114	14	for	for	ADP
admet-437	114	15	5	5	NUM
admet-437	114	16	min	min	NOUN
admet-437	114	17	at	at	ADP
admet-437	114	18	14000	14000	NUM
admet-437	114	19	rpm	rpm	NOUN
admet-437	114	20	in	in	ADP
admet-437	114	21	a	a	DET
admet-437	114	22	refrigerated	refrigerate	VERB
admet-437	114	23	centrifuge	centrifuge	NOUN
admet-437	114	24	(	(	PUNCT
admet-437	114	25	biofuge	biofuge	NOUN
admet-437	114	26	,	,	PUNCT
admet-437	114	27	heraeus	heraeus	NOUN
admet-437	114	28	,	,	PUNCT
admet-437	114	29	germany	germany	PROPN
admet-437	114	30	)	)	PUNCT
admet-437	114	31	maintained	maintain	VERB
admet-437	114	32	at	at	ADP
admet-437	114	33	4	4	NUM
admet-437	114	34	°	°	ADP
admet-437	114	35	c	c	NOUN
admet-437	114	36	for	for	ADP
admet-437	114	37	plasma	plasma	NOUN
admet-437	114	38	separation	separation	NOUN
admet-437	114	39	and	and	CCONJ
admet-437	114	40	stored	store	VERB
admet-437	114	41	frozen	frozen	ADJ
admet-437	114	42	at	at	ADP
admet-437	114	43	-80	-80	SYM
admet-437	114	44	±	±	NUM
admet-437	114	45	10	10	NUM
admet-437	114	46	°	°	ADP
admet-437	114	47	c	c	NOUN
admet-437	114	48	until	until	ADP
admet-437	114	49	analysis	analysis	NOUN
admet-437	114	50	.	.	PUNCT
admet-437	115	1	sample	sample	NOUN
admet-437	115	2	processing	processing	NOUN
admet-437	115	3	in	in	ADP
admet-437	115	4	vitro	vitro	X
admet-437	115	5	studies	study	NOUN
admet-437	115	6	samples	sample	VERB
admet-437	115	7	analysis	analysis	NOUN
admet-437	115	8	a	a	DET
admet-437	115	9	shimadzu	shimadzu	ADJ
admet-437	115	10	(	(	PUNCT
admet-437	115	11	shimadzu	shimadzu	PROPN
admet-437	115	12	,	,	PUNCT
admet-437	115	13	kyoto	kyoto	PROPN
admet-437	115	14	,	,	PUNCT
admet-437	115	15	japan	japan	PROPN
admet-437	115	16	)	)	PUNCT
admet-437	115	17	sil	sil	PROPN
admet-437	115	18	series	series	PROPN
admet-437	115	19	lc	lc	PROPN
admet-437	115	20	system	system	NOUN
admet-437	115	21	equipped	equip	VERB
admet-437	115	22	with	with	ADP
admet-437	115	23	a	a	DET
admet-437	115	24	degasser	degasser	PROPN
admet-437	115	25	(	(	PUNCT
admet-437	115	26	dgu-20a3	dgu-20a3	PROPN
admet-437	115	27	)	)	PUNCT
admet-437	115	28	,	,	PUNCT
admet-437	115	29	isopump	isopump	NOUN
admet-437	115	30	(	(	PUNCT
admet-437	115	31	lc-20	lc-20	PRON
admet-437	115	32	ad	ad	NOUN
admet-437	115	33	)	)	PUNCT
admet-437	115	34	and	and	CCONJ
admet-437	115	35	column	column	NOUN
admet-437	115	36	oven	oven	NOUN
admet-437	115	37	(	(	PUNCT
admet-437	115	38	cto-10as	cto-10as	NUM
admet-437	115	39	)	)	PUNCT
admet-437	115	40	along	along	ADP
admet-437	115	41	with	with	ADP
admet-437	115	42	an	an	DET
admet-437	115	43	auto	auto	NOUN
admet-437	115	44	-	-	PUNCT
admet-437	115	45	sampler	sampler	NOUN
admet-437	115	46	(	(	PUNCT
admet-437	115	47	sil	sil	PROPN
admet-437	115	48	-	-	PUNCT
admet-437	115	49	htc	htc	NOUN
admet-437	115	50	)	)	PUNCT
admet-437	115	51	was	be	AUX
admet-437	115	52	used	use	VERB
admet-437	115	53	to	to	PART
admet-437	115	54	inject	inject	VERB
admet-437	115	55	10	10	NUM
admet-437	115	56	µl	µl	ADP
admet-437	115	57	aliquots	aliquot	NOUN
admet-437	115	58	of	of	ADP
admet-437	115	59	the	the	DET
admet-437	115	60	processed	process	VERB
admet-437	115	61	samples	sample	NOUN
admet-437	115	62	on	on	ADP
admet-437	115	63	a	a	DET
admet-437	115	64	atlantis	atlantis	PROPN
admet-437	115	65	c18	c18	NOUN
admet-437	115	66	column	column	NOUN
admet-437	115	67	(	(	PUNCT
admet-437	115	68	50	50	NUM
admet-437	115	69	x	x	SYM
admet-437	115	70	4.6	4.6	NUM
admet-437	115	71	mm	mm	NOUN
admet-437	115	72	,	,	PUNCT
admet-437	115	73	3	3	NUM
admet-437	115	74	µm	µm	NOUN
admet-437	115	75	;	;	PUNCT
admet-437	115	76	waters	water	NOUN
admet-437	115	77	,	,	PUNCT
admet-437	115	78	ireland	ireland	PROPN
admet-437	115	79	,	,	PUNCT
admet-437	115	80	uk	uk	PROPN
admet-437	115	81	)	)	PUNCT
admet-437	115	82	,	,	PUNCT
admet-437	115	83	which	which	PRON
admet-437	115	84	was	be	AUX
admet-437	115	85	maintained	maintain	VERB
admet-437	115	86	at	at	ADP
admet-437	115	87	40	40	NUM
admet-437	115	88	°	°	NOUN
admet-437	115	89	c	c	NOUN
admet-437	115	90	.	.	PUNCT
admet-437	116	1	the	the	DET
admet-437	116	2	mobile	mobile	ADJ
admet-437	116	3	phase	phase	NOUN
admet-437	116	4	system	system	NOUN
admet-437	116	5	consisted	consist	VERB
admet-437	116	6	of	of	ADP
admet-437	116	7	reservoir	reservoir	PROPN
admet-437	116	8	a	a	DET
admet-437	116	9	(	(	PUNCT
admet-437	116	10	acetonitrile	acetonitrile	NOUN
admet-437	116	11	)	)	PUNCT
admet-437	116	12	and	and	CCONJ
admet-437	116	13	reservoir	reservoir	PROPN
admet-437	116	14	b	b	PROPN
admet-437	116	15	(	(	PUNCT
admet-437	116	16	0.2	0.2	NUM
admet-437	116	17	%	%	NOUN
admet-437	116	18	formic	formic	ADJ
admet-437	116	19	acid	acid	NOUN
admet-437	116	20	in	in	ADP
admet-437	116	21	water	water	NOUN
admet-437	116	22	)	)	PUNCT
admet-437	116	23	were	be	AUX
admet-437	116	24	run	run	VERB
admet-437	116	25	as	as	ADP
admet-437	116	26	per	per	ADP
admet-437	116	27	gradient	gradient	NOUN
admet-437	116	28	program	program	NOUN
admet-437	116	29	(	(	PUNCT
admet-437	116	30	0	0	NUM
admet-437	116	31	-	-	SYM
admet-437	116	32	0.1	0.1	NUM
admet-437	116	33	min	min	NOUN
admet-437	116	34	:	:	PUNCT
admet-437	116	35	10	10	NUM
admet-437	116	36	%	%	NOUN
admet-437	116	37	a	a	PRON
admet-437	116	38	and	and	CCONJ
admet-437	116	39	90	90	NUM
admet-437	116	40	%	%	NOUN
admet-437	116	41	b	b	NOUN
admet-437	116	42	;	;	PUNCT
admet-437	116	43	0.1	0.1	NUM
admet-437	116	44	-	-	SYM
admet-437	116	45	2.8	2.8	NUM
admet-437	116	46	min	min	NOUN
admet-437	116	47	:	:	PUNCT
admet-437	116	48	100	100	NUM
admet-437	116	49	%	%	NOUN
admet-437	116	50	a	a	PRON
admet-437	116	51	;	;	PUNCT
admet-437	116	52	2.9	2.9	NUM
admet-437	116	53	-	-	SYM
admet-437	116	54	4.0	4.0	NUM
admet-437	116	55	min	min	NOUN
admet-437	116	56	10	10	NUM
admet-437	116	57	%	%	NOUN
admet-437	116	58	a	a	PRON
admet-437	116	59	and	and	CCONJ
admet-437	116	60	90	90	NUM
admet-437	116	61	%	%	NOUN
admet-437	116	62	b	b	NOUN
admet-437	116	63	)	)	PUNCT
admet-437	116	64	.	.	PUNCT
admet-437	117	1	a	a	DET
admet-437	117	2	flow	flow	NOUN
admet-437	117	3	rate	rate	NOUN
admet-437	117	4	of	of	ADP
admet-437	117	5	0.8	0.8	NUM
admet-437	117	6	ml	ml	NOUN
admet-437	117	7	/	/	SYM
admet-437	117	8	min	min	NOUN
admet-437	117	9	with	with	ADP
admet-437	117	10	a	a	DET
admet-437	117	11	50	50	NUM
admet-437	117	12	%	%	NOUN
admet-437	117	13	splitter	splitter	NOUN
admet-437	117	14	was	be	AUX
admet-437	117	15	used	use	VERB
admet-437	117	16	throughout	throughout	ADP
admet-437	117	17	the	the	DET
admet-437	117	18	analytical	analytical	ADJ
admet-437	117	19	run	run	NOUN
admet-437	117	20	.	.	PUNCT
admet-437	118	1	quantitation	quantitation	NOUN
admet-437	118	2	was	be	AUX
admet-437	118	3	achieved	achieve	VERB
admet-437	118	4	by	by	ADP
admet-437	118	5	ms	ms	PROPN
admet-437	118	6	/	/	SYM
admet-437	118	7	ms	ms	PROPN
admet-437	118	8	detection	detection	NOUN
admet-437	118	9	in	in	ADP
admet-437	118	10	positive	positive	ADJ
admet-437	118	11	ion	ion	NOUN
admet-437	118	12	mode	mode	NOUN
admet-437	118	13	for	for	ADP
admet-437	118	14	ulixertinib	ulixertinib	NOUN
admet-437	118	15	using	use	VERB
admet-437	118	16	an	an	DET
admet-437	118	17	api-4000	api-4000	NOUN
admet-437	118	18	q	q	X
admet-437	118	19	trap	trap	NOUN
admet-437	118	20	mass	mass	NOUN
admet-437	118	21	spectrometer	spectrometer	NOUN
admet-437	118	22	(	(	PUNCT
admet-437	118	23	mds	mds	PROPN
admet-437	118	24	sciex	sciex	PROPN
admet-437	118	25	,	,	PUNCT
admet-437	118	26	toronto	toronto	PROPN
admet-437	118	27	,	,	PUNCT
admet-437	118	28	canada	canada	PROPN
admet-437	118	29	)	)	PUNCT
admet-437	118	30	equipped	equip	VERB
admet-437	118	31	with	with	ADP
admet-437	118	32	a	a	DET
admet-437	118	33	admet	admet	PROPN
admet-437	118	34	&	&	CCONJ
admet-437	118	35	dmpk	dmpk	PROPN
admet-437	118	36	5(4	5(4	NOUN
admet-437	118	37	)	)	PUNCT
admet-437	118	38	(	(	PUNCT
admet-437	118	39	2017	2017	NUM
admet-437	118	40	)	)	PUNCT
admet-437	118	41	212	212	NUM
admet-437	118	42	-	-	SYM
admet-437	118	43	223	223	NUM
admet-437	118	44	preclinical	preclinical	ADJ
admet-437	118	45	assessment	assessment	NOUN
admet-437	118	46	of	of	ADP
admet-437	118	47	ulixertinib	ulixertinib	PROPN
admet-437	118	48	doi	doi	PROPN
admet-437	118	49	:	:	PUNCT
admet-437	118	50	10.5599	10.5599	NUM
admet-437	118	51	/	/	SYM
admet-437	118	52	admet.5.4.437	admet.5.4.437	NUM
admet-437	118	53	217	217	NUM
admet-437	118	54	turboionspray	turboionspray	NOUN
admet-437	118	55	interface	interface	NOUN
admet-437	118	56	at	at	ADP
admet-437	118	57	450	450	NUM
admet-437	118	58	°	°	NOUN
admet-437	118	59	c	c	NOUN
admet-437	118	60	temperature	temperature	NOUN
admet-437	118	61	and	and	CCONJ
admet-437	118	62	5500	5500	NUM
admet-437	118	63	v	v	NOUN
admet-437	118	64	ion	ion	NOUN
admet-437	118	65	spray	spray	NOUN
admet-437	118	66	voltage	voltage	NOUN
admet-437	118	67	.	.	PUNCT
admet-437	119	1	the	the	DET
admet-437	119	2	source	source	NOUN
admet-437	119	3	parameters	parameter	NOUN
admet-437	119	4	viz	viz	PROPN
admet-437	119	5	.	.	PROPN
admet-437	119	6	,	,	PUNCT
admet-437	119	7	curtain	curtain	NOUN
admet-437	119	8	gas	gas	NOUN
admet-437	119	9	,	,	PUNCT
admet-437	119	10	gs1	gs1	NOUN
admet-437	119	11	,	,	PUNCT
admet-437	119	12	gs2	gs2	PROPN
admet-437	119	13	and	and	CCONJ
admet-437	119	14	cad	cad	PROPN
admet-437	119	15	were	be	AUX
admet-437	119	16	set	set	VERB
admet-437	119	17	at	at	ADP
admet-437	119	18	30	30	NUM
admet-437	119	19	,	,	PUNCT
admet-437	119	20	35	35	NUM
admet-437	119	21	,	,	PUNCT
admet-437	119	22	40	40	NUM
admet-437	119	23	and	and	CCONJ
admet-437	119	24	6	6	NUM
admet-437	119	25	psi	psi	NOUN
admet-437	119	26	.	.	PUNCT
admet-437	120	1	the	the	DET
admet-437	120	2	compound	compound	NOUN
admet-437	120	3	parameters	parameter	NOUN
admet-437	120	4	viz	viz	PROPN
admet-437	120	5	.	.	PROPN
admet-437	120	6	,	,	PUNCT
admet-437	120	7	declustering	declustere	VERB
admet-437	120	8	potential	potential	ADJ
admet-437	120	9	(	(	PUNCT
admet-437	120	10	dp	dp	NOUN
admet-437	120	11	)	)	PUNCT
admet-437	120	12	,	,	PUNCT
admet-437	120	13	entrance	entrance	NOUN
admet-437	120	14	potential	potential	NOUN
admet-437	120	15	(	(	PUNCT
admet-437	120	16	ep	ep	PROPN
admet-437	120	17	)	)	PUNCT
admet-437	120	18	,	,	PUNCT
admet-437	120	19	collision	collision	NOUN
admet-437	120	20	energy	energy	NOUN
admet-437	120	21	(	(	PUNCT
admet-437	120	22	ce	ce	PROPN
admet-437	120	23	)	)	PUNCT
admet-437	120	24	and	and	CCONJ
admet-437	120	25	collision	collision	NOUN
admet-437	120	26	cell	cell	NOUN
admet-437	120	27	exit	exit	NOUN
admet-437	120	28	potential	potential	NOUN
admet-437	120	29	(	(	PUNCT
admet-437	120	30	cxp	cxp	PROPN
admet-437	120	31	)	)	PUNCT
admet-437	120	32	were	be	AUX
admet-437	120	33	81	81	NUM
admet-437	120	34	,	,	PUNCT
admet-437	120	35	10	10	NUM
admet-437	120	36	,	,	PUNCT
admet-437	120	37	49	49	NUM
admet-437	120	38	and	and	CCONJ
admet-437	120	39	15	15	NUM
admet-437	120	40	v	v	NOUN
admet-437	120	41	for	for	ADP
admet-437	120	42	ulixertinib	ulixertinib	NOUN
admet-437	120	43	and	and	CCONJ
admet-437	120	44	80	80	NUM
admet-437	120	45	,	,	PUNCT
admet-437	120	46	10	10	NUM
admet-437	120	47	,	,	PUNCT
admet-437	120	48	29	29	NUM
admet-437	120	49	and	and	CCONJ
admet-437	120	50	14	14	NUM
admet-437	120	51	v	v	NOUN
admet-437	120	52	for	for	ADP
admet-437	120	53	the	the	DET
admet-437	120	54	is	is	NOUN
admet-437	120	55	.	.	PUNCT
admet-437	121	1	detection	detection	NOUN
admet-437	121	2	of	of	ADP
admet-437	121	3	the	the	DET
admet-437	121	4	ions	ion	NOUN
admet-437	121	5	was	be	AUX
admet-437	121	6	performed	perform	VERB
admet-437	121	7	in	in	ADP
admet-437	121	8	the	the	DET
admet-437	121	9	multiple	multiple	ADJ
admet-437	121	10	reaction	reaction	NOUN
admet-437	121	11	monitoring	monitoring	NOUN
admet-437	121	12	(	(	PUNCT
admet-437	121	13	mrm	mrm	PROPN
admet-437	121	14	)	)	PUNCT
admet-437	121	15	mode	mode	NOUN
admet-437	121	16	,	,	PUNCT
admet-437	121	17	monitoring	monitor	VERB
admet-437	121	18	the	the	DET
admet-437	121	19	transition	transition	NOUN
admet-437	121	20	of	of	ADP
admet-437	121	21	the	the	DET
admet-437	121	22	m	m	PROPN
admet-437	121	23	/	/	SYM
admet-437	121	24	z	z	PROPN
admet-437	121	25	433	433	NUM
admet-437	121	26	precursor	precursor	NOUN
admet-437	121	27	ion	ion	NOUN
admet-437	121	28	to	to	ADP
admet-437	121	29	the	the	DET
admet-437	121	30	m	m	PROPN
admet-437	121	31	/	/	SYM
admet-437	121	32	z	z	PROPN
admet-437	121	33	262	262	NUM
admet-437	121	34	product	product	NOUN
admet-437	121	35	ion	ion	NOUN
admet-437	121	36	for	for	ADP
admet-437	121	37	ulixertinib	ulixertinib	NOUN
admet-437	121	38	and	and	CCONJ
admet-437	121	39	m	m	PROPN
admet-437	121	40	/	/	SYM
admet-437	121	41	z	z	PROPN
admet-437	121	42	180	180	NUM
admet-437	121	43	precursor	precursor	NOUN
admet-437	121	44	ion	ion	NOUN
admet-437	121	45	to	to	ADP
admet-437	121	46	the	the	DET
admet-437	121	47	m	m	PROPN
admet-437	121	48	/	/	SYM
admet-437	121	49	z	z	PROPN
admet-437	121	50	110	110	NUM
admet-437	121	51	product	product	NOUN
admet-437	121	52	ion	ion	NOUN
admet-437	121	53	for	for	ADP
admet-437	121	54	the	the	DET
admet-437	121	55	is	is	NOUN
admet-437	121	56	.	.	PUNCT
admet-437	122	1	quadrupole	quadrupole	PROPN
admet-437	122	2	q1	q1	PROPN
admet-437	122	3	and	and	CCONJ
admet-437	122	4	q3	q3	PROPN
admet-437	122	5	were	be	AUX
admet-437	122	6	set	set	VERB
admet-437	122	7	on	on	ADP
admet-437	122	8	unit	unit	NOUN
admet-437	122	9	resolution	resolution	NOUN
admet-437	122	10	.	.	PUNCT
admet-437	123	1	the	the	DET
admet-437	123	2	dwell	dwell	NOUN
admet-437	123	3	time	time	NOUN
admet-437	123	4	was	be	AUX
admet-437	123	5	150	150	NUM
admet-437	123	6	msec	msec	NOUN
admet-437	123	7	.	.	PUNCT
admet-437	124	1	plasma	plasma	NOUN
admet-437	124	2	samples	sample	NOUN
admet-437	124	3	processing	processing	NOUN
admet-437	124	4	and	and	CCONJ
admet-437	124	5	analysis	analysis	NOUN
admet-437	124	6	an	an	DET
admet-437	124	7	aliquot	aliquot	NOUN
admet-437	124	8	of	of	ADP
admet-437	124	9	50	50	NUM
admet-437	124	10	µl	µl	ADP
admet-437	124	11	plasma	plasma	NOUN
admet-437	124	12	sample	sample	NOUN
admet-437	124	13	was	be	AUX
admet-437	124	14	precipitated	precipitate	VERB
admet-437	124	15	with	with	ADP
admet-437	124	16	200	200	NUM
admet-437	124	17	µl	µl	NOUN
admet-437	124	18	of	of	ADP
admet-437	124	19	acetonitrile	acetonitrile	NOUN
admet-437	124	20	:	:	PUNCT
admet-437	124	21	methanol	methanol	NOUN
admet-437	124	22	(	(	PUNCT
admet-437	124	23	1:1	1:1	NUM
admet-437	124	24	,	,	PUNCT
admet-437	124	25	v	v	NOUN
admet-437	124	26	/	/	SYM
admet-437	124	27	v	v	NOUN
admet-437	124	28	)	)	PUNCT
admet-437	124	29	enriched	enrich	VERB
admet-437	124	30	with	with	ADP
admet-437	124	31	internal	internal	ADJ
admet-437	124	32	standard	standard	NOUN
admet-437	124	33	(	(	PUNCT
admet-437	124	34	200	200	NUM
admet-437	124	35	ng	ng	PROPN
admet-437	124	36	/	/	SYM
admet-437	124	37	ml	ml	PROPN
admet-437	124	38	of	of	ADP
admet-437	124	39	phenacetin	phenacetin	NOUN
admet-437	124	40	)	)	PUNCT
admet-437	124	41	and	and	CCONJ
admet-437	124	42	centrifuged	centrifuge	VERB
admet-437	124	43	at	at	ADP
admet-437	124	44	14,000	14,000	NUM
admet-437	124	45	rpm	rpm	NOUN
admet-437	124	46	for	for	ADP
admet-437	124	47	5	5	NUM
admet-437	124	48	min	min	NOUN
admet-437	124	49	(	(	PUNCT
admet-437	124	50	eppendorf	eppendorf	PROPN
admet-437	124	51	5424r	5424r	NUM
admet-437	124	52	,	,	PUNCT
admet-437	124	53	germany	germany	PROPN
admet-437	124	54	)	)	PUNCT
admet-437	124	55	at	at	ADP
admet-437	124	56	5	5	NUM
admet-437	124	57	°	°	NOUN
admet-437	124	58	c	c	NOUN
admet-437	124	59	.	.	PUNCT
admet-437	125	1	clear	clear	ADJ
admet-437	125	2	supernatant	supernatant	NOUN
admet-437	125	3	(	(	PUNCT
admet-437	125	4	125	125	NUM
admet-437	125	5	µl	µl	NOUN
admet-437	125	6	)	)	PUNCT
admet-437	125	7	was	be	AUX
admet-437	125	8	transferred	transfer	VERB
admet-437	125	9	into	into	ADP
admet-437	125	10	vials	vial	NOUN
admet-437	125	11	and	and	CCONJ
admet-437	125	12	5	5	NUM
admet-437	125	13	µl	µl	NOUN
admet-437	125	14	of	of	ADP
admet-437	125	15	supernatant	supernatant	NOUN
admet-437	125	16	was	be	AUX
admet-437	125	17	injected	inject	VERB
admet-437	125	18	onto	onto	ADP
admet-437	125	19	lc	lc	NOUN
admet-437	125	20	-	-	PUNCT
admet-437	125	21	ms	ms	PROPN
admet-437	125	22	/	/	SYM
admet-437	125	23	ms	ms	NOUN
admet-437	125	24	system	system	NOUN
admet-437	125	25	for	for	ADP
admet-437	125	26	analysis	analysis	NOUN
admet-437	125	27	using	use	VERB
admet-437	125	28	a	a	DET
admet-437	125	29	validated	validate	VERB
admet-437	125	30	method	method	NOUN
admet-437	125	31	[	[	X
admet-437	125	32	16	16	NUM
admet-437	125	33	]	]	PUNCT
admet-437	125	34	.	.	PUNCT
admet-437	126	1	the	the	DET
admet-437	126	2	linearity	linearity	NOUN
admet-437	126	3	range	range	NOUN
admet-437	126	4	was	be	AUX
admet-437	126	5	1.05	1.05	NUM
admet-437	126	6	-	-	SYM
admet-437	126	7	2096	2096	NUM
admet-437	126	8	ng	ng	PROPN
admet-437	126	9	/	/	SYM
admet-437	126	10	ml	ml	PROPN
admet-437	126	11	.	.	PUNCT
admet-437	127	1	in	in	ADP
admet-437	127	2	-	-	PUNCT
admet-437	127	3	study	study	NOUN
admet-437	127	4	quality	quality	NOUN
admet-437	127	5	control	control	NOUN
admet-437	127	6	(	(	PUNCT
admet-437	127	7	qc	qc	PROPN
admet-437	127	8	)	)	PUNCT
admet-437	127	9	samples	sample	NOUN
admet-437	127	10	,	,	PUNCT
admet-437	127	11	supplemented	supplement	VERB
admet-437	127	12	with	with	ADP
admet-437	127	13	concentrations	concentration	NOUN
admet-437	127	14	of	of	ADP
admet-437	127	15	3.14	3.14	NUM
admet-437	127	16	,	,	PUNCT
admet-437	127	17	1048	1048	NUM
admet-437	127	18	and	and	CCONJ
admet-437	127	19	1747	1747	NUM
admet-437	127	20	ng	ng	PROPN
admet-437	127	21	/	/	SYM
admet-437	127	22	ml	ml	PROPN
admet-437	127	23	of	of	ADP
admet-437	127	24	ulixertinib	ulixertinib	NOUN
admet-437	127	25	,	,	PUNCT
admet-437	127	26	were	be	AUX
admet-437	127	27	analysed	analyse	VERB
admet-437	127	28	with	with	ADP
admet-437	127	29	the	the	DET
admet-437	127	30	unknowns	unknown	NOUN
admet-437	127	31	.	.	PUNCT
admet-437	128	1	plasma	plasma	NOUN
admet-437	128	2	samples	sample	NOUN
admet-437	128	3	showing	show	VERB
admet-437	128	4	high	high	ADJ
admet-437	128	5	concentration	concentration	NOUN
admet-437	128	6	above	above	ADP
admet-437	128	7	the	the	DET
admet-437	128	8	high	high	ADJ
admet-437	128	9	calibration	calibration	NOUN
admet-437	128	10	standard	standard	NOUN
admet-437	128	11	were	be	AUX
admet-437	128	12	diluted	dilute	VERB
admet-437	128	13	with	with	ADP
admet-437	128	14	appropriate	appropriate	ADJ
admet-437	128	15	animal	animal	NOUN
admet-437	128	16	species	specie	NOUN
admet-437	128	17	blank	blank	ADJ
admet-437	128	18	plasma	plasma	NOUN
admet-437	128	19	to	to	PART
admet-437	128	20	bring	bring	VERB
admet-437	128	21	the	the	DET
admet-437	128	22	concentration	concentration	NOUN
admet-437	128	23	within	within	ADP
admet-437	128	24	linearity	linearity	NOUN
admet-437	128	25	range	range	NOUN
admet-437	128	26	.	.	PUNCT
admet-437	129	1	for	for	ADP
admet-437	129	2	plasma	plasma	NOUN
admet-437	129	3	samples	sample	NOUN
admet-437	129	4	analysis	analysis	NOUN
admet-437	129	5	the	the	DET
admet-437	129	6	criteria	criterion	NOUN
admet-437	129	7	for	for	ADP
admet-437	129	8	acceptance	acceptance	NOUN
admet-437	129	9	of	of	ADP
admet-437	129	10	the	the	DET
admet-437	129	11	analytical	analytical	ADJ
admet-437	129	12	runs	run	NOUN
admet-437	129	13	encompassed	encompass	VERB
admet-437	129	14	the	the	DET
admet-437	129	15	following	following	NOUN
admet-437	129	16	:	:	PUNCT
admet-437	129	17	(	(	PUNCT
admet-437	129	18	i	i	NOUN
admet-437	129	19	)	)	PUNCT
admet-437	129	20	67	67	NUM
admet-437	129	21	%	%	NOUN
admet-437	129	22	of	of	ADP
admet-437	129	23	the	the	DET
admet-437	129	24	qc	qc	PROPN
admet-437	129	25	samples	sample	NOUN
admet-437	129	26	accuracy	accuracy	NOUN
admet-437	129	27	must	must	AUX
admet-437	129	28	be	be	AUX
admet-437	129	29	within	within	ADP
admet-437	129	30	85	85	NUM
admet-437	129	31	-	-	SYM
admet-437	129	32	115	115	NUM
admet-437	129	33	%	%	NOUN
admet-437	129	34	of	of	ADP
admet-437	129	35	the	the	DET
admet-437	129	36	nominal	nominal	ADJ
admet-437	129	37	concentration	concentration	NOUN
admet-437	129	38	(	(	PUNCT
admet-437	129	39	ii	ii	NOUN
admet-437	129	40	)	)	PUNCT
admet-437	129	41	not	not	PART
admet-437	129	42	less	less	ADJ
admet-437	129	43	than	than	ADP
admet-437	129	44	50	50	NUM
admet-437	129	45	%	%	NOUN
admet-437	129	46	at	at	ADP
admet-437	129	47	each	each	DET
admet-437	129	48	qc	qc	PROPN
admet-437	129	49	concentration	concentration	NOUN
admet-437	129	50	level	level	NOUN
admet-437	129	51	must	must	AUX
admet-437	129	52	meet	meet	VERB
admet-437	129	53	the	the	DET
admet-437	129	54	acceptance	acceptance	NOUN
admet-437	129	55	criteria	criterion	NOUN
admet-437	129	56	.	.	PUNCT
admet-437	130	1	following	follow	VERB
admet-437	130	2	completion	completion	NOUN
admet-437	130	3	of	of	ADP
admet-437	130	4	the	the	DET
admet-437	130	5	analysis	analysis	NOUN
admet-437	130	6	both	both	CCONJ
admet-437	130	7	the	the	DET
admet-437	130	8	linearity	linearity	NOUN
admet-437	130	9	and	and	CCONJ
admet-437	130	10	quality	quality	NOUN
admet-437	130	11	control	control	NOUN
admet-437	130	12	samples	sample	NOUN
admet-437	130	13	values	value	NOUN
admet-437	130	14	were	be	AUX
admet-437	130	15	found	find	VERB
admet-437	130	16	to	to	PART
admet-437	130	17	be	be	AUX
admet-437	130	18	within	within	ADP
admet-437	130	19	the	the	DET
admet-437	130	20	accepted	accepted	ADJ
admet-437	130	21	variable	variable	ADJ
admet-437	130	22	limits	limit	NOUN
admet-437	130	23	.	.	PUNCT
admet-437	131	1	pharmacokinetic	pharmacokinetic	ADJ
admet-437	131	2	analysis	analysis	NOUN
admet-437	131	3	pharmacokinetic	pharmacokinetic	ADJ
admet-437	131	4	parameters	parameter	NOUN
admet-437	131	5	were	be	AUX
admet-437	131	6	calculated	calculate	VERB
admet-437	131	7	by	by	ADP
admet-437	131	8	a	a	DET
admet-437	131	9	non	non	ADJ
admet-437	131	10	-	-	ADJ
admet-437	131	11	compartmental	compartmental	ADJ
admet-437	131	12	method	method	NOUN
admet-437	131	13	using	use	VERB
admet-437	131	14	phoenix	phoenix	PROPN
admet-437	131	15	winnonlin	winnonlin	PROPN
admet-437	131	16	7.0	7.0	NUM
admet-437	131	17	software	software	NOUN
admet-437	131	18	(	(	PUNCT
admet-437	131	19	pharsight	pharsight	NOUN
admet-437	131	20	,	,	PUNCT
admet-437	131	21	mountain	mountain	NOUN
admet-437	131	22	view	view	NOUN
admet-437	131	23	,	,	PUNCT
admet-437	131	24	ca	ca	PROPN
admet-437	131	25	,	,	PUNCT
admet-437	131	26	usa	usa	PROPN
admet-437	131	27	)	)	PUNCT
admet-437	131	28	.	.	PUNCT
admet-437	132	1	absolute	absolute	ADJ
admet-437	132	2	oral	oral	ADJ
admet-437	132	3	bioavailability	bioavailability	NOUN
admet-437	132	4	(	(	PUNCT
admet-437	132	5	f	f	X
admet-437	132	6	)	)	PUNCT
admet-437	132	7	was	be	AUX
admet-437	132	8	calculated	calculate	VERB
admet-437	132	9	using	use	VERB
admet-437	132	10	the	the	DET
admet-437	132	11	relationship	relationship	NOUN
admet-437	132	12	,	,	PUNCT
admet-437	132	13	f	f	X
admet-437	132	14	=	=	PUNCT
admet-437	133	1	[	[	X
admet-437	133	2	dose	dose	X
admet-437	133	3	(	(	PUNCT
admet-437	133	4	i.v	i.v	PROPN
admet-437	133	5	.	.	PUNCT
admet-437	133	6	)	)	PUNCT
admet-437	134	1	x	x	X
admet-437	134	2	auc(0-)oral	auc(0-)oral	ADV
admet-437	134	3	/	/	SYM
admet-437	134	4	dose	dose	NOUN
admet-437	134	5	(	(	PUNCT
admet-437	134	6	oral	oral	ADJ
admet-437	134	7	)	)	PUNCT
admet-437	134	8	x	x	SYM
admet-437	134	9	auc(0-)i.v	auc(0-)i.v	NOUN
admet-437	134	10	.	.	PUNCT
admet-437	134	11	]	]	PUNCT
admet-437	135	1	x	x	SYM
admet-437	135	2	100	100	X
admet-437	135	3	.	.	PUNCT
admet-437	135	4	results	result	NOUN
admet-437	135	5	in	in	ADP
admet-437	135	6	vitro	vitro	X
admet-437	135	7	studies	study	NOUN
admet-437	135	8	metabolic	metabolic	NOUN
admet-437	135	9	stability	stability	NOUN
admet-437	135	10	in	in	ADP
admet-437	135	11	liver	liver	NOUN
admet-437	135	12	microsomes	microsome	NOUN
admet-437	135	13	metabolic	metabolic	NOUN
admet-437	135	14	stability	stability	NOUN
admet-437	135	15	of	of	ADP
admet-437	135	16	ulixertinib	ulixertinib	NOUN
admet-437	135	17	in	in	ADP
admet-437	135	18	different	different	ADJ
admet-437	135	19	species	specie	NOUN
admet-437	135	20	of	of	ADP
admet-437	135	21	liver	liver	NOUN
admet-437	135	22	microsomes	microsome	NOUN
admet-437	135	23	is	be	AUX
admet-437	135	24	presented	present	VERB
admet-437	135	25	in	in	ADP
admet-437	135	26	table	table	NOUN
admet-437	135	27	1	1	NUM
admet-437	135	28	.	.	PUNCT
admet-437	135	29	ulixertinib	ulixertinib	PROPN
admet-437	135	30	was	be	AUX
admet-437	135	31	found	find	VERB
admet-437	135	32	to	to	PART
admet-437	135	33	be	be	AUX
admet-437	135	34	moderately	moderately	ADV
admet-437	135	35	stable	stable	ADJ
admet-437	135	36	in	in	ADP
admet-437	135	37	mice	mouse	NOUN
admet-437	135	38	and	and	CCONJ
admet-437	135	39	dog	dog	NOUN
admet-437	135	40	liver	liver	NOUN
admet-437	135	41	microsomes	microsome	NOUN
admet-437	135	42	and	and	CCONJ
admet-437	135	43	highly	highly	ADV
admet-437	135	44	stable	stable	ADJ
admet-437	135	45	rat	rat	NOUN
admet-437	135	46	and	and	CCONJ
admet-437	135	47	human	human	ADJ
admet-437	135	48	liver	liver	NOUN
admet-437	135	49	microsomes	microsome	NOUN
admet-437	135	50	.	.	PUNCT
admet-437	136	1	metabolic	metabolic	NOUN
admet-437	136	2	stability	stability	NOUN
admet-437	136	3	in	in	ADP
admet-437	136	4	hepatocytes	hepatocytes	ADJ
admet-437	136	5	hepatocyte	hepatocyte	NOUN
admet-437	136	6	stability	stability	NOUN
admet-437	136	7	of	of	ADP
admet-437	136	8	ulixertinib	ulixertinib	NOUN
admet-437	136	9	in	in	ADP
admet-437	136	10	different	different	ADJ
admet-437	136	11	species	specie	NOUN
admet-437	136	12	is	be	AUX
admet-437	136	13	presented	present	VERB
admet-437	136	14	in	in	ADP
admet-437	136	15	table	table	NOUN
admet-437	136	16	2	2	NUM
admet-437	136	17	.	.	PUNCT
admet-437	136	18	ulixertinib	ulixertinib	PROPN
admet-437	136	19	was	be	AUX
admet-437	136	20	found	find	VERB
admet-437	136	21	to	to	PART
admet-437	136	22	be	be	AUX
admet-437	136	23	highly	highly	ADV
admet-437	136	24	stable	stable	ADJ
admet-437	136	25	in	in	ADP
admet-437	136	26	rat	rat	NOUN
admet-437	136	27	and	and	CCONJ
admet-437	136	28	human	human	ADJ
admet-437	136	29	hepatocytes	hepatocyte	NOUN
admet-437	136	30	but	but	CCONJ
admet-437	136	31	moderately	moderately	ADV
admet-437	136	32	stable	stable	ADJ
admet-437	136	33	in	in	ADP
admet-437	136	34	mice	mouse	NOUN
admet-437	136	35	and	and	CCONJ
admet-437	136	36	dog	dog	NOUN
admet-437	136	37	hepatocytes	hepatocyte	NOUN
admet-437	136	38	.	.	PUNCT
admet-437	137	1	the	the	DET
admet-437	137	2	in	in	ADP
admet-437	137	3	vivo	vivo	ADJ
admet-437	137	4	intrinsic	intrinsic	ADJ
admet-437	137	5	clearance	clearance	NOUN
admet-437	137	6	(	(	PUNCT
admet-437	137	7	clint	clint	NOUN
admet-437	137	8	)	)	PUNCT
admet-437	137	9	was	be	AUX
admet-437	137	10	relatively	relatively	ADV
admet-437	137	11	low	low	ADJ
admet-437	137	12	to	to	PART
admet-437	137	13	moderate	moderate	VERB
admet-437	137	14	in	in	ADP
admet-437	137	15	rat	rat	NOUN
admet-437	137	16	and	and	CCONJ
admet-437	137	17	human	human	ADJ
admet-437	137	18	hepatocytes	hepatocyte	NOUN
admet-437	137	19	but	but	CCONJ
admet-437	137	20	high	high	ADJ
admet-437	137	21	in	in	ADP
admet-437	137	22	mice	mouse	NOUN
admet-437	137	23	and	and	CCONJ
admet-437	137	24	dog	dog	NOUN
admet-437	137	25	hepatocytes	hepatocyte	NOUN
admet-437	137	26	.	.	PUNCT
admet-437	138	1	caco-2	caco-2	NUM
admet-437	138	2	permeability	permeability	NOUN
admet-437	138	3	table	table	NOUN
admet-437	138	4	3	3	NUM
admet-437	138	5	shows	show	VERB
admet-437	138	6	the	the	DET
admet-437	138	7	rate	rate	NOUN
admet-437	138	8	of	of	ADP
admet-437	138	9	transport	transport	NOUN
admet-437	138	10	(	(	PUNCT
admet-437	138	11	papp	papp	NOUN
admet-437	138	12	)	)	PUNCT
admet-437	138	13	of	of	ADP
admet-437	138	14	ulixertinib	ulixertinib	NOUN
admet-437	138	15	and	and	CCONJ
admet-437	138	16	digoxin	digoxin	NOUN
admet-437	138	17	from	from	ADP
admet-437	138	18	a	a	DET
admet-437	138	19	→	→	SYM
admet-437	138	20	b	b	PROPN
admet-437	138	21	and	and	CCONJ
admet-437	138	22	b	b	PROPN
admet-437	138	23	→	→	PUNCT
admet-437	138	24	a	a	PRON
admet-437	138	25	along	along	ADP
admet-437	138	26	with	with	ADP
admet-437	138	27	efflux	efflux	NOUN
admet-437	138	28	ratio	ratio	NOUN
admet-437	138	29	values	value	NOUN
admet-437	138	30	.	.	PUNCT
admet-437	139	1	the	the	DET
admet-437	139	2	findings	finding	NOUN
admet-437	139	3	suggested	suggest	VERB
admet-437	139	4	that	that	SCONJ
admet-437	139	5	ulixertinib	ulixertinib	NOUN
admet-437	139	6	is	be	AUX
admet-437	139	7	a	a	DET
admet-437	139	8	medium	medium	ADJ
admet-437	139	9	permeable	permeable	ADJ
admet-437	139	10	compound	compound	NOUN
admet-437	139	11	and	and	CCONJ
admet-437	139	12	may	may	AUX
admet-437	139	13	be	be	AUX
admet-437	139	14	a	a	DET
admet-437	139	15	r.	r.	PROPN
admet-437	139	16	mullangi	mullangi	NOUN
admet-437	139	17	et	et	PROPN
admet-437	139	18	al	al	PROPN
admet-437	139	19	.	.	PROPN
admet-437	139	20	admet	admet	PROPN
admet-437	139	21	&	&	CCONJ
admet-437	139	22	dmpk	dmpk	PROPN
admet-437	139	23	5(4	5(4	NOUN
admet-437	139	24	)	)	PUNCT
admet-437	139	25	(	(	PUNCT
admet-437	139	26	2017	2017	NUM
admet-437	139	27	)	)	PUNCT
admet-437	139	28	212	212	NUM
admet-437	139	29	-	-	SYM
admet-437	139	30	223	223	NUM
admet-437	139	31	218	218	NUM
admet-437	139	32	substrate	substrate	NOUN
admet-437	139	33	of	of	ADP
admet-437	139	34	an	an	DET
admet-437	139	35	active	active	ADJ
admet-437	139	36	efflux	efflux	NOUN
admet-437	139	37	transporter	transporter	NOUN
admet-437	139	38	.	.	PUNCT
admet-437	140	1	table	table	NOUN
admet-437	140	2	1	1	NUM
admet-437	140	3	.	.	PUNCT
admet-437	140	4	metabolic	metabolic	NOUN
admet-437	140	5	stability	stability	NOUN
admet-437	140	6	data	datum	NOUN
admet-437	140	7	of	of	ADP
admet-437	140	8	ulixertinib	ulixertinib	NOUN
admet-437	140	9	at	at	ADP
admet-437	140	10	1	1	NUM
admet-437	140	11	µm	µm	NOUN
admet-437	140	12	in	in	ADP
admet-437	140	13	liver	liver	NOUN
admet-437	140	14	microsomes	microsome	NOUN
admet-437	140	15	of	of	ADP
admet-437	140	16	various	various	ADJ
admet-437	140	17	preclinical	preclinical	ADJ
admet-437	140	18	species	specie	NOUN
admet-437	140	19	species	specie	NOUN
admet-437	140	20	percent	percent	NOUN
admet-437	140	21	metabolized	metabolize	VERB
admet-437	140	22	t½	t½	NOUN
admet-437	140	23	(	(	PUNCT
admet-437	140	24	min	min	NOUN
admet-437	140	25	)	)	PUNCT
admet-437	140	26	mclint	mclint	NOUN
admet-437	140	27	(	(	PUNCT
admet-437	140	28	µl	µl	NOUN
admet-437	140	29	/	/	SYM
admet-437	140	30	min	min	NOUN
admet-437	140	31	/	/	SYM
admet-437	140	32	mg	mg	PROPN
admet-437	140	33	)	)	PUNCT
admet-437	140	34	clint	clint	NOUN
admet-437	140	35	(	(	PUNCT
admet-437	140	36	ml	ml	NOUN
admet-437	140	37	/	/	SYM
admet-437	140	38	min	min	NOUN
admet-437	140	39	/	/	SYM
admet-437	140	40	kg	kg	NOUN
admet-437	140	41	)	)	PUNCT
admet-437	140	42	mice	mouse	NOUN
admet-437	140	43	44.5	44.5	NUM
admet-437	140	44	36	36	NUM
admet-437	140	45	19.3	19.3	NUM
admet-437	140	46	27.7	27.7	NUM
admet-437	140	47	rat	rat	NOUN
admet-437	140	48	16.4	16.4	NUM
admet-437	140	49	122	122	NUM
admet-437	140	50	5.7	5.7	NUM
admet-437	140	51	7.6	7.6	NUM
admet-437	140	52	dog	dog	NOUN
admet-437	140	53	35.5	35.5	NUM
admet-437	140	54	52	52	NUM
admet-437	140	55	13.3	13.3	NUM
admet-437	140	56	9.1	9.1	NUM
admet-437	140	57	human	human	ADJ
admet-437	140	58	12.8	12.8	NUM
admet-437	140	59	142	142	NUM
admet-437	140	60	9.8	9.8	NUM
admet-437	140	61	5.4	5.4	NUM
admet-437	140	62	table	table	NOUN
admet-437	140	63	2	2	NUM
admet-437	140	64	.	.	PUNCT
admet-437	140	65	hepatocyte	hepatocyte	NOUN
admet-437	140	66	stability	stability	NOUN
admet-437	140	67	data	datum	NOUN
admet-437	140	68	of	of	ADP
admet-437	140	69	ulixertinib	ulixertinib	NOUN
admet-437	140	70	at	at	ADP
admet-437	140	71	3	3	NUM
admet-437	140	72	µm	µm	NOUN
admet-437	140	73	in	in	ADP
admet-437	140	74	liver	liver	NOUN
admet-437	140	75	hepatocytes	hepatocyte	NOUN
admet-437	140	76	of	of	ADP
admet-437	140	77	various	various	ADJ
admet-437	140	78	preclinical	preclinical	ADJ
admet-437	140	79	species	specie	NOUN
admet-437	140	80	species	specie	NOUN
admet-437	140	81	percent	percent	NOUN
admet-437	140	82	metabolized	metabolize	VERB
admet-437	140	83	t½	t½	NOUN
admet-437	140	84	(	(	PUNCT
admet-437	140	85	min	min	NOUN
admet-437	140	86	)	)	PUNCT
admet-437	140	87	hclint	hclint	NOUN
admet-437	140	88	(	(	PUNCT
admet-437	140	89	ml	ml	NOUN
admet-437	140	90	/	/	SYM
admet-437	140	91	min/106	min/106	NOUN
admet-437	140	92	cells	cell	NOUN
admet-437	140	93	)	)	PUNCT
admet-437	140	94	clint	clint	NOUN
admet-437	140	95	scaled	scale	VERB
admet-437	140	96	(	(	PUNCT
admet-437	140	97	ml	ml	NOUN
admet-437	140	98	/	/	SYM
admet-437	140	99	min	min	NOUN
admet-437	140	100	/	/	SYM
admet-437	140	101	kg	kg	NOUN
admet-437	140	102	)	)	PUNCT
admet-437	140	103	mice	mouse	NOUN
admet-437	140	104	79	79	NUM
admet-437	140	105	78	78	NUM
admet-437	140	106	8.9	8.9	NUM
admet-437	140	107	41.3	41.3	NUM
admet-437	140	108	rat	rat	NOUN
admet-437	140	109	27	27	NUM
admet-437	140	110	410	410	NUM
admet-437	140	111	1.7	1.7	NUM
admet-437	140	112	7.1	7.1	NUM
admet-437	140	113	dog	dog	NOUN
admet-437	140	114	76	76	NUM
admet-437	140	115	73	73	NUM
admet-437	140	116	9.1	9.1	NUM
admet-437	140	117	16.4	16.4	NUM
admet-437	140	118	human	human	NOUN
admet-437	140	119	37	37	NUM
admet-437	140	120	306	306	NUM
admet-437	140	121	2.3	2.3	NUM
admet-437	140	122	5.0	5.0	NUM
admet-437	140	123	table	table	NOUN
admet-437	140	124	3	3	NUM
admet-437	140	125	.	.	PUNCT
admet-437	140	126	permeability	permeability	NOUN
admet-437	140	127	data	datum	NOUN
admet-437	140	128	of	of	ADP
admet-437	140	129	ulixertinib	ulixertinib	NOUN
admet-437	140	130	in	in	ADP
admet-437	140	131	caco-2	caco-2	NUM
admet-437	140	132	cell	cell	NOUN
admet-437	140	133	monolayers	monolayer	NOUN
admet-437	140	134	%	%	NOUN
admet-437	140	135	recovery	recovery	NOUN
admet-437	140	136	permeability	permeability	NOUN
admet-437	140	137	(	(	PUNCT
admet-437	140	138	x	x	PROPN
admet-437	140	139	10	10	NUM
admet-437	140	140	-6	-6	NOUN
admet-437	140	141	cm	cm	NOUN
admet-437	140	142	/	/	SYM
admet-437	140	143	sec	sec	PROPN
admet-437	140	144	)	)	PUNCT
admet-437	140	145	efflux	efflux	VERB
admet-437	140	146	ratio	ratio	NOUN
admet-437	140	147	compound	compound	NOUN
admet-437	140	148	concentration	concentration	NOUN
admet-437	140	149	(	(	PUNCT
admet-437	140	150	µm	µm	NOUN
admet-437	140	151	)	)	PUNCT
admet-437	140	152	b	b	NOUN
admet-437	140	153			NOUN
admet-437	140	154	a	a	DET
admet-437	140	155	a	a	DET
admet-437	140	156			NOUN
admet-437	140	157	b	b	NOUN
admet-437	140	158	b	b	X
admet-437	140	159			NOUN
admet-437	140	160	a	a	DET
admet-437	140	161	a	a	DET
admet-437	140	162			NOUN
admet-437	140	163	b	b	NOUN
admet-437	140	164	b	b	NOUN
admet-437	140	165			NOUN
admet-437	140	166	a/	a/	VERB
admet-437	140	167	a	a	DET
admet-437	140	168			NOUN
admet-437	140	169	b	b	NOUN
admet-437	140	170	ulixertinib	ulixertinib	NOUN
admet-437	140	171	10	10	NUM
admet-437	140	172	79	79	NUM
admet-437	140	173	65	65	NUM
admet-437	140	174	8.09	8.09	NUM
admet-437	140	175	2.67	2.67	NUM
admet-437	140	176	3.02	3.02	NUM
admet-437	140	177	digoxin	digoxin	NOUN
admet-437	140	178	5.0	5.0	NUM
admet-437	140	179	98	98	NUM
admet-437	140	180	75	75	NUM
admet-437	140	181	10.5	10.5	NUM
admet-437	140	182	1.00	1.00	NUM
admet-437	140	183	10.5	10.5	NUM
admet-437	140	184	plasma	plasma	NOUN
admet-437	140	185	protein	protein	NOUN
admet-437	140	186	binding	bind	VERB
admet-437	140	187	ulixertinib	ulixertinib	NOUN
admet-437	140	188	had	have	VERB
admet-437	140	189	a	a	DET
admet-437	140	190	very	very	ADV
admet-437	140	191	high	high	ADJ
admet-437	140	192	binding	bind	VERB
admet-437	140	193	in	in	ADP
admet-437	140	194	rat	rat	NOUN
admet-437	140	195	plasma	plasma	NOUN
admet-437	140	196	followed	follow	VERB
admet-437	140	197	by	by	ADP
admet-437	140	198	mouse	mouse	NOUN
admet-437	140	199	and	and	CCONJ
admet-437	140	200	dog	dog	NOUN
admet-437	140	201	plasma	plasma	NOUN
admet-437	140	202	with	with	ADP
admet-437	140	203	fraction	fraction	NOUN
admet-437	140	204	unbound	unbound	NOUN
admet-437	140	205	of	of	ADP
admet-437	140	206	0.001	0.001	NUM
admet-437	140	207	,	,	PUNCT
admet-437	140	208	0.003	0.003	NUM
admet-437	140	209	and	and	CCONJ
admet-437	140	210	0.050	0.050	NUM
admet-437	140	211	,	,	PUNCT
admet-437	140	212	respectively	respectively	ADV
admet-437	140	213	.	.	PUNCT
admet-437	141	1	the	the	DET
admet-437	141	2	stability	stability	NOUN
admet-437	141	3	and	and	CCONJ
admet-437	141	4	recovery	recovery	NOUN
admet-437	141	5	of	of	ADP
admet-437	141	6	ulixertinib	ulixertinib	NOUN
admet-437	141	7	in	in	ADP
admet-437	141	8	plasma	plasma	NOUN
admet-437	141	9	was	be	AUX
admet-437	141	10	good	good	ADJ
admet-437	141	11	across	across	ADP
admet-437	141	12	the	the	DET
admet-437	141	13	species	specie	NOUN
admet-437	141	14	tested	test	VERB
admet-437	141	15	.	.	PUNCT
admet-437	142	1	cyp	cyp	ADJ
admet-437	142	2	inhibition	inhibition	NOUN
admet-437	142	3	the	the	DET
admet-437	142	4	predicted	predict	VERB
admet-437	142	5	ic50	ic50	PROPN
admet-437	142	6	values	value	NOUN
admet-437	142	7	of	of	ADP
admet-437	142	8	ulixertinib	ulixertinib	NOUN
admet-437	142	9	were	be	AUX
admet-437	142	10	determined	determine	VERB
admet-437	142	11	for	for	ADP
admet-437	142	12	cyp	cyp	ADJ
admet-437	142	13	-	-	PUNCT
admet-437	142	14	specific	specific	ADJ
admet-437	142	15	hydroxylation	hydroxylation	NOUN
admet-437	142	16	of	of	ADP
admet-437	142	17	midazolam	midazolam	PROPN
admet-437	142	18	,	,	PUNCT
admet-437	142	19	bufuralol	bufuralol	NOUN
admet-437	142	20	,	,	PUNCT
admet-437	142	21	diclofenac	diclofenac	NOUN
admet-437	142	22	and	and	CCONJ
admet-437	142	23	omeprazole	omeprazole	NOUN
admet-437	142	24	for	for	ADP
admet-437	142	25	cyp	cyp	ADJ
admet-437	142	26	3a4	3a4	NUM
admet-437	142	27	,	,	PUNCT
admet-437	142	28	2d6	2d6	NUM
admet-437	142	29	,	,	PUNCT
admet-437	142	30	2c9	2c9	NUM
admet-437	142	31	and	and	CCONJ
admet-437	142	32	2c19	2c19	NOUN
admet-437	142	33	,	,	PUNCT
admet-437	142	34	respectively	respectively	ADV
admet-437	142	35	and	and	CCONJ
admet-437	142	36	deethylation	deethylation	NOUN
admet-437	142	37	of	of	ADP
admet-437	142	38	cyp1a2	cyp1a2	PROPN
admet-437	142	39	.	.	PROPN
admet-437	142	40	ulixertinib	ulixertinib	PROPN
admet-437	142	41	did	do	AUX
admet-437	142	42	not	not	PART
admet-437	142	43	show	show	VERB
admet-437	142	44	notable	notable	ADJ
admet-437	142	45	inhibition	inhibition	NOUN
admet-437	142	46	against	against	ADP
admet-437	142	47	these	these	DET
admet-437	142	48	enzymes	enzyme	NOUN
admet-437	142	49	and	and	CCONJ
admet-437	142	50	the	the	DET
admet-437	142	51	predicted	predict	VERB
admet-437	142	52	ic50	ic50	PROPN
admet-437	142	53	values	value	NOUN
admet-437	142	54	of	of	ADP
admet-437	142	55	ulixertinib	ulixertinib	NOUN
admet-437	142	56	were	be	AUX
admet-437	142	57	found	find	VERB
admet-437	142	58	to	to	PART
admet-437	142	59	be	be	AUX
admet-437	142	60	~10	~10	PUNCT
admet-437	142	61	and	and	CCONJ
admet-437	142	62	20	20	NUM
admet-437	142	63	µm	µm	NOUN
admet-437	142	64	for	for	ADP
admet-437	142	65	cyp	cyp	ADJ
admet-437	142	66	3a4	3a4	NUM
admet-437	142	67	and	and	CCONJ
admet-437	142	68	2d6	2d6	NUM
admet-437	142	69	,	,	PUNCT
admet-437	142	70	respectively	respectively	ADV
admet-437	142	71	indicating	indicate	VERB
admet-437	142	72	it	it	PRON
admet-437	142	73	is	be	AUX
admet-437	142	74	a	a	DET
admet-437	142	75	weak	weak	ADJ
admet-437	142	76	inhibitor	inhibitor	NOUN
admet-437	142	77	against	against	ADP
admet-437	142	78	these	these	DET
admet-437	142	79	two	two	NUM
admet-437	142	80	cyps	cyp	NOUN
admet-437	142	81	.	.	PUNCT
admet-437	143	1	furthermore	furthermore	ADV
admet-437	143	2	,	,	PUNCT
admet-437	143	3	its	its	PRON
admet-437	143	4	inhibitory	inhibitory	ADJ
admet-437	143	5	effect	effect	NOUN
admet-437	143	6	was	be	AUX
admet-437	143	7	much	much	ADV
admet-437	143	8	weaker	weak	ADJ
admet-437	143	9	against	against	ADP
admet-437	143	10	cyp1a2	cyp1a2	PROPN
admet-437	143	11	,	,	PUNCT
admet-437	143	12	2c9	2c9	NUM
admet-437	143	13	and	and	CCONJ
admet-437	143	14	2c19	2c19	NOUN
admet-437	143	15	as	as	SCONJ
admet-437	143	16	its	its	PRON
admet-437	143	17	ic50	ic50	PROPN
admet-437	143	18	was	be	AUX
admet-437	143	19	>	>	X
admet-437	143	20	20	20	NUM
admet-437	143	21	µm	µm	NOUN
admet-437	143	22	.	.	PUNCT
admet-437	144	1	thus	thus	ADV
admet-437	144	2	,	,	PUNCT
admet-437	144	3	when	when	SCONJ
admet-437	144	4	compared	compare	VERB
admet-437	144	5	with	with	ADP
admet-437	144	6	known	know	VERB
admet-437	144	7	inhibitors	inhibitor	NOUN
admet-437	144	8	,	,	PUNCT
admet-437	144	9	ulixertinib	ulixertinib	PROPN
admet-437	144	10	shows	show	VERB
admet-437	144	11	less	less	ADV
admet-437	144	12	significant	significant	ADJ
admet-437	144	13	inhibition	inhibition	NOUN
admet-437	144	14	of	of	ADP
admet-437	144	15	cyp	cyp	ADJ
admet-437	144	16	enzyme	enzyme	NOUN
admet-437	144	17	activity	activity	NOUN
admet-437	144	18	in	in	ADP
admet-437	144	19	vitro	vitro	X
admet-437	144	20	(	(	PUNCT
admet-437	144	21	table	table	NOUN
admet-437	144	22	4	4	NUM
admet-437	144	23	)	)	PUNCT
admet-437	144	24	.	.	PUNCT
admet-437	145	1	cyp	cyp	ADJ
admet-437	145	2	induction	induction	NOUN
admet-437	145	3	admet	admet	PROPN
admet-437	145	4	&	&	CCONJ
admet-437	145	5	dmpk	dmpk	PROPN
admet-437	145	6	5(4	5(4	NOUN
admet-437	145	7	)	)	PUNCT
admet-437	145	8	(	(	PUNCT
admet-437	145	9	2017	2017	NUM
admet-437	145	10	)	)	PUNCT
admet-437	145	11	212	212	NUM
admet-437	145	12	-	-	SYM
admet-437	145	13	223	223	NUM
admet-437	145	14	preclinical	preclinical	ADJ
admet-437	145	15	assessment	assessment	NOUN
admet-437	145	16	of	of	ADP
admet-437	145	17	ulixertinib	ulixertinib	PROPN
admet-437	145	18	doi	doi	PROPN
admet-437	145	19	:	:	PUNCT
admet-437	145	20	10.5599	10.5599	NUM
admet-437	145	21	/	/	SYM
admet-437	145	22	admet.5.4.437	admet.5.4.437	NUM
admet-437	145	23	219	219	NUM
admet-437	145	24	ulixertinib	ulixertinib	NOUN
admet-437	145	25	was	be	AUX
admet-437	145	26	tested	test	VERB
admet-437	145	27	at	at	ADP
admet-437	145	28	two	two	NUM
admet-437	145	29	different	different	ADJ
admet-437	145	30	concentrations	concentration	NOUN
admet-437	145	31	(	(	PUNCT
admet-437	145	32	1	1	NUM
admet-437	145	33	and	and	CCONJ
admet-437	145	34	10	10	NUM
admet-437	145	35	µm	µm	NUM
admet-437	145	36	)	)	PUNCT
admet-437	145	37	.	.	PUNCT
admet-437	146	1	the	the	DET
admet-437	146	2	readings	reading	NOUN
admet-437	146	3	suggested	suggest	VERB
admet-437	146	4	no	no	PRON
admet-437	146	5	or	or	CCONJ
admet-437	146	6	very	very	ADV
admet-437	146	7	less	less	ADJ
admet-437	146	8	percent	percent	NOUN
admet-437	146	9	activation	activation	NOUN
admet-437	146	10	compared	compare	VERB
admet-437	146	11	against	against	ADP
admet-437	146	12	rifampicin	rifampicin	NOUN
admet-437	146	13	,	,	PUNCT
admet-437	146	14	a	a	DET
admet-437	146	15	known	know	VERB
admet-437	146	16	cyp3a4	cyp3a4	NOUN
admet-437	146	17	inducer	inducer	NOUN
admet-437	146	18	.	.	PUNCT
admet-437	147	1	table	table	NOUN
admet-437	147	2	4	4	NUM
admet-437	147	3	.	.	PUNCT
admet-437	148	1	ic50	ic50	PROPN
admet-437	148	2	values	value	NOUN
admet-437	148	3	for	for	ADP
admet-437	148	4	cyp450	cyp450	NOUN
admet-437	148	5	inhibition	inhibition	NOUN
admet-437	148	6	by	by	ADP
admet-437	148	7	ulixertinib	ulixertinib	NOUN
admet-437	148	8	and	and	CCONJ
admet-437	148	9	other	other	ADJ
admet-437	148	10	known	know	VERB
admet-437	148	11	cyp	cyp	ADJ
admet-437	148	12	inhibitors	inhibitor	NOUN
admet-437	148	13	ic50	ic50	PROPN
admet-437	148	14	(	(	PUNCT
admet-437	148	15	µm	µm	NOUN
admet-437	148	16	)	)	PUNCT
admet-437	148	17	inhibitor	inhibitor	NOUN
admet-437	148	18	cyp3a4	cyp3a4	PROPN
admet-437	148	19	cyp2d6	cyp2d6	PROPN
admet-437	148	20	cyp2c9	cyp2c9	PROPN
admet-437	148	21	cyp2c19	cyp2c19	PROPN
admet-437	148	22	cyp1a2	cyp1a2	PROPN
admet-437	148	23	ulixertinib	ulixertinib	PROPN
admet-437	148	24	~10	~10	X
admet-437	148	25	~20	~20	X
admet-437	148	26	>	>	SYM
admet-437	148	27	20	20	NUM
admet-437	148	28	>	>	SYM
admet-437	148	29	20	20	NUM
admet-437	148	30	>	>	SYM
admet-437	148	31	20	20	NUM
admet-437	148	32	ketoconazole	ketoconazole	NOUN
admet-437	148	33	0.08	0.08	NUM
admet-437	148	34	nt	nt	INTJ
admet-437	148	35	nt	not	PART
admet-437	148	36	nt	not	PART
admet-437	148	37	nt	not	PART
admet-437	148	38	quinidine	quinidine	VERB
admet-437	148	39	nt	not	PART
admet-437	148	40	0.12	0.12	NUM
admet-437	148	41	nt	not	PART
admet-437	148	42	nt	not	PART
admet-437	148	43	nt	not	PART
admet-437	148	44	sulphaphenazole	sulphaphenazole	NOUN
admet-437	148	45	nt	not	PART
admet-437	148	46	nt	not	PART
admet-437	148	47	0.72	0.72	NUM
admet-437	148	48	nt	not	PART
admet-437	148	49	nt	not	PART
admet-437	148	50	nootkatone	nootkatone	NOUN
admet-437	149	1	nt	not	PART
admet-437	149	2	nt	not	PART
admet-437	149	3	nt	not	PART
admet-437	149	4	1.02	1.02	NUM
admet-437	149	5	nt	not	PART
admet-437	149	6	furafylline	furafylline	NOUN
admet-437	149	7	nt	not	PART
admet-437	149	8	nt	not	PART
admet-437	149	9	nt	not	PART
admet-437	149	10	nt	not	PART
admet-437	149	11	0.58	0.58	NUM
admet-437	149	12	rhcyp	rhcyp	ADJ
admet-437	149	13	metabolism	metabolism	NOUN
admet-437	149	14	data	datum	NOUN
admet-437	149	15	following	follow	VERB
admet-437	149	16	incubations	incubation	NOUN
admet-437	149	17	with	with	ADP
admet-437	149	18	different	different	ADJ
admet-437	149	19	cyp	cyp	ADJ
admet-437	149	20	isozymes	isozyme	NOUN
admet-437	149	21	(	(	PUNCT
admet-437	149	22	cyp1a2	cyp1a2	PROPN
admet-437	149	23	,	,	PUNCT
admet-437	149	24	2b6	2b6	NUM
admet-437	149	25	,	,	PUNCT
admet-437	149	26	2c8	2c8	NUM
admet-437	149	27	,	,	PUNCT
admet-437	149	28	2c9	2c9	NUM
admet-437	149	29	,	,	PUNCT
admet-437	149	30	2c19	2c19	NOUN
admet-437	149	31	,	,	PUNCT
admet-437	149	32	2d6	2d6	NUM
admet-437	149	33	and	and	CCONJ
admet-437	149	34	3a4	3a4	NUM
admet-437	149	35	)	)	PUNCT
admet-437	149	36	considered	consider	VERB
admet-437	149	37	in	in	ADP
admet-437	149	38	the	the	DET
admet-437	149	39	panel	panel	NOUN
admet-437	149	40	suggested	suggest	VERB
admet-437	149	41	very	very	ADV
admet-437	149	42	minimal	minimal	ADJ
admet-437	149	43	contribution	contribution	NOUN
admet-437	149	44	of	of	ADP
admet-437	149	45	cyp1a2	cyp1a2	PROPN
admet-437	149	46	,	,	PUNCT
admet-437	149	47	2c9	2c9	NUM
admet-437	149	48	,	,	PUNCT
admet-437	149	49	2c19	2c19	NOUN
admet-437	149	50	,	,	PUNCT
admet-437	149	51	2d6	2d6	NUM
admet-437	149	52	and	and	CCONJ
admet-437	149	53	3a4	3a4	NUM
admet-437	149	54	towards	towards	ADP
admet-437	149	55	the	the	DET
admet-437	149	56	metabolism	metabolism	NOUN
admet-437	149	57	of	of	ADP
admet-437	149	58	ulixertinib	ulixertinib	NOUN
admet-437	149	59	involving	involve	VERB
admet-437	149	60	oxidation	oxidation	NOUN
admet-437	149	61	and	and	CCONJ
admet-437	149	62	dealkylation	dealkylation	NOUN
admet-437	149	63	.	.	PUNCT
admet-437	150	1	this	this	DET
admet-437	150	2	data	data	NOUN
admet-437	150	3	is	be	AUX
admet-437	150	4	corroborating	corroborate	VERB
admet-437	150	5	with	with	ADP
admet-437	150	6	the	the	DET
admet-437	150	7	work	work	NOUN
admet-437	150	8	reported	report	VERB
admet-437	150	9	by	by	ADP
admet-437	150	10	germann	germann	PROPN
admet-437	150	11	et	et	PROPN
admet-437	150	12	al	al	PROPN
admet-437	151	1	[	[	X
admet-437	151	2	6	6	NUM
admet-437	151	3	]	]	PUNCT
admet-437	151	4	.	.	PUNCT
admet-437	152	1	pharmacokinetic	pharmacokinetic	ADJ
admet-437	152	2	studies	study	NOUN
admet-437	152	3	the	the	DET
admet-437	152	4	profiles	profile	NOUN
admet-437	152	5	of	of	ADP
admet-437	152	6	plasma	plasma	NOUN
admet-437	152	7	concentration	concentration	NOUN
admet-437	152	8	for	for	ADP
admet-437	152	9	ulixertinib	ulixertinib	NOUN
admet-437	152	10	following	follow	VERB
admet-437	152	11	single	single	ADJ
admet-437	152	12	oral	oral	ADJ
admet-437	152	13	and	and	CCONJ
admet-437	152	14	intravenous	intravenous	ADJ
admet-437	152	15	administration	administration	NOUN
admet-437	152	16	to	to	ADP
admet-437	152	17	mice	mouse	NOUN
admet-437	152	18	,	,	PUNCT
admet-437	152	19	rats	rat	NOUN
admet-437	152	20	and	and	CCONJ
admet-437	152	21	dogs	dog	NOUN
admet-437	152	22	are	be	AUX
admet-437	152	23	shown	show	VERB
admet-437	152	24	in	in	ADP
admet-437	152	25	figure	figure	NOUN
admet-437	152	26	2a	2a	NUM
admet-437	152	27	and	and	CCONJ
admet-437	152	28	2b	2b	NOUN
admet-437	152	29	,	,	PUNCT
admet-437	152	30	respectively	respectively	ADV
admet-437	152	31	.	.	PUNCT
admet-437	153	1	the	the	DET
admet-437	153	2	estimates	estimate	NOUN
admet-437	153	3	of	of	ADP
admet-437	153	4	pharmacokinetic	pharmacokinetic	ADJ
admet-437	153	5	parameters	parameter	NOUN
admet-437	153	6	in	in	ADP
admet-437	153	7	these	these	DET
admet-437	153	8	species	specie	NOUN
admet-437	153	9	are	be	AUX
admet-437	153	10	summarized	summarize	VERB
admet-437	153	11	in	in	ADP
admet-437	153	12	table	table	NOUN
admet-437	153	13	5	5	NUM
admet-437	153	14	.	.	NOUN
admet-437	153	15	0	0	NUM
admet-437	154	1	4	4	NUM
admet-437	154	2	8	8	NUM
admet-437	154	3	12	12	NUM
admet-437	154	4	16	16	NUM
admet-437	154	5	20	20	NUM
admet-437	154	6	24	24	NUM
admet-437	154	7	1	1	NUM
admet-437	154	8	10	10	NUM
admet-437	154	9	100	100	NUM
admet-437	154	10	1000	1000	NUM
admet-437	154	11	10000	10000	NUM
admet-437	154	12	100000	100000	NUM
admet-437	154	13	balb	balb	ADJ
admet-437	154	14	/	/	SYM
admet-437	154	15	c	c	NOUN
admet-437	154	16	mice	mice	NOUN
admet-437	154	17	plasma	plasma	NOUN
admet-437	154	18	concentration	concentration	NOUN
admet-437	154	19	versus	versus	ADP
admet-437	154	20	time	time	NOUN
admet-437	154	21	profile	profile	NOUN
admet-437	154	22	of	of	ADP
admet-437	154	23	ulixertinib	ulixertinib	NOUN
admet-437	154	24	by	by	ADP
admet-437	154	25	oral	oral	ADJ
admet-437	154	26	route	route	NOUN
admet-437	154	27	at	at	ADP
admet-437	154	28	10	10	NUM
admet-437	154	29	mg	mg	NUM
admet-437	154	30	/	/	SYM
admet-437	154	31	kg	kg	NOUN
admet-437	154	32	time	time	NOUN
admet-437	154	33	(	(	PUNCT
admet-437	154	34	h	h	NOUN
admet-437	154	35	)	)	PUNCT
admet-437	154	36	c	c	NOUN
admet-437	154	37	o	o	NOUN
admet-437	154	38	n	n	ADP
admet-437	154	39	c	c	NOUN
admet-437	154	40	e	e	X
admet-437	154	41	n	n	X
admet-437	154	42	tr	tr	DET
admet-437	154	43	a	a	DET
admet-437	154	44	ti	ti	NOUN
admet-437	154	45	o	o	NOUN
admet-437	154	46	n	n	NOUN
admet-437	154	47	i	i	PRON
admet-437	154	48	n	n	CCONJ
admet-437	154	49	p	p	X
admet-437	154	50	la	la	PROPN
admet-437	154	51	s	s	NOUN
admet-437	154	52	m	m	VERB
admet-437	154	53	a	a	PRON
admet-437	154	54	(	(	PUNCT
admet-437	154	55	n	n	CCONJ
admet-437	154	56	g	g	NOUN
admet-437	154	57	/m	/m	PUNCT
admet-437	154	58	l	l	NOUN
admet-437	154	59	)	)	PUNCT
admet-437	155	1	m	m	VERB
admet-437	155	2	e	e	NOUN
admet-437	155	3	a	a	DET
admet-437	155	4	n	n	NUM
admet-437	155	5	±	±	NUM
admet-437	155	6	s	s	NOUN
admet-437	155	7	.d	.d	NOUN
admet-437	155	8	.	.	PUNCT
admet-437	156	1	sd	sd	ADP
admet-437	156	2	rats	rat	NOUN
admet-437	156	3	dogs	dog	NOUN
admet-437	156	4	0	0	NUM
admet-437	156	5	4	4	NUM
admet-437	156	6	8	8	NUM
admet-437	156	7	12	12	NUM
admet-437	156	8	16	16	NUM
admet-437	156	9	20	20	NUM
admet-437	156	10	24	24	NUM
admet-437	156	11	1	1	NUM
admet-437	156	12	10	10	NUM
admet-437	156	13	100	100	NUM
admet-437	156	14	1000	1000	NUM
admet-437	156	15	10000	10000	NUM
admet-437	156	16	balb	balb	ADJ
admet-437	156	17	/	/	SYM
admet-437	156	18	c	c	NOUN
admet-437	156	19	mice	mice	NOUN
admet-437	156	20	plasma	plasma	NOUN
admet-437	156	21	concentration	concentration	NOUN
admet-437	156	22	versus	versus	ADP
admet-437	156	23	time	time	NOUN
admet-437	156	24	profile	profile	NOUN
admet-437	156	25	of	of	ADP
admet-437	156	26	ulixertinib	ulixertinib	NOUN
admet-437	156	27	by	by	ADP
admet-437	156	28	intravenous	intravenous	ADJ
admet-437	156	29	route	route	NOUN
admet-437	156	30	at	at	ADP
admet-437	156	31	1	1	NUM
admet-437	156	32	mg	mg	PROPN
admet-437	156	33	/	/	SYM
admet-437	156	34	kg	kg	NOUN
admet-437	156	35	time	time	NOUN
admet-437	156	36	(	(	PUNCT
admet-437	156	37	h	h	NOUN
admet-437	156	38	)	)	PUNCT
admet-437	156	39	c	c	NOUN
admet-437	157	1	o	o	NOUN
admet-437	157	2	n	n	ADP
admet-437	157	3	c	c	NOUN
admet-437	157	4	e	e	X
admet-437	157	5	n	n	X
admet-437	157	6	tr	tr	DET
admet-437	157	7	a	a	DET
admet-437	157	8	ti	ti	NOUN
admet-437	157	9	o	o	NOUN
admet-437	157	10	n	n	NOUN
admet-437	157	11	i	i	PRON
admet-437	157	12	n	n	CCONJ
admet-437	157	13	p	p	X
admet-437	157	14	la	la	PROPN
admet-437	157	15	s	s	NOUN
admet-437	157	16	m	m	VERB
admet-437	157	17	a	a	PRON
admet-437	157	18	(	(	PUNCT
admet-437	157	19	n	n	CCONJ
admet-437	157	20	g	g	NOUN
admet-437	157	21	/m	/m	PUNCT
admet-437	157	22	l	l	NOUN
admet-437	157	23	)	)	PUNCT
admet-437	158	1	m	m	VERB
admet-437	158	2	e	e	NOUN
admet-437	158	3	a	a	DET
admet-437	158	4	n	n	NUM
admet-437	158	5	±	±	NUM
admet-437	158	6	s	s	NOUN
admet-437	158	7	.d	.d	NOUN
admet-437	158	8	.	.	PUNCT
admet-437	159	1	sd	sd	ADP
admet-437	159	2	rats	rat	NOUN
admet-437	159	3	dogs	dog	NOUN
admet-437	159	4	figure	figure	VERB
admet-437	159	5	2	2	NUM
admet-437	159	6	.	.	PUNCT
admet-437	159	7	plasma	plasma	NOUN
admet-437	159	8	concentration	concentration	NOUN
admet-437	159	9	-	-	PUNCT
admet-437	159	10	time	time	NOUN
admet-437	159	11	profiles	profile	NOUN
admet-437	159	12	of	of	ADP
admet-437	159	13	ulixertinib	ulixertinib	NOUN
admet-437	159	14	after	after	ADP
admet-437	159	15	(	(	PUNCT
admet-437	159	16	a	a	DET
admet-437	159	17	)	)	PUNCT
admet-437	159	18	oral	oral	NOUN
admet-437	159	19	(	(	PUNCT
admet-437	159	20	10	10	NUM
admet-437	159	21	mg	mg	NUM
admet-437	159	22	/	/	SYM
admet-437	159	23	kg	kg	NOUN
admet-437	159	24	)	)	PUNCT
admet-437	159	25	and	and	CCONJ
admet-437	159	26	(	(	PUNCT
admet-437	159	27	b	b	NOUN
admet-437	159	28	)	)	PUNCT
admet-437	159	29	intravenous	intravenous	ADJ
admet-437	159	30	(	(	PUNCT
admet-437	159	31	1	1	NUM
admet-437	159	32	mg	mg	PROPN
admet-437	159	33	/	/	SYM
admet-437	159	34	kg	kg	NOUN
admet-437	159	35	)	)	PUNCT
admet-437	159	36	administration	administration	NOUN
admet-437	159	37	to	to	ADP
admet-437	159	38	male	male	ADJ
admet-437	159	39	balb	balb	ADJ
admet-437	159	40	/	/	SYM
admet-437	159	41	c	c	NOUN
admet-437	159	42	mice	mouse	NOUN
admet-437	159	43	(	(	PUNCT
admet-437	159	44	mean	mean	VERB
admet-437	159	45			PROPN
admet-437	159	46	s.d	s.d	PROPN
admet-437	159	47	,	,	PUNCT
admet-437	159	48	n	n	NOUN
admet-437	159	49	=	=	NUM
admet-437	159	50	12	12	NUM
admet-437	159	51	)	)	PUNCT
admet-437	159	52	,	,	PUNCT
admet-437	159	53	sprague	sprague	NOUN
admet-437	159	54	dawley	dawley	NOUN
admet-437	159	55	rats	rat	NOUN
admet-437	159	56	(	(	PUNCT
admet-437	159	57	mean	mean	VERB
admet-437	159	58			PROPN
admet-437	159	59	s.d	s.d	PROPN
admet-437	159	60	,	,	PUNCT
admet-437	159	61	n	n	NOUN
admet-437	159	62	=	=	SYM
admet-437	159	63	4	4	NUM
admet-437	159	64	)	)	PUNCT
admet-437	159	65	and	and	CCONJ
admet-437	159	66	beagle	beagle	NOUN
admet-437	159	67	dogs	dog	NOUN
admet-437	159	68	(	(	PUNCT
admet-437	159	69	mean	mean	VERB
admet-437	159	70	,	,	PUNCT
admet-437	159	71	n	n	NOUN
admet-437	159	72	=	=	SYM
admet-437	159	73	2	2	NUM
admet-437	159	74	)	)	PUNCT
admet-437	159	75	.	.	PUNCT
admet-437	160	1	a	a	DET
admet-437	160	2	b	b	PROPN
admet-437	160	3	r.	r.	PROPN
admet-437	160	4	mullangi	mullangi	PROPN
admet-437	160	5	et	et	PROPN
admet-437	160	6	al	al	PROPN
admet-437	160	7	.	.	PROPN
admet-437	160	8	admet	admet	PROPN
admet-437	160	9	&	&	CCONJ
admet-437	160	10	dmpk	dmpk	PROPN
admet-437	160	11	5(4	5(4	NOUN
admet-437	160	12	)	)	PUNCT
admet-437	160	13	(	(	PUNCT
admet-437	160	14	2017	2017	NUM
admet-437	160	15	)	)	PUNCT
admet-437	160	16	212	212	NUM
admet-437	160	17	-	-	SYM
admet-437	160	18	223	223	NUM
admet-437	160	19	220	220	NUM
admet-437	160	20	in	in	ADP
admet-437	160	21	the	the	DET
admet-437	160	22	mice	mouse	NOUN
admet-437	160	23	,	,	PUNCT
admet-437	160	24	plasma	plasma	NOUN
admet-437	160	25	concentrations	concentration	NOUN
admet-437	160	26	of	of	ADP
admet-437	160	27	ulixertinib	ulixertinib	NOUN
admet-437	160	28	decreased	decrease	VERB
admet-437	160	29	mono	mono	NOUN
admet-437	160	30	-	-	PUNCT
admet-437	160	31	exponentially	exponentially	ADV
admet-437	160	32	manner	manner	NOUN
admet-437	160	33	after	after	ADP
admet-437	160	34	1	1	NUM
admet-437	160	35	mg	mg	PROPN
admet-437	160	36	/	/	SYM
admet-437	160	37	kg	kg	PROPN
admet-437	160	38	intravenous	intravenous	ADJ
admet-437	160	39	administration	administration	NOUN
admet-437	160	40	.	.	PUNCT
admet-437	161	1	the	the	DET
admet-437	161	2	clearance	clearance	NOUN
admet-437	161	3	was	be	AUX
admet-437	161	4	6.24	6.24	NUM
admet-437	161	5	ml	ml	NOUN
admet-437	161	6	/	/	SYM
admet-437	161	7	min	min	NOUN
admet-437	161	8	/	/	SYM
admet-437	161	9	kg	kg	X
admet-437	162	1	[	[	X
admet-437	162	2	7	7	NUM
admet-437	162	3	%	%	NOUN
admet-437	162	4	hepatic	hepatic	ADJ
admet-437	162	5	blood	blood	NOUN
admet-437	162	6	flow	flow	NOUN
admet-437	162	7	(	(	PUNCT
admet-437	162	8	hbf	hbf	PROPN
admet-437	162	9	)	)	PUNCT
admet-437	162	10	]	]	PUNCT
admet-437	162	11	.	.	PUNCT
admet-437	163	1	the	the	DET
admet-437	163	2	in	in	ADP
admet-437	163	3	vivo	vivo	ADJ
admet-437	163	4	clearance	clearance	NOUN
admet-437	163	5	was	be	AUX
admet-437	163	6	bit	bite	VERB
admet-437	163	7	over	over	ADP
admet-437	163	8	predicted	predict	VERB
admet-437	163	9	by	by	ADP
admet-437	163	10	the	the	DET
admet-437	163	11	in	in	ADV
admet-437	163	12	vitro	vitro	X
admet-437	163	13	microsomes	microsome	NOUN
admet-437	163	14	(	(	PUNCT
admet-437	163	15	~4	~4	NOUN
admet-437	163	16	-	-	ADJ
admet-437	163	17	fold	fold	ADJ
admet-437	163	18	)	)	PUNCT
admet-437	163	19	and	and	CCONJ
admet-437	163	20	hepatocytes	hepatocyte	NOUN
admet-437	163	21	(	(	PUNCT
admet-437	163	22	~6	~6	ADJ
admet-437	163	23	-	-	ADJ
admet-437	163	24	fold	fold	ADJ
admet-437	163	25	)	)	PUNCT
admet-437	163	26	scaled	scaled	ADJ
admet-437	163	27	clearance	clearance	NOUN
admet-437	163	28	.	.	PUNCT
admet-437	164	1	ulixertinib	ulixertinib	PROPN
admet-437	164	2	had	have	VERB
admet-437	164	3	a	a	DET
admet-437	164	4	high	high	ADJ
admet-437	164	5	volume	volume	NOUN
admet-437	164	6	of	of	ADP
admet-437	164	7	distribution	distribution	NOUN
admet-437	164	8	of	of	ADP
admet-437	164	9	0.56	0.56	NUM
admet-437	164	10	l	l	NOUN
admet-437	164	11	/	/	SYM
admet-437	164	12	kg	kg	PROPN
admet-437	164	13	in	in	ADP
admet-437	164	14	mice	mouse	NOUN
admet-437	164	15	,	,	PUNCT
admet-437	164	16	which	which	PRON
admet-437	164	17	is	be	AUX
admet-437	164	18	38	38	NUM
admet-437	164	19	times	time	NOUN
admet-437	164	20	higher	high	ADJ
admet-437	164	21	than	than	ADP
admet-437	164	22	that	that	PRON
admet-437	164	23	of	of	ADP
admet-437	164	24	total	total	ADJ
admet-437	164	25	body	body	NOUN
admet-437	164	26	water	water	NOUN
admet-437	164	27	(	(	PUNCT
admet-437	164	28	tbw	tbw	PROPN
admet-437	164	29	)	)	PUNCT
admet-437	164	30	of	of	ADP
admet-437	164	31	0.015	0.015	NUM
admet-437	164	32	l	l	NOUN
admet-437	164	33	/	/	SYM
admet-437	164	34	kg	kg	PROPN
admet-437	165	1	[	[	X
admet-437	165	2	17	17	NUM
admet-437	165	3	]	]	PUNCT
admet-437	165	4	.	.	PUNCT
admet-437	166	1	the	the	DET
admet-437	166	2	terminal	terminal	PROPN
admet-437	166	3	t1/2	t1/2	PROPN
admet-437	166	4	was	be	AUX
admet-437	166	5	found	find	VERB
admet-437	166	6	to	to	PART
admet-437	166	7	be	be	AUX
admet-437	166	8	1.04	1.04	NUM
admet-437	166	9	h.	h.	NOUN
admet-437	166	10	post	post	PROPN
admet-437	166	11	oral	oral	PROPN
admet-437	166	12	administration	administration	PROPN
admet-437	166	13	maximum	maximum	PROPN
admet-437	166	14	plasma	plasma	NOUN
admet-437	166	15	concentrations	concentration	NOUN
admet-437	166	16	(	(	PUNCT
admet-437	166	17	cmax	cmax	NOUN
admet-437	166	18	:	:	PUNCT
admet-437	166	19	7768	7768	NUM
admet-437	166	20	ng	ng	PROPN
admet-437	166	21	/	/	SYM
admet-437	166	22	ml	ml	PROPN
admet-437	166	23	)	)	PUNCT
admet-437	166	24	attained	attain	VERB
admet-437	166	25	at	at	ADP
admet-437	166	26	0.5	0.5	NUM
admet-437	166	27	h	h	NOUN
admet-437	166	28	indicating	indicate	VERB
admet-437	166	29	rapid	rapid	ADJ
admet-437	166	30	absorption	absorption	NOUN
admet-437	166	31	from	from	ADP
admet-437	166	32	gastrointestinal	gastrointestinal	ADJ
admet-437	166	33	tract	tract	NOUN
admet-437	166	34	.	.	PUNCT
admet-437	167	1	the	the	DET
admet-437	167	2	terminal	terminal	PROPN
admet-437	167	3	t1/2	t1/2	NOUN
admet-437	167	4	(	(	PUNCT
admet-437	167	5	2.06	2.06	NUM
admet-437	167	6	h	h	NOUN
admet-437	167	7	)	)	PUNCT
admet-437	167	8	determined	determine	VERB
admet-437	167	9	after	after	SCONJ
admet-437	167	10	oral	oral	ADJ
admet-437	167	11	administration	administration	NOUN
admet-437	167	12	was	be	AUX
admet-437	167	13	longer	long	ADJ
admet-437	167	14	than	than	ADP
admet-437	167	15	that	that	PRON
admet-437	167	16	after	after	ADP
admet-437	167	17	intravenous	intravenous	ADJ
admet-437	167	18	administration	administration	NOUN
admet-437	167	19	(	(	PUNCT
admet-437	167	20	1.04	1.04	NUM
admet-437	167	21	h	h	NOUN
admet-437	167	22	)	)	PUNCT
admet-437	167	23	,	,	PUNCT
admet-437	167	24	which	which	PRON
admet-437	167	25	may	may	AUX
admet-437	167	26	indicate	indicate	VERB
admet-437	167	27	multiple	multiple	ADJ
admet-437	167	28	sites	site	NOUN
admet-437	167	29	absorption	absorption	NOUN
admet-437	167	30	.	.	PUNCT
admet-437	168	1	the	the	DET
admet-437	168	2	auc0-	auc0-	NOUN
admet-437	168	3	attained	attain	VERB
admet-437	168	4	post	post	NOUN
admet-437	168	5	oral	oral	ADJ
admet-437	168	6	dose	dose	NOUN
admet-437	168	7	was	be	AUX
admet-437	168	8	24460	24460	NUM
admet-437	168	9	ng*h	ng*h	NUM
admet-437	168	10	/	/	SYM
admet-437	168	11	ml	ml	NOUN
admet-437	168	12	.	.	PUNCT
admet-437	169	1	the	the	DET
admet-437	169	2	oral	oral	ADJ
admet-437	169	3	bioavailability	bioavailability	NOUN
admet-437	169	4	in	in	ADP
admet-437	169	5	mice	mouse	NOUN
admet-437	169	6	at	at	ADP
admet-437	169	7	10	10	NUM
admet-437	169	8	mg	mg	NOUN
admet-437	169	9	/	/	SYM
admet-437	169	10	kg	kg	PROPN
admet-437	169	11	was	be	AUX
admet-437	169	12	92	92	NUM
admet-437	169	13	%	%	NOUN
admet-437	169	14	(	(	PUNCT
admet-437	169	15	table	table	NOUN
admet-437	169	16	5	5	NUM
admet-437	169	17	)	)	PUNCT
admet-437	169	18	.	.	PUNCT
admet-437	170	1	table	table	NOUN
admet-437	170	2	5	5	NUM
admet-437	170	3	.	.	PUNCT
admet-437	170	4	pharmacokinetic	pharmacokinetic	ADJ
admet-437	170	5	parameters	parameter	NOUN
admet-437	170	6	of	of	ADP
admet-437	170	7	ulixertinib	ulixertinib	NOUN
admet-437	170	8	after	after	ADP
admet-437	170	9	intravenous	intravenous	ADJ
admet-437	170	10	and	and	CCONJ
admet-437	170	11	oral	oral	ADJ
admet-437	170	12	administration	administration	NOUN
admet-437	170	13	to	to	ADP
admet-437	170	14	mice	mouse	NOUN
admet-437	170	15	,	,	PUNCT
admet-437	170	16	rats	rat	NOUN
admet-437	170	17	and	and	CCONJ
admet-437	170	18	dogs	dog	NOUN
admet-437	170	19	at	at	ADP
admet-437	170	20	1	1	NUM
admet-437	170	21	and	and	CCONJ
admet-437	170	22	10	10	NUM
admet-437	170	23	mg	mg	NUM
admet-437	170	24	/	/	SYM
admet-437	170	25	kg	kg	PROPN
admet-437	170	26	,	,	PUNCT
admet-437	170	27	respectively	respectively	ADV
admet-437	170	28	strain	strain	VERB
admet-437	170	29	route	route	NOUN
admet-437	170	30	of	of	ADP
admet-437	170	31	adm	adm	PROPN
admet-437	170	32	.	.	PUNCT
admet-437	171	1	dose	dose	PROPN
admet-437	171	2	(	(	PUNCT
admet-437	171	3	mg	mg	PROPN
admet-437	171	4	/	/	SYM
admet-437	171	5	kg	kg	PROPN
admet-437	171	6	)	)	PUNCT
admet-437	171	7	auc0-∞	auc0-∞	PROPN
admet-437	172	1	(	(	PUNCT
admet-437	172	2	ng	ng	PROPN
admet-437	172	3	h	h	PROPN
admet-437	172	4	/	/	SYM
admet-437	172	5	ml	ml	NOUN
admet-437	172	6	)	)	PUNCT
admet-437	172	7	cmax	cmax	NOUN
admet-437	172	8	/	/	SYM
admet-437	172	9	co	co	X
admet-437	172	10	(	(	PUNCT
admet-437	172	11	ng	ng	PROPN
admet-437	172	12	/	/	SYM
admet-437	172	13	ml	ml	NOUN
admet-437	172	14	)	)	PUNCT
admet-437	172	15	tmax	tmax	ADV
admet-437	172	16	(	(	PUNCT
admet-437	172	17	h	h	NOUN
admet-437	172	18	)	)	PUNCT
admet-437	172	19	t½	t½	PROPN
admet-437	172	20	(	(	PUNCT
admet-437	172	21	h	h	NOUN
admet-437	172	22	)	)	PUNCT
admet-437	172	23	cl	cl	NOUN
admet-437	172	24	(	(	PUNCT
admet-437	172	25	ml	ml	NOUN
admet-437	172	26	/	/	SYM
admet-437	172	27	min	min	NOUN
admet-437	172	28	/	/	SYM
admet-437	172	29	kg	kg	NOUN
admet-437	172	30	)	)	PUNCT
admet-437	172	31	vd	vd	NOUN
admet-437	172	32	(	(	PUNCT
admet-437	172	33	l	l	NOUN
admet-437	172	34	/	/	SYM
admet-437	172	35	kg	kg	NOUN
admet-437	172	36	)	)	PUNCT
admet-437	172	37	f	f	PROPN
admet-437	172	38	(	(	PUNCT
admet-437	172	39	%	%	INTJ
admet-437	172	40	)	)	PUNCT
admet-437	173	1	balbc	balbc	PROPN
admet-437	173	2	mice	mouse	NOUN
admet-437	173	3	intravenous	intravenous	ADJ
admet-437	173	4	1.0	1.0	NUM
admet-437	173	5	2672	2672	NUM
admet-437	173	6	1918	1918	NUM
admet-437	173	7	--1.04	--1.04	PUNCT
admet-437	173	8	6.24	6.24	NUM
admet-437	173	9	0.56	0.56	NUM
admet-437	173	10	--	--	PUNCT
admet-437	173	11	oral	oral	ADJ
admet-437	173	12	10	10	NUM
admet-437	173	13	24460	24460	NUM
admet-437	173	14	7768	7768	NUM
admet-437	173	15	0.50	0.50	NUM
admet-437	173	16	2.06	2.06	NUM
admet-437	173	17	----91.6	----91.6	PROPN
admet-437	173	18	sprague	sprague	PROPN
admet-437	173	19	dawley	dawley	NOUN
admet-437	173	20	rats	rat	NOUN
admet-437	173	21	intravenous	intravenous	ADJ
admet-437	173	22	1.0	1.0	NUM
admet-437	173	23	10179	10179	NUM
admet-437	173	24	±	±	NUM
admet-437	173	25	1528	1528	NUM
admet-437	173	26	6644	6644	NUM
admet-437	173	27	±	±	NUM
admet-437	173	28	1812	1812	NUM
admet-437	173	29	--	--	PUNCT
admet-437	173	30	2.52	2.52	NUM
admet-437	173	31	±	±	NUM
admet-437	173	32	0.07	0.07	NUM
admet-437	173	33	1.67	1.67	NUM
admet-437	173	34	±	±	NUM
admet-437	173	35	0.25	0.25	NUM
admet-437	173	36	0.36	0.36	NUM
admet-437	173	37	±	±	NUM
admet-437	173	38	0.06	0.06	NUM
admet-437	173	39	--	--	PUNCT
admet-437	173	40	oral	oral	ADJ
admet-437	173	41	10	10	NUM
admet-437	173	42	98421	98421	NUM
admet-437	173	43	±	±	NOUN
admet-437	173	44	14005	14005	NUM
admet-437	173	45	15026	15026	NUM
admet-437	173	46	±	±	NOUN
admet-437	173	47	2098	2098	NUM
admet-437	173	48	0.75	0.75	NUM
admet-437	173	49	±	±	NUM
admet-437	173	50	0.29	0.29	NUM
admet-437	173	51	2.02	2.02	NUM
admet-437	173	52	±	±	NUM
admet-437	173	53	0.17	0.17	NUM
admet-437	173	54	----97.7	----97.7	NOUN
admet-437	173	55	beagle	beagle	NOUN
admet-437	173	56	dogs	dog	NOUN
admet-437	173	57	intravenous	intravenous	ADJ
admet-437	173	58	1.0	1.0	NUM
admet-437	173	59	1091	1091	NUM
admet-437	173	60	1033	1033	NUM
admet-437	173	61	--1.21	--1.21	PROPN
admet-437	173	62	15.5	15.5	NUM
admet-437	173	63	1.61	1.61	NUM
admet-437	173	64	--	--	PUNCT
admet-437	173	65	oral	oral	ADJ
admet-437	173	66	10	10	NUM
admet-437	173	67	3687	3687	NUM
admet-437	173	68	1442	1442	NUM
admet-437	173	69	2.00	2.00	NUM
admet-437	173	70	1.29	1.29	NUM
admet-437	173	71	----33.8	----33.8	ADV
admet-437	173	72	in	in	ADP
admet-437	173	73	the	the	DET
admet-437	173	74	rats	rat	NOUN
admet-437	173	75	,	,	PUNCT
admet-437	173	76	plasma	plasma	NOUN
admet-437	173	77	concentrations	concentration	NOUN
admet-437	173	78	of	of	ADP
admet-437	173	79	ulixertinib	ulixertinib	NOUN
admet-437	173	80	decreased	decrease	VERB
admet-437	173	81	mono	mono	NOUN
admet-437	173	82	-	-	PUNCT
admet-437	173	83	exponentially	exponentially	ADV
admet-437	173	84	manner	manner	NOUN
admet-437	173	85	after	after	ADP
admet-437	173	86	1	1	NUM
admet-437	173	87	mg	mg	PROPN
admet-437	173	88	/	/	SYM
admet-437	173	89	kg	kg	PROPN
admet-437	173	90	intravenous	intravenous	ADJ
admet-437	173	91	administration	administration	NOUN
admet-437	173	92	.	.	PUNCT
admet-437	174	1	the	the	DET
admet-437	174	2	clearance	clearance	NOUN
admet-437	174	3	was	be	AUX
admet-437	174	4	found	find	VERB
admet-437	174	5	to	to	PART
admet-437	174	6	be	be	AUX
admet-437	174	7	1.67	1.67	NUM
admet-437	174	8	ml	ml	NOUN
admet-437	174	9	/	/	SYM
admet-437	174	10	min	min	NOUN
admet-437	174	11	/	/	SYM
admet-437	174	12	kg	kg	PROPN
admet-437	174	13	(	(	PUNCT
admet-437	174	14	3	3	NUM
admet-437	174	15	%	%	NOUN
admet-437	174	16	of	of	ADP
admet-437	174	17	hbf	hbf	PROPN
admet-437	174	18	)	)	PUNCT
admet-437	174	19	,	,	PUNCT
admet-437	174	20	which	which	PRON
admet-437	174	21	is	be	AUX
admet-437	174	22	in	in	ADP
admet-437	174	23	good	good	ADJ
admet-437	174	24	agreement	agreement	NOUN
admet-437	174	25	with	with	ADP
admet-437	174	26	in	in	ADP
admet-437	174	27	vitro	vitro	X
admet-437	174	28	(	(	PUNCT
admet-437	174	29	microsomes	microsome	NOUN
admet-437	174	30	and	and	CCONJ
admet-437	174	31	hepatocytes	hepatocyte	NOUN
admet-437	174	32	)	)	PUNCT
admet-437	174	33	scaled	scale	VERB
admet-437	174	34	clearance	clearance	NOUN
admet-437	174	35	.	.	PUNCT
admet-437	175	1	the	the	DET
admet-437	175	2	volume	volume	NOUN
admet-437	175	3	of	of	ADP
admet-437	175	4	distribution	distribution	NOUN
admet-437	175	5	(	(	PUNCT
admet-437	175	6	0.36	0.36	NUM
admet-437	175	7	l	l	NOUN
admet-437	175	8	/	/	SYM
admet-437	175	9	kg	kg	NOUN
admet-437	175	10	)	)	PUNCT
admet-437	175	11	of	of	ADP
admet-437	175	12	ulixertinib	ulixertinib	NOUN
admet-437	175	13	in	in	ADP
admet-437	175	14	rat	rat	NOUN
admet-437	175	15	is	be	AUX
admet-437	175	16	approximated	approximate	VERB
admet-437	175	17	to	to	ADP
admet-437	175	18	tbw	tbw	PROPN
admet-437	175	19	.	.	PUNCT
admet-437	176	1	the	the	DET
admet-437	176	2	terminal	terminal	PROPN
admet-437	176	3	t1/2	t1/2	PROPN
admet-437	176	4	was	be	AUX
admet-437	176	5	found	find	VERB
admet-437	176	6	to	to	PART
admet-437	176	7	be	be	AUX
admet-437	176	8	2.52	2.52	NUM
admet-437	176	9	h.	h.	NOUN
admet-437	176	10	in	in	ADP
admet-437	176	11	rats	rat	NOUN
admet-437	176	12	also	also	ADV
admet-437	176	13	post	post	VERB
admet-437	176	14	oral	oral	ADJ
admet-437	176	15	administration	administration	NOUN
admet-437	176	16	early	early	ADV
admet-437	176	17	tmax	tmax	ADP
admet-437	176	18	of	of	ADP
admet-437	176	19	0.75	0.75	NUM
admet-437	176	20	h	h	NOUN
admet-437	176	21	suggesting	suggest	VERB
admet-437	176	22	that	that	SCONJ
admet-437	176	23	ulixertinib	ulixertinib	NOUN
admet-437	176	24	has	have	VERB
admet-437	176	25	a	a	DET
admet-437	176	26	rapid	rapid	ADJ
admet-437	176	27	absorption	absorption	NOUN
admet-437	176	28	from	from	ADP
admet-437	176	29	gastrointestinal	gastrointestinal	ADJ
admet-437	176	30	tract	tract	NOUN
admet-437	176	31	.	.	PUNCT
admet-437	177	1	the	the	DET
admet-437	177	2	auc0-	auc0-	NOUN
admet-437	177	3	and	and	CCONJ
admet-437	177	4	cmax	cmax	NOUN
admet-437	177	5	attained	attain	VERB
admet-437	177	6	post	post	PROPN
admet-437	177	7	oral	oral	ADJ
admet-437	177	8	dose	dose	NOUN
admet-437	177	9	was	be	AUX
admet-437	177	10	98421	98421	NUM
admet-437	177	11	ng*h	ng*h	NUM
admet-437	177	12	/	/	SYM
admet-437	177	13	ml	ml	NOUN
admet-437	177	14	and	and	CCONJ
admet-437	177	15	15026	15026	NUM
admet-437	177	16	ng	ng	PROPN
admet-437	177	17	/	/	SYM
admet-437	177	18	ml	ml	PROPN
admet-437	177	19	,	,	PUNCT
admet-437	177	20	respectively	respectively	ADV
admet-437	177	21	.	.	PUNCT
admet-437	178	1	the	the	DET
admet-437	178	2	terminal	terminal	PROPN
admet-437	178	3	t1/2	t1/2	NOUN
admet-437	178	4	determined	determine	VERB
admet-437	178	5	after	after	SCONJ
admet-437	178	6	oral	oral	ADJ
admet-437	178	7	administration	administration	NOUN
admet-437	178	8	is	be	AUX
admet-437	178	9	2.02	2.02	NUM
admet-437	178	10	h	h	NOUN
admet-437	178	11	,	,	PUNCT
admet-437	178	12	which	which	PRON
admet-437	178	13	is	be	AUX
admet-437	178	14	comparable	comparable	ADJ
admet-437	178	15	to	to	ADP
admet-437	178	16	intravenous	intravenous	ADJ
admet-437	178	17	route	route	NOUN
admet-437	178	18	half	half	ADJ
admet-437	178	19	-	-	PUNCT
admet-437	178	20	life	life	NOUN
admet-437	178	21	.	.	PUNCT
admet-437	179	1	the	the	DET
admet-437	179	2	oral	oral	ADJ
admet-437	179	3	bioavailability	bioavailability	NOUN
admet-437	179	4	in	in	ADP
admet-437	179	5	rat	rat	NOUN
admet-437	179	6	at	at	ADP
admet-437	179	7	10	10	NUM
admet-437	179	8	mg	mg	NOUN
admet-437	179	9	/	/	SYM
admet-437	179	10	kg	kg	PROPN
admet-437	179	11	was	be	AUX
admet-437	179	12	98	98	NUM
admet-437	179	13	%	%	NOUN
admet-437	179	14	(	(	PUNCT
admet-437	179	15	table	table	NOUN
admet-437	179	16	5	5	NUM
admet-437	179	17	)	)	PUNCT
admet-437	179	18	.	.	PUNCT
admet-437	180	1	in	in	ADP
admet-437	180	2	the	the	DET
admet-437	180	3	dogs	dog	NOUN
admet-437	180	4	also	also	ADV
admet-437	180	5	plasma	plasma	VERB
admet-437	180	6	concentrations	concentration	NOUN
admet-437	180	7	of	of	ADP
admet-437	180	8	ulixertinib	ulixertinib	NOUN
admet-437	180	9	decreased	decrease	VERB
admet-437	180	10	mono	mono	NOUN
admet-437	180	11	-	-	PUNCT
admet-437	180	12	exponentially	exponentially	ADV
admet-437	180	13	manner	manner	NOUN
admet-437	180	14	after	after	ADP
admet-437	180	15	1	1	NUM
admet-437	180	16	mg	mg	PROPN
admet-437	180	17	/	/	SYM
admet-437	180	18	kg	kg	PROPN
admet-437	180	19	intravenous	intravenous	ADJ
admet-437	180	20	administration	administration	NOUN
admet-437	180	21	.	.	PUNCT
admet-437	181	1	the	the	DET
admet-437	181	2	clearance	clearance	NOUN
admet-437	181	3	was	be	AUX
admet-437	181	4	15.5	15.5	NUM
admet-437	181	5	ml	ml	NOUN
admet-437	181	6	/	/	SYM
admet-437	181	7	min	min	NOUN
admet-437	181	8	/	/	SYM
admet-437	181	9	kg	kg	X
admet-437	181	10	(	(	PUNCT
admet-437	181	11	~50	~50	NUM
admet-437	181	12	%	%	INTJ
admet-437	181	13	hbf	hbf	PROPN
admet-437	181	14	)	)	PUNCT
admet-437	181	15	.	.	PUNCT
admet-437	182	1	the	the	DET
admet-437	182	2	in	in	ADP
admet-437	182	3	vivo	vivo	ADJ
admet-437	182	4	clearance	clearance	NOUN
admet-437	182	5	was	be	AUX
admet-437	182	6	in	in	ADP
admet-437	182	7	good	good	ADJ
admet-437	182	8	agreement	agreement	NOUN
admet-437	182	9	with	with	ADP
admet-437	182	10	in	in	ADP
admet-437	182	11	vitro	vitro	X
admet-437	182	12	(	(	PUNCT
admet-437	182	13	microsomes	microsome	NOUN
admet-437	182	14	and	and	CCONJ
admet-437	182	15	hepatocytes	hepatocyte	NOUN
admet-437	182	16	)	)	PUNCT
admet-437	182	17	predicted	predict	VERB
admet-437	182	18	scaled	scaled	ADJ
admet-437	182	19	clearance	clearance	NOUN
admet-437	182	20	.	.	PUNCT
admet-437	183	1	the	the	DET
admet-437	183	2	apparent	apparent	ADJ
admet-437	183	3	volume	volume	NOUN
admet-437	183	4	of	of	ADP
admet-437	183	5	distribution	distribution	NOUN
admet-437	183	6	1.61	1.61	NUM
admet-437	183	7	l	l	NOUN
admet-437	183	8	/	/	SYM
admet-437	183	9	kg	kg	PROPN
admet-437	183	10	of	of	ADP
admet-437	183	11	ulixertinib	ulixertinib	NOUN
admet-437	183	12	in	in	ADP
admet-437	183	13	dogs	dog	NOUN
admet-437	183	14	is	be	AUX
admet-437	183	15	approximated	approximate	VERB
admet-437	183	16	to	to	ADP
admet-437	183	17	tbw	tbw	PROPN
admet-437	183	18	.	.	PUNCT
admet-437	184	1	the	the	DET
admet-437	184	2	terminal	terminal	PROPN
admet-437	184	3	t1/2	t1/2	PROPN
admet-437	184	4	was	be	AUX
admet-437	184	5	found	find	VERB
admet-437	184	6	to	to	PART
admet-437	184	7	be	be	AUX
admet-437	184	8	1.21	1.21	NUM
admet-437	184	9	h.	h.	NOUN
admet-437	184	10	in	in	ADP
admet-437	184	11	dogs	dog	NOUN
admet-437	184	12	post	post	VERB
admet-437	184	13	oral	oral	ADJ
admet-437	184	14	administration	administration	NOUN
admet-437	184	15	,	,	PUNCT
admet-437	184	16	maximum	maximum	ADJ
admet-437	184	17	plasma	plasma	NOUN
admet-437	184	18	concentrations	concentration	NOUN
admet-437	184	19	(	(	PUNCT
admet-437	184	20	1442	1442	NUM
admet-437	184	21	ng	ng	PROPN
admet-437	184	22	/	/	SYM
admet-437	184	23	ml	ml	NOUN
admet-437	184	24	)	)	PUNCT
admet-437	184	25	of	of	ADP
admet-437	184	26	ulixertinib	ulixertinib	NOUN
admet-437	184	27	observed	observe	VERB
admet-437	184	28	at	at	ADP
admet-437	184	29	2.00	2.00	NUM
admet-437	184	30	h	h	NOUN
admet-437	184	31	,	,	PUNCT
admet-437	184	32	indicating	indicate	VERB
admet-437	184	33	it	it	PRON
admet-437	184	34	is	be	AUX
admet-437	184	35	a	a	DET
admet-437	184	36	delayed	delayed	ADJ
admet-437	184	37	tmax	tmax	ADP
admet-437	184	38	(	(	PUNCT
admet-437	184	39	when	when	SCONJ
admet-437	184	40	compared	compare	VERB
admet-437	184	41	with	with	ADP
admet-437	184	42	tmax	tmax	ADJ
admet-437	184	43	value	value	NOUN
admet-437	184	44	of	of	ADP
admet-437	184	45	rodents	rodent	NOUN
admet-437	184	46	)	)	PUNCT
admet-437	184	47	.	.	PUNCT
admet-437	185	1	the	the	DET
admet-437	185	2	auc0-	auc0-	NOUN
admet-437	185	3	was	be	AUX
admet-437	185	4	3687	3687	NUM
admet-437	185	5	ng	ng	PROPN
admet-437	185	6	h	h	PROPN
admet-437	185	7	/	/	SYM
admet-437	185	8	ml	ml	PROPN
admet-437	185	9	.	.	PUNCT
admet-437	186	1	the	the	DET
admet-437	186	2	terminal	terminal	PROPN
admet-437	186	3	t1/2	t1/2	NOUN
admet-437	186	4	determined	determine	VERB
admet-437	186	5	after	after	SCONJ
admet-437	186	6	oral	oral	ADJ
admet-437	186	7	administration	administration	NOUN
admet-437	186	8	was	be	AUX
admet-437	186	9	1.29	1.29	NUM
admet-437	186	10	h.	h.	NOUN
admet-437	186	11	the	the	DET
admet-437	186	12	oral	oral	ADJ
admet-437	186	13	bioavailability	bioavailability	NOUN
admet-437	186	14	in	in	ADP
admet-437	186	15	dogs	dog	NOUN
admet-437	186	16	at	at	ADP
admet-437	186	17	10	10	NUM
admet-437	186	18	mg	mg	NOUN
admet-437	186	19	/	/	SYM
admet-437	186	20	kg	kg	PROPN
admet-437	186	21	was	be	AUX
admet-437	186	22	34	34	NUM
admet-437	186	23	%	%	NOUN
admet-437	186	24	(	(	PUNCT
admet-437	186	25	table	table	NOUN
admet-437	186	26	5	5	NUM
admet-437	186	27	)	)	PUNCT
admet-437	186	28	.	.	PUNCT
admet-437	187	1	admet	admet	PROPN
admet-437	187	2	&	&	CCONJ
admet-437	187	3	dmpk	dmpk	PROPN
admet-437	187	4	5(4	5(4	NOUN
admet-437	187	5	)	)	PUNCT
admet-437	187	6	(	(	PUNCT
admet-437	187	7	2017	2017	NUM
admet-437	187	8	)	)	PUNCT
admet-437	187	9	212	212	NUM
admet-437	187	10	-	-	SYM
admet-437	187	11	223	223	NUM
admet-437	187	12	preclinical	preclinical	ADJ
admet-437	187	13	assessment	assessment	NOUN
admet-437	187	14	of	of	ADP
admet-437	187	15	ulixertinib	ulixertinib	PROPN
admet-437	187	16	doi	doi	PROPN
admet-437	187	17	:	:	PUNCT
admet-437	187	18	10.5599	10.5599	NUM
admet-437	187	19	/	/	SYM
admet-437	187	20	admet.5.4.437	admet.5.4.437	NUM
admet-437	187	21	221	221	NUM
admet-437	187	22	discussion	discussion	NOUN
admet-437	187	23	ras	ras	NOUN
admet-437	187	24	/	/	SYM
admet-437	187	25	raf	raf	PROPN
admet-437	187	26	/	/	SYM
admet-437	187	27	mek	mek	PROPN
admet-437	187	28	signaling	signal	VERB
admet-437	187	29	pathway	pathway	NOUN
admet-437	187	30	is	be	AUX
admet-437	187	31	frequently	frequently	ADV
admet-437	187	32	activated	activate	VERB
admet-437	187	33	in	in	ADP
admet-437	187	34	many	many	ADJ
admet-437	187	35	cancers	cancer	NOUN
admet-437	187	36	[	[	X
admet-437	187	37	2	2	NUM
admet-437	187	38	]	]	PUNCT
admet-437	187	39	and	and	CCONJ
admet-437	187	40	clinical	clinical	ADJ
admet-437	187	41	efficacy	efficacy	NOUN
admet-437	187	42	of	of	ADP
admet-437	187	43	braf	braf	NOUN
admet-437	187	44	and	and	CCONJ
admet-437	187	45	mek	mek	PROPN
admet-437	187	46	inhibitors	inhibitor	NOUN
admet-437	187	47	confirms	confirm	VERB
admet-437	187	48	targeting	target	VERB
admet-437	187	49	ras	ras	NOUN
admet-437	187	50	/	/	SYM
admet-437	187	51	raf	raf	PROPN
admet-437	187	52	/	/	SYM
admet-437	187	53	mek	mek	PROPN
admet-437	187	54	pathway	pathway	NOUN
admet-437	187	55	has	have	VERB
admet-437	187	56	therapeutic	therapeutic	ADJ
admet-437	187	57	potential	potential	ADJ
admet-437	187	58	and	and	CCONJ
admet-437	187	59	great	great	ADJ
admet-437	187	60	promise	promise	NOUN
admet-437	187	61	[	[	X
admet-437	187	62	18	18	NUM
admet-437	187	63	]	]	PUNCT
admet-437	187	64	.	.	PUNCT
admet-437	188	1	most	most	ADJ
admet-437	188	2	of	of	ADP
admet-437	188	3	the	the	DET
admet-437	188	4	resistance	resistance	NOUN
admet-437	188	5	mechanisms	mechanism	NOUN
admet-437	188	6	to	to	ADP
admet-437	188	7	braf	braf	NOUN
admet-437	188	8	and	and	CCONJ
admet-437	188	9	mek	mek	PROPN
admet-437	188	10	inhibitors	inhibitor	NOUN
admet-437	188	11	ultimately	ultimately	ADV
admet-437	188	12	lead	lead	VERB
admet-437	188	13	to	to	PART
admet-437	188	14	increase	increase	VERB
admet-437	188	15	in	in	ADP
admet-437	188	16	phosphorylation	phosphorylation	NOUN
admet-437	188	17	of	of	ADP
admet-437	188	18	erk1/2	erk1/2	PROPN
admet-437	189	1	[	[	X
admet-437	189	2	3	3	NUM
admet-437	189	3	]	]	PUNCT
admet-437	189	4	.	.	PUNCT
admet-437	190	1	therefore	therefore	ADV
admet-437	190	2	,	,	PUNCT
admet-437	190	3	inhibition	inhibition	NOUN
admet-437	190	4	of	of	ADP
admet-437	190	5	erk1/2	erk1/2	PROPN
admet-437	190	6	offers	offer	VERB
admet-437	190	7	a	a	DET
admet-437	190	8	promising	promising	ADJ
admet-437	190	9	strategy	strategy	NOUN
admet-437	190	10	to	to	PART
admet-437	190	11	address	address	VERB
admet-437	190	12	both	both	PRON
admet-437	190	13	innate	innate	ADJ
admet-437	190	14	and	and	CCONJ
admet-437	190	15	acquired	acquire	VERB
admet-437	190	16	resistance	resistance	NOUN
admet-437	190	17	to	to	ADP
admet-437	190	18	braf	braf	NOUN
admet-437	190	19	and	and	CCONJ
admet-437	190	20	mek	mek	PROPN
admet-437	190	21	inhibitors	inhibitor	NOUN
admet-437	190	22	in	in	ADP
admet-437	190	23	various	various	ADJ
admet-437	190	24	solid	solid	ADJ
admet-437	190	25	tumors	tumor	NOUN
admet-437	190	26	.	.	PUNCT
admet-437	191	1	ulixertinib	ulixertinib	PROPN
admet-437	191	2	is	be	AUX
admet-437	191	3	a	a	DET
admet-437	191	4	novel	novel	ADJ
admet-437	191	5	compound	compound	NOUN
admet-437	191	6	,	,	PUNCT
admet-437	191	7	which	which	PRON
admet-437	191	8	selectively	selectively	ADV
admet-437	191	9	and	and	CCONJ
admet-437	191	10	potently	potently	ADV
admet-437	191	11	inhibits	inhibit	VERB
admet-437	191	12	erk1/2	erk1/2	PROPN
admet-437	191	13	kinases	kinase	NOUN
admet-437	191	14	in	in	ADP
admet-437	191	15	a	a	DET
admet-437	191	16	reversible	reversible	ADJ
admet-437	191	17	,	,	PUNCT
admet-437	191	18	atp	atp	NOUN
admet-437	191	19	-	-	PUNCT
admet-437	191	20	competitive	competitive	ADJ
admet-437	191	21	fashion	fashion	NOUN
admet-437	191	22	.	.	PUNCT
admet-437	192	1	as	as	ADP
admet-437	192	2	a	a	DET
admet-437	192	3	single	single	ADJ
admet-437	192	4	-	-	PUNCT
admet-437	192	5	agent	agent	NOUN
admet-437	192	6	it	it	PRON
admet-437	192	7	inhibits	inhibit	VERB
admet-437	192	8	tumor	tumor	NOUN
admet-437	192	9	growth	growth	NOUN
admet-437	192	10	in	in	ADP
admet-437	192	11	vivo	vivo	NOUN
admet-437	192	12	in	in	ADP
admet-437	192	13	braf	braf	NOUN
admet-437	192	14	-	-	PUNCT
admet-437	192	15	mutant	mutant	ADJ
admet-437	192	16	melanoma	melanoma	NOUN
admet-437	192	17	and	and	CCONJ
admet-437	192	18	colorectal	colorectal	ADJ
admet-437	192	19	xenografts	xenograft	NOUN
admet-437	192	20	as	as	ADV
admet-437	192	21	well	well	ADV
admet-437	192	22	as	as	ADP
admet-437	192	23	in	in	ADP
admet-437	192	24	kras	kra	NOUN
admet-437	192	25	-	-	PUNCT
admet-437	192	26	mutant	mutant	ADJ
admet-437	192	27	colorectal	colorectal	ADJ
admet-437	192	28	and	and	CCONJ
admet-437	192	29	pancreatic	pancreatic	ADJ
admet-437	192	30	models	model	NOUN
admet-437	192	31	[	[	X
admet-437	192	32	6	6	NUM
admet-437	192	33	]	]	PUNCT
admet-437	192	34	.	.	PUNCT
admet-437	193	1	in	in	ADP
admet-437	193	2	phase-1	phase-1	NUM
admet-437	193	3	clinical	clinical	ADJ
admet-437	193	4	studies	study	NOUN
admet-437	193	5	,	,	PUNCT
admet-437	193	6	ulixertinib	ulixertinib	PROPN
admet-437	193	7	was	be	AUX
admet-437	193	8	well	well	ADV
admet-437	193	9	tolerated	tolerate	VERB
admet-437	193	10	by	by	ADP
admet-437	193	11	patients	patient	NOUN
admet-437	193	12	with	with	ADP
admet-437	193	13	advanced	advanced	ADJ
admet-437	193	14	solid	solid	ADJ
admet-437	193	15	tumors	tumor	NOUN
admet-437	193	16	.	.	PUNCT
admet-437	194	1	ulixertinib	ulixertinib	PROPN
admet-437	194	2	showed	show	VERB
admet-437	194	3	linear	linear	ADJ
admet-437	194	4	pharmacokinetics	pharmacokinetic	NOUN
admet-437	194	5	up	up	ADP
admet-437	194	6	to	to	ADP
admet-437	194	7	600	600	NUM
admet-437	194	8	mg	mg	NOUN
admet-437	194	9	(	(	PUNCT
admet-437	194	10	b.i.d	b.i.d	PROPN
admet-437	194	11	)	)	PUNCT
admet-437	194	12	,	,	PUNCT
admet-437	194	13	this	this	PRON
admet-437	194	14	was	be	AUX
admet-437	194	15	found	find	VERB
admet-437	194	16	to	to	PART
admet-437	194	17	be	be	AUX
admet-437	194	18	mtd	mtd	PROPN
admet-437	194	19	[	[	X
admet-437	194	20	7	7	NUM
admet-437	194	21	]	]	PUNCT
admet-437	194	22	.	.	PUNCT
admet-437	195	1	to	to	ADP
admet-437	195	2	the	the	DET
admet-437	195	3	best	good	ADJ
admet-437	195	4	of	of	ADP
admet-437	195	5	our	our	PRON
admet-437	195	6	knowledge	knowledge	NOUN
admet-437	195	7	there	there	PRON
admet-437	195	8	is	be	VERB
admet-437	195	9	no	no	DET
admet-437	195	10	preclinical	preclinical	ADJ
admet-437	195	11	pharmacokinetic	pharmacokinetic	ADJ
admet-437	195	12	data	datum	NOUN
admet-437	195	13	reported	report	VERB
admet-437	195	14	for	for	ADP
admet-437	195	15	erk1/2	erk1/2	PROPN
admet-437	195	16	inhibitors	inhibitor	NOUN
admet-437	195	17	in	in	ADP
admet-437	195	18	the	the	DET
admet-437	195	19	literature	literature	NOUN
admet-437	195	20	.	.	PUNCT
admet-437	196	1	preclinical	preclinical	ADJ
admet-437	196	2	pharmacokinetics	pharmacokinetic	NOUN
admet-437	196	3	of	of	ADP
admet-437	196	4	a	a	DET
admet-437	196	5	novel	novel	ADJ
admet-437	196	6	target	target	NOUN
admet-437	196	7	class	class	NOUN
admet-437	196	8	drug	drug	NOUN
admet-437	196	9	has	have	VERB
admet-437	196	10	great	great	ADJ
admet-437	196	11	influence	influence	NOUN
admet-437	196	12	on	on	ADP
admet-437	196	13	the	the	DET
admet-437	196	14	development	development	NOUN
admet-437	196	15	and	and	CCONJ
admet-437	196	16	investigation	investigation	NOUN
admet-437	196	17	of	of	ADP
admet-437	196	18	potential	potential	ADJ
admet-437	196	19	candidates	candidate	NOUN
admet-437	196	20	for	for	ADP
admet-437	196	21	the	the	DET
admet-437	196	22	further	further	ADJ
admet-437	196	23	drug	drug	NOUN
admet-437	196	24	design	design	NOUN
admet-437	196	25	,	,	PUNCT
admet-437	196	26	which	which	PRON
admet-437	196	27	necessitates	necessitate	VERB
admet-437	196	28	a	a	PRON
admet-437	196	29	through	through	ADP
admet-437	196	30	exploration	exploration	NOUN
admet-437	196	31	and	and	CCONJ
admet-437	196	32	understanding	understanding	NOUN
admet-437	196	33	of	of	ADP
admet-437	196	34	pharmacokinetic	pharmacokinetic	ADJ
admet-437	196	35	disposition	disposition	NOUN
admet-437	196	36	.	.	PUNCT
admet-437	197	1	this	this	PRON
admet-437	197	2	is	be	AUX
admet-437	197	3	important	important	ADJ
admet-437	197	4	since	since	SCONJ
admet-437	197	5	in	in	ADP
admet-437	197	6	vivo	vivo	ADJ
admet-437	197	7	pharmacokinetic	pharmacokinetic	ADJ
admet-437	197	8	behavior	behavior	NOUN
admet-437	197	9	and	and	CCONJ
admet-437	197	10	pharmacokinetic	pharmacokinetic	ADJ
admet-437	197	11	-	-	PUNCT
admet-437	197	12	pharmacodynamic	pharmacodynamic	ADJ
admet-437	197	13	correlation	correlation	NOUN
admet-437	197	14	act	act	NOUN
admet-437	197	15	as	as	ADP
admet-437	197	16	surrogates	surrogate	NOUN
admet-437	197	17	for	for	ADP
admet-437	197	18	clinical	clinical	ADJ
admet-437	197	19	effectiveness	effectiveness	NOUN
admet-437	197	20	of	of	ADP
admet-437	197	21	potential	potential	ADJ
admet-437	197	22	drug	drug	NOUN
admet-437	197	23	candidates	candidate	NOUN
admet-437	197	24	.	.	PUNCT
admet-437	198	1	in	in	ADP
admet-437	198	2	this	this	DET
admet-437	198	3	paper	paper	NOUN
admet-437	198	4	we	we	PRON
admet-437	198	5	report	report	VERB
admet-437	198	6	the	the	DET
admet-437	198	7	metabolic	metabolic	NOUN
admet-437	198	8	stability	stability	NOUN
admet-437	198	9	,	,	PUNCT
admet-437	198	10	permeability	permeability	NOUN
admet-437	198	11	,	,	PUNCT
admet-437	198	12	protein	protein	NOUN
admet-437	198	13	binding	bind	VERB
admet-437	198	14	,	,	PUNCT
admet-437	198	15	cyp	cyp	ADJ
admet-437	198	16	inhibition	inhibition	NOUN
admet-437	198	17	,	,	PUNCT
admet-437	198	18	cyp	cyp	ADJ
admet-437	198	19	induction	induction	NOUN
admet-437	198	20	,	,	PUNCT
admet-437	198	21	cyp	cyp	ADJ
admet-437	198	22	phenotyping	phenotyping	NOUN
admet-437	198	23	and	and	CCONJ
admet-437	198	24	pharmacokinetics	pharmacokinetic	NOUN
admet-437	198	25	in	in	ADP
admet-437	198	26	mice	mouse	NOUN
admet-437	198	27	,	,	PUNCT
admet-437	198	28	rats	rat	NOUN
admet-437	198	29	and	and	CCONJ
admet-437	198	30	dogs	dog	NOUN
admet-437	198	31	for	for	ADP
admet-437	198	32	ulixertinib	ulixertinib	NOUN
admet-437	198	33	.	.	PUNCT
admet-437	199	1	the	the	DET
admet-437	199	2	metabolic	metabolic	NOUN
admet-437	199	3	stability	stability	NOUN
admet-437	199	4	data	datum	NOUN
admet-437	199	5	suggested	suggest	VERB
admet-437	199	6	that	that	SCONJ
admet-437	199	7	ulixertinib	ulixertinib	NOUN
admet-437	199	8	is	be	AUX
admet-437	199	9	moderately	moderately	ADV
admet-437	199	10	to	to	PART
admet-437	199	11	highly	highly	ADV
admet-437	199	12	stable	stable	ADJ
admet-437	199	13	under	under	ADP
admet-437	199	14	in	in	ADP
admet-437	199	15	vitro	vitro	X
admet-437	199	16	conditions	condition	NOUN
admet-437	199	17	using	use	VERB
admet-437	199	18	liver	liver	NOUN
admet-437	199	19	microsomal	microsomal	NOUN
admet-437	199	20	and	and	CCONJ
admet-437	199	21	hepatocytes	hepatocytes	ADJ
admet-437	199	22	preparations	preparation	NOUN
admet-437	199	23	of	of	ADP
admet-437	199	24	various	various	ADJ
admet-437	199	25	pre	pre	ADJ
admet-437	199	26	-	-	ADJ
admet-437	199	27	clinical	clinical	ADJ
admet-437	199	28	species	specie	NOUN
admet-437	199	29	and	and	CCONJ
admet-437	199	30	humans	human	NOUN
admet-437	199	31	.	.	PUNCT
admet-437	200	1	the	the	DET
admet-437	200	2	caco-2	caco-2	NUM
admet-437	200	3	cell	cell	NOUN
admet-437	200	4	monolayer	monolayer	NOUN
admet-437	200	5	transport	transport	NOUN
admet-437	200	6	assay	assay	NOUN
admet-437	200	7	is	be	AUX
admet-437	200	8	well	well	ADV
admet-437	200	9	established	establish	VERB
admet-437	200	10	test	test	NOUN
admet-437	200	11	system	system	NOUN
admet-437	200	12	for	for	ADP
admet-437	200	13	estimating	estimate	VERB
admet-437	200	14	drug	drug	NOUN
admet-437	200	15	absorption	absorption	NOUN
admet-437	200	16	[	[	X
admet-437	200	17	19	19	NUM
admet-437	200	18	]	]	PUNCT
admet-437	200	19	.	.	PUNCT
admet-437	201	1	this	this	DET
admet-437	201	2	caco-2	caco-2	NUM
admet-437	201	3	cell	cell	NOUN
admet-437	201	4	monolayer	monolayer	NOUN
admet-437	201	5	system	system	NOUN
admet-437	201	6	generated	generate	VERB
admet-437	201	7	papp	papp	NOUN
admet-437	201	8	value	value	NOUN
admet-437	201	9	in	in	ADP
admet-437	201	10	absorptive	absorptive	ADJ
admet-437	201	11	direction	direction	NOUN
admet-437	201	12	for	for	ADP
admet-437	201	13	ulixertinib	ulixertinib	NOUN
admet-437	201	14	was	be	AUX
admet-437	201	15	2.67	2.67	NUM
admet-437	201	16	x	x	SYM
admet-437	201	17	10	10	NUM
admet-437	201	18	-	-	SYM
admet-437	201	19	6	6	NUM
admet-437	201	20	cm	cm	NOUN
admet-437	201	21	/	/	SYM
admet-437	201	22	sec	sec	PROPN
admet-437	201	23	,	,	PUNCT
admet-437	201	24	indicating	indicate	VERB
admet-437	201	25	it	it	PRON
admet-437	201	26	is	be	AUX
admet-437	201	27	a	a	DET
admet-437	201	28	moderately	moderately	ADV
admet-437	201	29	permeable	permeable	ADJ
admet-437	201	30	compound	compound	NOUN
admet-437	201	31	,	,	PUNCT
admet-437	201	32	however	however	ADV
admet-437	201	33	the	the	DET
admet-437	201	34	papp	papp	NOUN
admet-437	201	35	value	value	NOUN
admet-437	201	36	in	in	ADP
admet-437	201	37	secretive	secretive	ADJ
admet-437	201	38	direction	direction	NOUN
admet-437	201	39	appeared	appear	VERB
admet-437	201	40	to	to	ADP
admet-437	201	41	much	much	ADV
admet-437	201	42	higher	high	ADJ
admet-437	201	43	(	(	PUNCT
admet-437	201	44	8.09	8.09	NUM
admet-437	201	45	x	x	SYM
admet-437	201	46	10	10	NUM
admet-437	201	47	-6	-6	NOUN
admet-437	201	48	cm	cm	NOUN
admet-437	201	49	/	/	SYM
admet-437	201	50	sec	sec	PROPN
admet-437	201	51	)	)	PUNCT
admet-437	201	52	,	,	PUNCT
admet-437	201	53	suggesting	suggest	VERB
admet-437	201	54	involvement	involvement	NOUN
admet-437	201	55	of	of	ADP
admet-437	201	56	efflux	efflux	ADJ
admet-437	201	57	transporters	transporter	NOUN
admet-437	201	58	in	in	ADP
admet-437	201	59	the	the	DET
admet-437	201	60	caco-2	caco-2	NUM
admet-437	201	61	monolayer	monolayer	NOUN
admet-437	201	62	.	.	PUNCT
admet-437	202	1	our	our	PRON
admet-437	202	2	results	result	NOUN
admet-437	202	3	indicate	indicate	VERB
admet-437	202	4	that	that	SCONJ
admet-437	202	5	ulixertinib	ulixertinib	NOUN
admet-437	202	6	weakly	weakly	ADV
admet-437	202	7	inhibits	inhibit	VERB
admet-437	202	8	the	the	DET
admet-437	202	9	major	major	ADJ
admet-437	202	10	cyps	cyps	PROPN
admet-437	202	11	tested	test	VERB
admet-437	202	12	and	and	CCONJ
admet-437	202	13	ic50	ic50	PROPN
admet-437	202	14	values	value	NOUN
admet-437	202	15	are	be	AUX
admet-437	202	16	greater	great	ADJ
admet-437	202	17	than	than	ADP
admet-437	202	18	20	20	NUM
admet-437	202	19	µm	µm	NOUN
admet-437	202	20	(	(	PUNCT
admet-437	202	21	for	for	ADP
admet-437	202	22	most	most	ADJ
admet-437	202	23	of	of	ADP
admet-437	202	24	cyps	cyps	PROPN
admet-437	202	25	tested	test	VERB
admet-437	202	26	)	)	PUNCT
admet-437	202	27	.	.	PUNCT
admet-437	203	1	ulixertinib	ulixertinib	PROPN
admet-437	203	2	did	do	AUX
admet-437	203	3	not	not	PART
admet-437	203	4	show	show	VERB
admet-437	203	5	propensity	propensity	NOUN
admet-437	203	6	to	to	PART
admet-437	203	7	induce	induce	VERB
admet-437	203	8	cyp34	cyp34	NOUN
admet-437	203	9	.	.	PUNCT
admet-437	204	1	so	so	ADV
admet-437	204	2	,	,	PUNCT
admet-437	204	3	cyp	cyp	ADJ
admet-437	204	4	inhibition	inhibition	NOUN
admet-437	204	5	or	or	CCONJ
admet-437	204	6	induction	induction	NOUN
admet-437	204	7	is	be	AUX
admet-437	204	8	likely	likely	ADJ
admet-437	204	9	to	to	PART
admet-437	204	10	represent	represent	VERB
admet-437	204	11	a	a	DET
admet-437	204	12	clinically	clinically	ADV
admet-437	204	13	significant	significant	ADJ
admet-437	204	14	risk	risk	NOUN
admet-437	204	15	of	of	ADP
admet-437	204	16	drug	drug	NOUN
admet-437	204	17	-	-	PUNCT
admet-437	204	18	drug	drug	NOUN
admet-437	204	19	interactions	interaction	NOUN
admet-437	204	20	.	.	PUNCT
admet-437	205	1	ulixertinib	ulixertinib	PROPN
admet-437	205	2	oral	oral	ADJ
admet-437	205	3	absorption	absorption	NOUN
admet-437	205	4	in	in	ADP
admet-437	205	5	mice	mouse	NOUN
admet-437	205	6	and	and	CCONJ
admet-437	205	7	rats	rat	NOUN
admet-437	205	8	was	be	AUX
admet-437	205	9	not	not	PART
admet-437	205	10	limited	limit	VERB
admet-437	205	11	by	by	ADP
admet-437	205	12	efflux	efflux	NOUN
admet-437	205	13	as	as	ADP
admet-437	205	14	bioavailability	bioavailability	NOUN
admet-437	205	15	in	in	ADP
admet-437	205	16	these	these	DET
admet-437	205	17	two	two	NUM
admet-437	205	18	species	specie	NOUN
admet-437	205	19	was	be	AUX
admet-437	205	20	>	>	X
admet-437	205	21	92	92	NUM
admet-437	205	22	%	%	NOUN
admet-437	205	23	.	.	PUNCT
admet-437	206	1	however	however	ADV
admet-437	206	2	in	in	ADP
admet-437	206	3	dogs	dog	NOUN
admet-437	206	4	the	the	DET
admet-437	206	5	oral	oral	ADJ
admet-437	206	6	bioavailability	bioavailability	NOUN
admet-437	206	7	was	be	AUX
admet-437	206	8	34	34	NUM
admet-437	206	9	%	%	NOUN
admet-437	206	10	and	and	CCONJ
admet-437	206	11	this	this	PRON
admet-437	206	12	may	may	AUX
admet-437	206	13	be	be	AUX
admet-437	206	14	due	due	ADJ
admet-437	206	15	to	to	ADP
admet-437	206	16	high	high	ADJ
admet-437	206	17	unbound	unbound	NOUN
admet-437	206	18	concentrations	concentration	NOUN
admet-437	206	19	(	(	PUNCT
admet-437	206	20	fu	fu	NOUN
admet-437	206	21	0.05	0.05	NUM
admet-437	206	22	in	in	ADP
admet-437	206	23	dog	dog	NOUN
admet-437	206	24	plasma	plasma	NOUN
admet-437	206	25	vs	vs	ADP
admet-437	206	26	0.001	0.001	NUM
admet-437	206	27	and	and	CCONJ
admet-437	206	28	0.003	0.003	NUM
admet-437	206	29	in	in	ADP
admet-437	206	30	mice	mouse	NOUN
admet-437	206	31	and	and	CCONJ
admet-437	206	32	rat	rat	NOUN
admet-437	206	33	plasma	plasma	NOUN
admet-437	206	34	,	,	PUNCT
admet-437	206	35	respectively	respectively	ADV
admet-437	206	36	)	)	PUNCT
admet-437	206	37	in	in	ADP
admet-437	206	38	plasma	plasma	NOUN
admet-437	206	39	and	and	CCONJ
admet-437	206	40	extensive	extensive	ADJ
admet-437	206	41	metabolism	metabolism	NOUN
admet-437	206	42	in	in	ADP
admet-437	206	43	dogs	dog	NOUN
admet-437	206	44	thus	thus	ADV
admet-437	206	45	ulixertinib	ulixertinib	NOUN
admet-437	206	46	had	have	VERB
admet-437	206	47	relatively	relatively	ADV
admet-437	206	48	high	high	ADJ
admet-437	206	49	plasma	plasma	NOUN
admet-437	206	50	clearance	clearance	NOUN
admet-437	206	51	.	.	PUNCT
admet-437	207	1	in	in	ADP
admet-437	207	2	addition	addition	NOUN
admet-437	207	3	,	,	PUNCT
admet-437	207	4	higher	high	ADJ
admet-437	207	5	volume	volume	NOUN
admet-437	207	6	of	of	ADP
admet-437	207	7	distribution	distribution	NOUN
admet-437	207	8	of	of	ADP
admet-437	207	9	mice	mouse	NOUN
admet-437	207	10	indicates	indicate	VERB
admet-437	207	11	that	that	SCONJ
admet-437	207	12	ulixertinib	ulixertinib	NOUN
admet-437	207	13	is	be	AUX
admet-437	207	14	highly	highly	ADV
admet-437	207	15	distributed	distribute	VERB
admet-437	207	16	in	in	ADP
admet-437	207	17	mice	mouse	NOUN
admet-437	207	18	compared	compare	VERB
admet-437	207	19	to	to	ADP
admet-437	207	20	rats	rat	NOUN
admet-437	207	21	and	and	CCONJ
admet-437	207	22	dogs	dog	NOUN
admet-437	207	23	.	.	PUNCT
admet-437	208	1	ulixertinib	ulixertinib	PROPN
admet-437	208	2	demonstrated	demonstrate	VERB
admet-437	208	3	high	high	ADJ
admet-437	208	4	plasma	plasma	NOUN
admet-437	208	5	clearance	clearance	NOUN
admet-437	208	6	in	in	ADP
admet-437	208	7	dogs	dog	NOUN
admet-437	208	8	compared	compare	VERB
admet-437	208	9	to	to	ADP
admet-437	208	10	rats	rat	NOUN
admet-437	208	11	and	and	CCONJ
admet-437	208	12	mice	mouse	NOUN
admet-437	208	13	,	,	PUNCT
admet-437	208	14	which	which	PRON
admet-437	208	15	is	be	AUX
admet-437	208	16	50	50	NUM
admet-437	208	17	,	,	PUNCT
admet-437	208	18	3.0	3.0	NUM
admet-437	208	19	and	and	CCONJ
admet-437	208	20	7.0	7.0	NUM
admet-437	208	21	%	%	NOUN
admet-437	208	22	of	of	ADP
admet-437	208	23	hbf	hbf	PROPN
admet-437	208	24	,	,	PUNCT
admet-437	208	25	respectively	respectively	ADV
admet-437	208	26	and	and	CCONJ
admet-437	208	27	was	be	AUX
admet-437	208	28	very	very	ADV
admet-437	208	29	much	much	ADV
admet-437	208	30	predicted	predict	VERB
admet-437	208	31	by	by	ADP
admet-437	208	32	the	the	DET
admet-437	208	33	in	in	ADV
admet-437	208	34	vitro	vitro	X
admet-437	208	35	experiment	experiment	NOUN
admet-437	208	36	,	,	PUNCT
admet-437	208	37	indicating	indicate	VERB
admet-437	208	38	the	the	DET
admet-437	208	39	difference	difference	NOUN
admet-437	208	40	in	in	ADP
admet-437	208	41	hepatic	hepatic	ADJ
admet-437	208	42	metabolism	metabolism	NOUN
admet-437	208	43	.	.	PUNCT
admet-437	209	1	conclusions	conclusion	NOUN
admet-437	209	2	in	in	ADP
admet-437	209	3	conclusion	conclusion	NOUN
admet-437	209	4	,	,	PUNCT
admet-437	209	5	the	the	DET
admet-437	209	6	preclinical	preclinical	ADJ
admet-437	209	7	data	datum	NOUN
admet-437	209	8	gathered	gather	VERB
admet-437	209	9	in	in	ADP
admet-437	209	10	this	this	DET
admet-437	209	11	work	work	NOUN
admet-437	209	12	provided	provide	VERB
admet-437	209	13	evidence	evidence	NOUN
admet-437	209	14	that	that	SCONJ
admet-437	209	15	ulixertinib	ulixertinib	NOUN
admet-437	209	16	has	have	AUX
admet-437	209	17	excellent	excellent	ADJ
admet-437	209	18	oral	oral	ADJ
admet-437	209	19	bioavailability	bioavailability	NOUN
admet-437	209	20	in	in	ADP
admet-437	209	21	rodents	rodent	NOUN
admet-437	209	22	and	and	CCONJ
admet-437	209	23	acceptable	acceptable	ADJ
admet-437	209	24	bioavailability	bioavailability	NOUN
admet-437	209	25	in	in	ADP
admet-437	209	26	dogs	dog	NOUN
admet-437	209	27	,	,	PUNCT
admet-437	209	28	adequate	adequate	ADJ
admet-437	209	29	metabolic	metabolic	NOUN
admet-437	209	30	stability	stability	NOUN
admet-437	209	31	and	and	CCONJ
admet-437	209	32	devoid	devoid	ADJ
admet-437	209	33	of	of	ADP
admet-437	209	34	drug	drug	NOUN
admet-437	209	35	-	-	PUNCT
admet-437	209	36	drug	drug	NOUN
admet-437	209	37	interactions	interaction	NOUN
admet-437	209	38	liability	liability	NOUN
admet-437	209	39	and	and	CCONJ
admet-437	209	40	different	different	ADJ
admet-437	209	41	mechanism	mechanism	NOUN
admet-437	209	42	of	of	ADP
admet-437	209	43	action	action	NOUN
admet-437	209	44	may	may	AUX
admet-437	209	45	provide	provide	VERB
admet-437	209	46	differentiating	differentiate	VERB
admet-437	209	47	features	feature	NOUN
admet-437	209	48	from	from	ADP
admet-437	209	49	other	other	ADJ
admet-437	209	50	oncology	oncology	NOUN
admet-437	209	51	compounds	compound	NOUN
admet-437	209	52	in	in	ADP
admet-437	209	53	this	this	DET
admet-437	209	54	class	class	NOUN
admet-437	209	55	.	.	PUNCT
admet-437	210	1	overall	overall	ADV
admet-437	210	2	,	,	PUNCT
admet-437	210	3	looking	look	VERB
admet-437	210	4	at	at	ADP
admet-437	210	5	the	the	DET
admet-437	210	6	ulixertinib	ulixertinib	ADJ
admet-437	210	7	preclinical	preclinical	ADJ
admet-437	210	8	data	datum	NOUN
admet-437	210	9	presented	present	VERB
admet-437	210	10	by	by	ADP
admet-437	210	11	us	we	PRON
admet-437	210	12	and	and	CCONJ
admet-437	210	13	its	its	PRON
admet-437	210	14	current	current	ADJ
admet-437	210	15	clinical	clinical	ADJ
admet-437	210	16	data	datum	NOUN
admet-437	210	17	provide	provide	VERB
admet-437	210	18	a	a	DET
admet-437	210	19	good	good	ADJ
admet-437	210	20	platform	platform	NOUN
admet-437	210	21	for	for	ADP
admet-437	210	22	researches	research	NOUN
admet-437	210	23	to	to	PART
admet-437	210	24	develop	develop	VERB
admet-437	210	25	novel	novel	ADJ
admet-437	210	26	erk1/2	erk1/2	PART
admet-437	210	27	inhibitors	inhibitor	NOUN
admet-437	210	28	with	with	ADP
admet-437	210	29	potential	potential	ADJ
admet-437	210	30	benefit	benefit	NOUN
admet-437	210	31	as	as	ADP
admet-437	210	32	a	a	DET
admet-437	210	33	single	single	ADJ
admet-437	210	34	or	or	CCONJ
admet-437	210	35	concomitant	concomitant	ADJ
admet-437	210	36	solid	solid	ADJ
admet-437	210	37	tumor	tumor	NOUN
admet-437	210	38	therapy	therapy	NOUN
admet-437	210	39	.	.	PUNCT
admet-437	211	1	r.	r.	PROPN
admet-437	211	2	mullangi	mullangi	VERB
admet-437	211	3	et	et	PROPN
admet-437	211	4	al	al	PROPN
admet-437	211	5	.	.	PROPN
admet-437	211	6	admet	admet	PROPN
admet-437	211	7	&	&	CCONJ
admet-437	211	8	dmpk	dmpk	PROPN
admet-437	211	9	5(4	5(4	NOUN
admet-437	211	10	)	)	PUNCT
admet-437	211	11	(	(	PUNCT
admet-437	211	12	2017	2017	NUM
admet-437	211	13	)	)	PUNCT
admet-437	211	14	212	212	NUM
admet-437	211	15	-	-	SYM
admet-437	211	16	223	223	NUM
admet-437	211	17	222	222	NUM
admet-437	211	18	conflict	conflict	NOUN
admet-437	211	19	of	of	ADP
admet-437	211	20	interest	interest	NOUN
admet-437	211	21	:	:	PUNCT
admet-437	211	22	the	the	DET
admet-437	211	23	authors	author	NOUN
admet-437	211	24	have	have	VERB
admet-437	211	25	no	no	DET
admet-437	211	26	conflict	conflict	NOUN
admet-437	211	27	of	of	ADP
admet-437	211	28	interest	interest	NOUN
admet-437	211	29	references	reference	NOUN
admet-437	211	30	[	[	X
admet-437	211	31	1	1	NUM
admet-437	211	32	]	]	PUNCT
admet-437	211	33	a.	a.	NOUN
admet-437	211	34	akinleye	akinleye	NOUN
admet-437	211	35	,	,	PUNCT
admet-437	211	36	m.	m.	PROPN
admet-437	211	37	furqan	furqan	PROPN
admet-437	211	38	,	,	PUNCT
admet-437	211	39	n.	n.	PROPN
admet-437	211	40	mukhi	mukhi	PROPN
admet-437	211	41	,	,	PUNCT
admet-437	211	42	p.	p.	PROPN
admet-437	211	43	ravella	ravella	PROPN
admet-437	211	44	,	,	PUNCT
admet-437	211	45	d.	d.	PROPN
admet-437	211	46	liu	liu	PROPN
admet-437	211	47	.	.	PUNCT
admet-437	212	1	mek	mek	PROPN
admet-437	212	2	and	and	CCONJ
admet-437	212	3	the	the	DET
admet-437	212	4	inhibitors	inhibitor	NOUN
admet-437	212	5	:	:	PUNCT
admet-437	212	6	from	from	ADP
admet-437	212	7	bench	bench	NOUN
admet-437	212	8	to	to	ADP
admet-437	212	9	bedside	bedside	NOUN
admet-437	212	10	.	.	PUNCT
admet-437	213	1	journal	journal	PROPN
admet-437	213	2	of	of	ADP
admet-437	213	3	hematology	hematology	PROPN
admet-437	213	4	&	&	CCONJ
admet-437	213	5	oncology	oncology	NOUN
admet-437	213	6	6	6	NUM
admet-437	213	7	(	(	PUNCT
admet-437	213	8	2013	2013	NUM
admet-437	213	9	)	)	PUNCT
admet-437	213	10	27	27	NUM
admet-437	213	11	.	.	PUNCT
admet-437	214	1	[	[	X
admet-437	214	2	2	2	X
admet-437	214	3	]	]	PUNCT
admet-437	214	4	d.	d.	PROPN
admet-437	214	5	mattallanas	mattallanas	PROPN
admet-437	214	6	,	,	PUNCT
admet-437	214	7	p.	p.	PROPN
admet-437	214	8	crespo	crespo	PROPN
admet-437	214	9	.	.	PUNCT
admet-437	215	1	new	new	ADJ
admet-437	215	2	druggable	druggable	ADJ
admet-437	215	3	targets	target	NOUN
admet-437	215	4	in	in	ADP
admet-437	215	5	the	the	DET
admet-437	215	6	ras	ras	NOUN
admet-437	215	7	pathway	pathway	NOUN
admet-437	215	8	?	?	PUNCT
admet-437	216	1	current	current	ADJ
admet-437	216	2	opinion	opinion	NOUN
admet-437	216	3	in	in	ADP
admet-437	216	4	molecular	molecular	ADJ
admet-437	216	5	therapeutics	therapeutic	NOUN
admet-437	216	6	12	12	NUM
admet-437	216	7	(	(	PUNCT
admet-437	216	8	2010	2010	NUM
admet-437	216	9	)	)	PUNCT
admet-437	216	10	674	674	NUM
admet-437	216	11	-	-	NUM
admet-437	216	12	683	683	NUM
admet-437	216	13	.	.	PUNCT
admet-437	217	1	[	[	X
admet-437	217	2	3	3	X
admet-437	217	3	]	]	X
admet-437	217	4	m.	m.	NOUN
admet-437	217	5	warthaka	warthaka	PROPN
admet-437	217	6	,	,	PUNCT
admet-437	217	7	c.h	c.h	PROPN
admet-437	217	8	.	.	PROPN
admet-437	217	9	adelmann	adelmann	PROPN
admet-437	217	10	,	,	PUNCT
admet-437	217	11	t.s	t.s	PROPN
admet-437	217	12	.	.	PROPN
admet-437	217	13	kaoud	kaoud	PROPN
admet-437	217	14	,	,	PUNCT
admet-437	217	15	r.	r.	PROPN
admet-437	217	16	edupuganti	edupuganti	PROPN
admet-437	217	17	,	,	PUNCT
admet-437	217	18	c	c	X
admet-437	217	19	,	,	PUNCT
admet-437	217	20	yan	yan	PROPN
admet-437	217	21	,	,	PUNCT
admet-437	217	22	w.h	w.h	PROPN
admet-437	217	23	.	.	PROPN
admet-437	217	24	johnson	johnson	PROPN
admet-437	217	25	jr	jr	PROPN
admet-437	217	26	,	,	PUNCT
admet-437	217	27	s.	s.	PROPN
admet-437	217	28	ferguson	ferguson	PROPN
admet-437	217	29	,	,	PUNCT
admet-437	217	30	c.d	c.d	PROPN
admet-437	217	31	.	.	PROPN
admet-437	217	32	tavares	tavare	NOUN
admet-437	217	33	,	,	PUNCT
admet-437	217	34	l.j	l.j	PROPN
admet-437	217	35	.	.	PROPN
admet-437	217	36	pence	pence	PROPN
admet-437	217	37	,	,	PUNCT
admet-437	217	38	e.v	e.v	PROPN
admet-437	217	39	.	.	PROPN
admet-437	217	40	anslyn	anslyn	PROPN
admet-437	217	41	,	,	PUNCT
admet-437	217	42	p.	p.	PROPN
admet-437	217	43	ren	ren	PROPN
admet-437	217	44	,	,	PUNCT
admet-437	217	45	k.y	k.y	PROPN
admet-437	217	46	.	.	PROPN
admet-437	217	47	tsai	tsai	PROPN
admet-437	217	48	,	,	PUNCT
admet-437	217	49	k.n	k.n	PROPN
admet-437	217	50	.	.	PROPN
admet-437	217	51	dalby	dalby	PROPN
admet-437	217	52	.	.	PUNCT
admet-437	218	1	quantification	quantification	NOUN
admet-437	218	2	of	of	ADP
admet-437	218	3	a	a	DET
admet-437	218	4	pharmacodynamic	pharmacodynamic	ADJ
admet-437	218	5	erk	erk	PROPN
admet-437	218	6	end	end	NOUN
admet-437	218	7	point	point	NOUN
admet-437	218	8	in	in	ADP
admet-437	218	9	melanoma	melanoma	NOUN
admet-437	218	10	cell	cell	NOUN
admet-437	218	11	lysates	lysate	NOUN
admet-437	218	12	:	:	PUNCT
admet-437	218	13	toward	toward	ADP
admet-437	218	14	personalized	personalize	VERB
admet-437	218	15	precision	precision	NOUN
admet-437	218	16	medicine	medicine	NOUN
admet-437	218	17	.	.	PUNCT
admet-437	219	1	acs	acs	PROPN
admet-437	219	2	medicinal	medicinal	ADJ
admet-437	219	3	chemistry	chemistry	NOUN
admet-437	219	4	letters	letter	NOUN
admet-437	219	5	5	5	NUM
admet-437	219	6	(	(	PUNCT
admet-437	219	7	2015	2015	NUM
admet-437	219	8	)	)	PUNCT
admet-437	219	9	47	47	NUM
admet-437	219	10	-	-	SYM
admet-437	219	11	52	52	NUM
admet-437	219	12	.	.	PUNCT
admet-437	220	1	[	[	X
admet-437	220	2	4	4	NUM
admet-437	220	3	]	]	X
admet-437	220	4	j.l	j.l	PROPN
admet-437	220	5	.	.	PROPN
admet-437	220	6	bos	bos	PROPN
admet-437	220	7	.	.	PUNCT
admet-437	221	1	ras	ras	PROPN
admet-437	221	2	oncogenes	oncogene	NOUN
admet-437	221	3	in	in	ADP
admet-437	221	4	human	human	ADJ
admet-437	221	5	cancer	cancer	NOUN
admet-437	221	6	:	:	PUNCT
admet-437	221	7	a	a	DET
admet-437	221	8	review	review	NOUN
admet-437	221	9	.	.	PUNCT
admet-437	222	1	cancer	cancer	NOUN
admet-437	222	2	research	research	NOUN
admet-437	222	3	49	49	NUM
admet-437	222	4	(	(	PUNCT
admet-437	222	5	1989	1989	NUM
admet-437	222	6	)	)	PUNCT
admet-437	222	7	4682	4682	NUM
admet-437	222	8	-	-	SYM
admet-437	222	9	4689	4689	NUM
admet-437	222	10	.	.	PUNCT
admet-437	223	1	[	[	X
admet-437	223	2	5	5	NUM
admet-437	223	3	]	]	X
admet-437	223	4	w.j	w.j	PROPN
admet-437	223	5	.	.	PROPN
admet-437	223	6	ding	ding	PROPN
admet-437	223	7	,	,	PUNCT
admet-437	223	8	w.p	w.p	PROPN
admet-437	223	9	.	.	PROPN
admet-437	223	10	tao	tao	PROPN
admet-437	223	11	,	,	PUNCT
admet-437	223	12	t.	t.	PROPN
admet-437	223	13	zeng	zeng	PROPN
admet-437	223	14	,	,	PUNCT
admet-437	223	15	j.j	j.j	PROPN
admet-437	223	16	.	.	PROPN
admet-437	223	17	deng	deng	PROPN
admet-437	223	18	,	,	PUNCT
admet-437	223	19	h.b	h.b	PROPN
admet-437	223	20	.	.	PROPN
admet-437	223	21	lei	lei	PROPN
admet-437	223	22	,	,	PUNCT
admet-437	223	23	w.	w.	PROPN
admet-437	223	24	ge	ge	PROPN
admet-437	223	25	.	.	PROPN
admet-437	224	1	selective	selective	PROPN
admet-437	224	2	erk	erk	PROPN
admet-437	224	3	inhibitor	inhibitor	PROPN
admet-437	224	4	inhibits	inhibit	VERB
admet-437	224	5	proliferation	proliferation	NOUN
admet-437	224	6	and	and	CCONJ
admet-437	224	7	induces	induce	VERB
admet-437	224	8	apoptosis	apoptosis	NOUN
admet-437	224	9	in	in	ADP
admet-437	224	10	lymphoma	lymphoma	NOUN
admet-437	224	11	cell	cell	NOUN
admet-437	224	12	lines	line	NOUN
admet-437	224	13	.	.	PUNCT
admet-437	225	1	international	international	ADJ
admet-437	225	2	journal	journal	NOUN
admet-437	225	3	of	of	ADP
admet-437	225	4	clinical	clinical	ADJ
admet-437	225	5	experimental	experimental	ADJ
admet-437	225	6	medicine	medicine	NOUN
admet-437	225	7	9	9	NUM
admet-437	225	8	(	(	PUNCT
admet-437	225	9	2016	2016	NUM
admet-437	225	10	)	)	PUNCT
admet-437	225	11	10955	10955	NUM
admet-437	225	12	-	-	SYM
admet-437	225	13	10962	10962	NUM
admet-437	225	14	.	.	PUNCT
admet-437	226	1	[	[	X
admet-437	226	2	6	6	NUM
admet-437	226	3	]	]	X
admet-437	226	4	u.	u.	NOUN
admet-437	226	5	germann	germann	PROPN
admet-437	226	6	,	,	PUNCT
admet-437	226	7	b.	b.	PROPN
admet-437	226	8	furey	furey	PROPN
admet-437	226	9	,	,	PUNCT
admet-437	226	10	j.	j.	PROPN
admet-437	226	11	roix	roix	PROPN
admet-437	226	12	,	,	PUNCT
admet-437	226	13	w.	w.	PROPN
admet-437	226	14	markland	markland	PROPN
admet-437	226	15	,	,	PUNCT
admet-437	226	16	r.	r.	PROPN
admet-437	226	17	hoover	hoover	PROPN
admet-437	226	18	,	,	PUNCT
admet-437	226	19	a.	a.	PROPN
admet-437	226	20	aronov	aronov	PROPN
admet-437	226	21	,	,	PUNCT
admet-437	226	22	m.	m.	PROPN
admet-437	226	23	hale	hale	PROPN
admet-437	226	24	,	,	PUNCT
admet-437	226	25	g.	g.	PROPN
admet-437	226	26	chen	chen	PROPN
admet-437	226	27	,	,	PUNCT
admet-437	226	28	g.	g.	PROPN
admet-437	226	29	martinezbotella	martinezbotella	PROPN
admet-437	226	30	,	,	PUNCT
admet-437	226	31	r.	r.	PROPN
admet-437	226	32	alargova	alargova	PROPN
admet-437	226	33	,	,	PUNCT
admet-437	226	34	b.	b.	PROPN
admet-437	226	35	fan	fan	PROPN
admet-437	226	36	,	,	PUNCT
admet-437	226	37	d.	d.	PROPN
admet-437	226	38	sorrell	sorrell	PROPN
admet-437	226	39	,	,	PUNCT
admet-437	226	40	k.	k.	PROPN
admet-437	226	41	meshaw	meshaw	PROPN
admet-437	226	42	,	,	PUNCT
admet-437	226	43	p.	p.	NOUN
admet-437	226	44	shapiro	shapiro	PROPN
admet-437	226	45	,	,	PUNCT
admet-437	226	46	m.	m.	NOUN
admet-437	226	47	j.	j.	PROPN
admet-437	226	48	wick	wick	PROPN
admet-437	226	49	,	,	PUNCT
admet-437	226	50	c.	c.	PROPN
admet-437	226	51	benes	benes	PROPN
admet-437	226	52	,	,	PUNCT
admet-437	226	53	m.	m.	NOUN
admet-437	226	54	garnett	garnett	PROPN
admet-437	226	55	,	,	PUNCT
admet-437	226	56	g.	g.	PROPN
admet-437	226	57	decrescenzo	decrescenzo	PROPN
admet-437	226	58	,	,	PUNCT
admet-437	226	59	m.	m.	NOUN
admet-437	226	60	namchuk	namchuk	PROPN
admet-437	226	61	,	,	PUNCT
admet-437	226	62	s.	s.	PROPN
admet-437	226	63	saha	saha	PROPN
admet-437	226	64	,	,	PUNCT
admet-437	226	65	d.j	d.j	PROPN
admet-437	226	66	.	.	PROPN
admet-437	226	67	welsch	welsch	PROPN
admet-437	226	68	.	.	PUNCT
admet-437	227	1	the	the	DET
admet-437	227	2	selective	selective	ADJ
admet-437	227	3	erk	erk	PROPN
admet-437	227	4	inhibitor	inhibitor	NOUN
admet-437	227	5	bvd-523	bvd-523	NOUN
admet-437	227	6	is	be	AUX
admet-437	227	7	active	active	ADJ
admet-437	227	8	in	in	ADP
admet-437	227	9	models	model	NOUN
admet-437	227	10	of	of	ADP
admet-437	227	11	mapk	mapk	NOUN
admet-437	227	12	pathway	pathway	NOUN
admet-437	227	13	-	-	PUNCT
admet-437	227	14	dependent	dependent	ADJ
admet-437	227	15	cancers	cancer	NOUN
admet-437	227	16	,	,	PUNCT
admet-437	227	17	including	include	VERB
admet-437	227	18	those	those	PRON
admet-437	227	19	with	with	ADP
admet-437	227	20	intrinsic	intrinsic	ADJ
admet-437	227	21	and	and	CCONJ
admet-437	227	22	acquired	acquire	VERB
admet-437	227	23	drug	drug	NOUN
admet-437	227	24	resistance	resistance	NOUN
admet-437	227	25	.	.	PUNCT
admet-437	228	1	cancer	cancer	NOUN
admet-437	228	2	research	research	NOUN
admet-437	228	3	75	75	NUM
admet-437	228	4	(	(	PUNCT
admet-437	228	5	2015	2015	NUM
admet-437	228	6	)	)	PUNCT
admet-437	229	1	abstract	abstract	ADV
admet-437	229	2	no	no	INTJ
admet-437	229	3	.	.	PUNCT
admet-437	229	4	4693	4693	NUM
admet-437	229	5	.	.	PUNCT
admet-437	230	1	[	[	X
admet-437	230	2	7	7	X
admet-437	230	3	]	]	X
admet-437	230	4	j.r	j.r	PROPN
admet-437	230	5	.	.	PROPN
admet-437	230	6	infante	infante	PROPN
admet-437	230	7	,	,	PUNCT
admet-437	230	8	f.	f.	PROPN
admet-437	230	9	janku	janku	PROPN
admet-437	230	10	,	,	PUNCT
admet-437	230	11	a.w	a.w	PROPN
admet-437	230	12	.	.	PROPN
admet-437	230	13	tolcher	tolcher	PROPN
admet-437	230	14	,	,	PUNCT
admet-437	230	15	m.r	m.r	PROPN
admet-437	230	16	.	.	PROPN
admet-437	230	17	patel	patel	PROPN
admet-437	230	18	,	,	PUNCT
admet-437	230	19	r.j	r.j	PROPN
admet-437	230	20	.	.	PROPN
admet-437	230	21	sullivan	sullivan	PROPN
admet-437	230	22	,	,	PUNCT
admet-437	230	23	k.	k.	PROPN
admet-437	230	24	flaherty	flaherty	PROPN
admet-437	230	25	,	,	PUNCT
admet-437	230	26	r.d	r.d	PROPN
admet-437	230	27	.	.	PROPN
admet-437	230	28	carvajal	carvajal	PROPN
admet-437	230	29	,	,	PUNCT
admet-437	230	30	a.m.	a.m.	PROPN
admet-437	230	31	varghese	varghese	PROPN
admet-437	230	32	,	,	PUNCT
admet-437	230	33	d.j	d.j	PROPN
admet-437	230	34	.	.	PROPN
admet-437	230	35	lee	lee	PROPN
admet-437	230	36	wong	wong	PROPN
admet-437	230	37	,	,	PUNCT
admet-437	230	38	m.	m.	NOUN
admet-437	230	39	sznol	sznol	PROPN
admet-437	230	40	,	,	PUNCT
admet-437	230	41	j.a	j.a	PROPN
admet-437	230	42	.	.	PROPN
admet-437	230	43	sosman	sosman	PROPN
admet-437	230	44	,	,	PUNCT
admet-437	230	45	a.	a.	PROPN
admet-437	230	46	wang	wang	PROPN
admet-437	230	47	-	-	PUNCT
admet-437	230	48	gillam	gillam	PROPN
admet-437	230	49	,	,	PUNCT
admet-437	230	50	h.a	h.a	PROPN
admet-437	230	51	.	.	PROPN
admet-437	230	52	burris	burris	PROPN
admet-437	230	53	,	,	PUNCT
admet-437	230	54	a.	a.	PROPN
admet-437	230	55	ribas	ribas	PROPN
admet-437	230	56	,	,	PUNCT
admet-437	230	57	s.p	s.p	PROPN
admet-437	230	58	.	.	PROPN
admet-437	230	59	patel	patel	PROPN
admet-437	230	60	,	,	PUNCT
admet-437	230	61	d.j	d.j	PROPN
admet-437	230	62	.	.	PROPN
admet-437	230	63	welsch	welsch	PROPN
admet-437	230	64	,	,	PUNCT
admet-437	230	65	s.	s.	PROPN
admet-437	230	66	saha	saha	PROPN
admet-437	230	67	.	.	PUNCT
admet-437	231	1	dose	dose	NOUN
admet-437	231	2	escalation	escalation	NOUN
admet-437	231	3	stage	stage	NOUN
admet-437	231	4	of	of	ADP
admet-437	231	5	a	a	DET
admet-437	231	6	first	first	ADJ
admet-437	231	7	-	-	PUNCT
admet-437	231	8	in	in	ADP
admet-437	231	9	-	-	PUNCT
admet-437	231	10	class	class	NOUN
admet-437	231	11	phase	phase	NOUN
admet-437	231	12	i	i	PRON
admet-437	231	13	study	study	VERB
admet-437	231	14	of	of	ADP
admet-437	231	15	the	the	DET
admet-437	231	16	novel	novel	ADJ
admet-437	231	17	oral	oral	NOUN
admet-437	231	18	erk	erk	PROPN
admet-437	231	19	1/2	1/2	NUM
admet-437	231	20	kinase	kinase	PROPN
admet-437	231	21	inhibitor	inhibitor	NOUN
admet-437	231	22	bvd-523	bvd-523	NOUN
admet-437	231	23	(	(	PUNCT
admet-437	231	24	ulixertinib	ulixertinib	PROPN
admet-437	231	25	)	)	PUNCT
admet-437	231	26	in	in	ADP
admet-437	231	27	patients	patient	NOUN
admet-437	231	28	with	with	ADP
admet-437	231	29	advanced	advanced	ADJ
admet-437	231	30	solid	solid	ADJ
admet-437	231	31	tumors	tumor	NOUN
admet-437	231	32	.	.	PUNCT
admet-437	232	1	journal	journal	NOUN
admet-437	232	2	of	of	ADP
admet-437	232	3	clinical	clinical	ADJ
admet-437	232	4	oncology	oncology	NOUN
admet-437	232	5	33	33	NUM
admet-437	232	6	(	(	PUNCT
admet-437	232	7	2015	2015	NUM
admet-437	232	8	)	)	PUNCT
admet-437	232	9	abstract	abstract	ADJ
admet-437	232	10	no	no	INTJ
admet-437	232	11	.	.	PUNCT
admet-437	232	12	2506	2506	NUM
admet-437	232	13	.	.	PUNCT
admet-437	233	1	[	[	X
admet-437	233	2	8	8	NUM
admet-437	233	3	]	]	X
admet-437	233	4	r.s	r.s	PROPN
admet-437	233	5	.	.	PROPN
admet-437	233	6	obach	obach	PROPN
admet-437	233	7	.	.	PUNCT
admet-437	234	1	prediction	prediction	NOUN
admet-437	234	2	of	of	ADP
admet-437	234	3	human	human	ADJ
admet-437	234	4	clearance	clearance	NOUN
admet-437	234	5	of	of	ADP
admet-437	234	6	twenty	twenty	NUM
admet-437	234	7	-	-	PUNCT
admet-437	234	8	nine	nine	NUM
admet-437	234	9	drugs	drug	NOUN
admet-437	234	10	from	from	ADP
admet-437	234	11	hepatic	hepatic	ADJ
admet-437	234	12	microsomal	microsomal	ADJ
admet-437	234	13	intrinsic	intrinsic	ADJ
admet-437	234	14	clearance	clearance	NOUN
admet-437	234	15	data	datum	NOUN
admet-437	234	16	:	:	PUNCT
admet-437	234	17	an	an	DET
admet-437	234	18	examination	examination	NOUN
admet-437	234	19	of	of	ADP
admet-437	234	20	in	in	ADP
admet-437	234	21	vitro	vitro	X
admet-437	234	22	half	half	ADJ
admet-437	234	23	-	-	PUNCT
admet-437	234	24	life	life	NOUN
admet-437	234	25	approach	approach	NOUN
admet-437	234	26	and	and	CCONJ
admet-437	234	27	nonspecific	nonspecific	ADJ
admet-437	234	28	binding	bind	VERB
admet-437	234	29	to	to	ADP
admet-437	234	30	microsomes	microsome	NOUN
admet-437	234	31	.	.	PUNCT
admet-437	235	1	drug	drug	NOUN
admet-437	235	2	metabolism	metabolism	NOUN
admet-437	235	3	and	and	CCONJ
admet-437	235	4	disposition	disposition	NOUN
admet-437	235	5	27	27	NUM
admet-437	235	6	(	(	PUNCT
admet-437	235	7	1999	1999	NUM
admet-437	235	8	)	)	PUNCT
admet-437	235	9	1350	1350	NUM
admet-437	235	10	-	-	SYM
admet-437	235	11	1359	1359	NUM
admet-437	235	12	.	.	PUNCT
admet-437	236	1	[	[	X
admet-437	236	2	9	9	NUM
admet-437	236	3	]	]	X
admet-437	236	4	d.f	d.f	PROPN
admet-437	236	5	.	.	PROPN
admet-437	236	6	mcginnity	mcginnity	PROPN
admet-437	236	7	,	,	PUNCT
admet-437	236	8	m.g	m.g	PROPN
admet-437	236	9	.	.	PROPN
admet-437	236	10	soars	soars	PROPN
admet-437	236	11	,	,	PUNCT
admet-437	236	12	r.a	r.a	PROPN
admet-437	236	13	.	.	PROPN
admet-437	236	14	urbanowicz	urbanowicz	PROPN
admet-437	236	15	,	,	PUNCT
admet-437	236	16	r.j	r.j	PROPN
admet-437	236	17	.	.	PROPN
admet-437	236	18	riley	riley	PROPN
admet-437	236	19	.	.	PUNCT
admet-437	237	1	evaluation	evaluation	NOUN
admet-437	237	2	of	of	ADP
admet-437	237	3	fresh	fresh	ADJ
admet-437	237	4	and	and	CCONJ
admet-437	237	5	cryopreserved	cryopreserved	ADJ
admet-437	237	6	hepatocytes	hepatocyte	NOUN
admet-437	237	7	as	as	ADP
admet-437	237	8	in	in	ADP
admet-437	237	9	vitro	vitro	X
admet-437	237	10	drug	drug	NOUN
admet-437	237	11	metabolism	metabolism	NOUN
admet-437	237	12	tools	tool	NOUN
admet-437	237	13	for	for	ADP
admet-437	237	14	the	the	DET
admet-437	237	15	prediction	prediction	NOUN
admet-437	237	16	of	of	ADP
admet-437	237	17	metabolic	metabolic	NOUN
admet-437	237	18	clearance	clearance	NOUN
admet-437	237	19	.	.	PUNCT
admet-437	238	1	drug	drug	NOUN
admet-437	238	2	metabolism	metabolism	NOUN
admet-437	238	3	and	and	CCONJ
admet-437	238	4	disposition	disposition	NOUN
admet-437	238	5	32	32	NUM
admet-437	238	6	(	(	PUNCT
admet-437	238	7	2004	2004	NUM
admet-437	238	8	)	)	PUNCT
admet-437	238	9	1247	1247	NUM
admet-437	238	10	-	-	SYM
admet-437	238	11	1253	1253	NUM
admet-437	238	12	.	.	PUNCT
admet-437	239	1	[	[	X
admet-437	239	2	10	10	NUM
admet-437	239	3	]	]	PUNCT
admet-437	239	4	z.	z.	PROPN
admet-437	239	5	wang	wang	PROPN
admet-437	239	6	,	,	PUNCT
admet-437	239	7	c.e	c.e	PROPN
admet-437	239	8	.	.	PROPN
admet-437	239	9	hop	hop	PROPN
admet-437	239	10	,	,	PUNCT
admet-437	239	11	k.h	k.h	PROPN
admet-437	239	12	.	.	PROPN
admet-437	239	13	leung	leung	PROPN
admet-437	239	14	,	,	PUNCT
admet-437	239	15	j.	j.	PROPN
admet-437	239	16	pang	pang	PROPN
admet-437	239	17	.	.	PUNCT
admet-437	240	1	determination	determination	NOUN
admet-437	240	2	of	of	ADP
admet-437	240	3	in	in	ADP
admet-437	240	4	vitro	vitro	X
admet-437	240	5	permeability	permeability	NOUN
admet-437	240	6	of	of	ADP
admet-437	240	7	drug	drug	NOUN
admet-437	240	8	candidates	candidate	NOUN
admet-437	240	9	through	through	ADP
admet-437	240	10	a	a	DET
admet-437	240	11	caco-2	caco-2	NUM
admet-437	240	12	cell	cell	NOUN
admet-437	240	13	monolayer	monolayer	NOUN
admet-437	240	14	by	by	ADP
admet-437	240	15	liquid	liquid	ADJ
admet-437	240	16	chromatography	chromatography	NOUN
admet-437	240	17	/	/	SYM
admet-437	240	18	tandem	tandem	PROPN
admet-437	240	19	mass	mass	PROPN
admet-437	240	20	spectrometry	spectrometry	NOUN
admet-437	240	21	.	.	PUNCT
admet-437	241	1	journal	journal	PROPN
admet-437	241	2	of	of	ADP
admet-437	241	3	mass	mass	ADJ
admet-437	241	4	spectrometry	spectrometry	NOUN
admet-437	241	5	35	35	NUM
admet-437	241	6	(	(	PUNCT
admet-437	241	7	2000	2000	NUM
admet-437	241	8	)	)	PUNCT
admet-437	241	9	71	71	NUM
admet-437	241	10	-	-	SYM
admet-437	241	11	76	76	NUM
admet-437	241	12	.	.	PUNCT
admet-437	242	1	[	[	X
admet-437	242	2	11	11	NUM
admet-437	242	3	]	]	X
admet-437	242	4	p.v	p.v	PROPN
admet-437	242	5	.	.	PROPN
admet-437	242	6	balimane	balimane	PROPN
admet-437	242	7	,	,	PUNCT
admet-437	242	8	y.h	y.h	PROPN
admet-437	242	9	.	.	PROPN
admet-437	242	10	han	han	PROPN
admet-437	242	11	,	,	PUNCT
admet-437	242	12	s.	s.	PROPN
admet-437	242	13	chong	chong	PROPN
admet-437	242	14	.	.	PUNCT
admet-437	243	1	current	current	ADJ
admet-437	243	2	industrial	industrial	ADJ
admet-437	243	3	practices	practice	NOUN
admet-437	243	4	of	of	ADP
admet-437	243	5	assessing	assess	VERB
admet-437	243	6	permeability	permeability	NOUN
admet-437	243	7	and	and	CCONJ
admet-437	243	8	pglycoprotein	pglycoprotein	ADJ
admet-437	243	9	interaction	interaction	NOUN
admet-437	243	10	.	.	PUNCT
admet-437	244	1	journal	journal	PROPN
admet-437	244	2	of	of	ADP
admet-437	244	3	aaps	aap	NOUN
admet-437	244	4	8	8	NUM
admet-437	244	5	(	(	PUNCT
admet-437	244	6	2006	2006	NUM
admet-437	244	7	)	)	PUNCT
admet-437	244	8	e1	e1	NOUN
admet-437	244	9	-	-	SYM
admet-437	244	10	13	13	NUM
admet-437	244	11	.	.	PUNCT
admet-437	245	1	[	[	X
admet-437	245	2	12	12	NUM
admet-437	245	3	]	]	X
admet-437	245	4	i.	i.	PROPN
admet-437	245	5	kariv	kariv	PROPN
admet-437	245	6	,	,	PUNCT
admet-437	245	7	h.	h.	PROPN
admet-437	245	8	cao	cao	PROPN
admet-437	245	9	,	,	PUNCT
admet-437	245	10	k.r	k.r	PROPN
admet-437	245	11	.	.	PROPN
admet-437	245	12	oldenburg	oldenburg	PROPN
admet-437	245	13	.	.	PUNCT
admet-437	246	1	development	development	NOUN
admet-437	246	2	of	of	ADP
admet-437	246	3	a	a	DET
admet-437	246	4	high	high	ADJ
admet-437	246	5	throughput	throughput	NOUN
admet-437	246	6	equilibrium	equilibrium	NOUN
admet-437	246	7	dialysis	dialysis	NOUN
admet-437	246	8	method	method	NOUN
admet-437	246	9	.	.	PUNCT
admet-437	247	1	journal	journal	NOUN
admet-437	247	2	of	of	ADP
admet-437	247	3	pharmaceutical	pharmaceutical	PROPN
admet-437	247	4	sciences	science	NOUN
admet-437	247	5	90	90	NUM
admet-437	247	6	(	(	PUNCT
admet-437	247	7	2001	2001	NUM
admet-437	247	8	)	)	PUNCT
admet-437	248	1	580	580	NUM
admet-437	248	2	-	-	SYM
admet-437	248	3	587	587	NUM
admet-437	248	4	.	.	PUNCT
admet-437	249	1	[	[	X
admet-437	249	2	13	13	NUM
admet-437	249	3	]	]	X
admet-437	249	4	r.s	r.s	PROPN
admet-437	249	5	obach	obach	PROPN
admet-437	249	6	,	,	PUNCT
admet-437	249	7	r.l	r.l	PROPN
admet-437	249	8	.	.	PROPN
admet-437	249	9	walsky	walsky	PROPN
admet-437	249	10	,	,	PUNCT
admet-437	249	11	k.	k.	PROPN
admet-437	249	12	venkatakrishnan	venkatakrishnan	PROPN
admet-437	249	13	,	,	PUNCT
admet-437	249	14	e.a	e.a	PROPN
admet-437	249	15	.	.	PROPN
admet-437	249	16	gaman	gaman	PROPN
admet-437	249	17	,	,	PUNCT
admet-437	249	18	j.b	j.b	PROPN
admet-437	249	19	.	.	PROPN
admet-437	249	20	houston	houston	PROPN
admet-437	249	21	,	,	PUNCT
admet-437	249	22	l.m	l.m	PROPN
admet-437	249	23	.	.	PROPN
admet-437	249	24	tremaine	tremaine	PROPN
admet-437	249	25	.	.	PUNCT
admet-437	250	1	the	the	DET
admet-437	250	2	utility	utility	NOUN
admet-437	250	3	of	of	ADP
admet-437	250	4	in	in	ADP
admet-437	250	5	vitro	vitro	X
admet-437	250	6	cytochrome	cytochrome	NOUN
admet-437	250	7	p450	p450	PROPN
admet-437	250	8	inhibition	inhibition	NOUN
admet-437	250	9	data	datum	NOUN
admet-437	250	10	in	in	ADP
admet-437	250	11	the	the	DET
admet-437	250	12	prediction	prediction	NOUN
admet-437	250	13	of	of	ADP
admet-437	250	14	drug	drug	NOUN
admet-437	250	15	-	-	PUNCT
admet-437	250	16	drug	drug	NOUN
admet-437	250	17	interactions	interaction	NOUN
admet-437	250	18	.	.	PUNCT
admet-437	251	1	journal	journal	NOUN
admet-437	251	2	of	of	ADP
admet-437	251	3	pharmacology	pharmacology	NOUN
admet-437	251	4	and	and	CCONJ
admet-437	251	5	experimental	experimental	ADJ
admet-437	251	6	therapeutics	therapeutic	NOUN
admet-437	251	7	316	316	NUM
admet-437	251	8	(	(	PUNCT
admet-437	251	9	2006	2006	NUM
admet-437	251	10	)	)	PUNCT
admet-437	251	11	336	336	NUM
admet-437	251	12	-	-	SYM
admet-437	251	13	348	348	NUM
admet-437	251	14	.	.	PUNCT
admet-437	252	1	[	[	X
admet-437	252	2	14	14	NUM
admet-437	252	3	]	]	X
admet-437	252	4	v.	v.	PROPN
admet-437	252	5	chu	chu	PROPN
admet-437	252	6	,	,	PUNCT
admet-437	252	7	h.j	h.j	PROPN
admet-437	252	8	.	.	PROPN
admet-437	252	9	einolf	einolf	PROPN
admet-437	252	10	,	,	PUNCT
admet-437	252	11	r.	r.	PROPN
admet-437	252	12	evers	evers	PROPN
admet-437	252	13	,	,	PUNCT
admet-437	252	14	g.	g.	PROPN
admet-437	252	15	kumar	kumar	PROPN
admet-437	252	16	,	,	PUNCT
admet-437	252	17	d.	d.	PROPN
admet-437	252	18	moore	moore	PROPN
admet-437	252	19	,	,	PUNCT
admet-437	252	20	s.	s.	PROPN
admet-437	252	21	ripp	ripp	PROPN
admet-437	252	22	,	,	PUNCT
admet-437	252	23	j.	j.	PROPN
admet-437	252	24	silva	silva	PROPN
admet-437	252	25	,	,	PUNCT
admet-437	252	26	v.	v.	PROPN
admet-437	252	27	sinha	sinha	PROPN
admet-437	252	28	,	,	PUNCT
admet-437	252	29	m.	m.	NOUN
admet-437	252	30	sinz	sinz	PROPN
admet-437	252	31	,	,	PUNCT
admet-437	252	32	a.	a.	NOUN
admet-437	252	33	skerjanec	skerjanec	NOUN
admet-437	252	34	.	.	PUNCT
admet-437	253	1	in	in	ADP
admet-437	253	2	vitro	vitro	X
admet-437	253	3	and	and	CCONJ
admet-437	253	4	in	in	ADP
admet-437	253	5	vivo	vivo	ADJ
admet-437	253	6	induction	induction	NOUN
admet-437	253	7	of	of	ADP
admet-437	253	8	cytochrome	cytochrome	NOUN
admet-437	253	9	p450	p450	NUM
admet-437	253	10	:	:	PUNCT
admet-437	253	11	a	a	DET
admet-437	253	12	survey	survey	NOUN
admet-437	253	13	of	of	ADP
admet-437	253	14	the	the	DET
admet-437	253	15	current	current	ADJ
admet-437	253	16	practices	practice	NOUN
admet-437	253	17	and	and	CCONJ
admet-437	253	18	recommendations	recommendation	NOUN
admet-437	253	19	:	:	PUNCT
admet-437	253	20	a	a	DET
admet-437	253	21	pharmaceutical	pharmaceutical	ADJ
admet-437	253	22	research	research	NOUN
admet-437	253	23	and	and	CCONJ
admet-437	253	24	manufacturers	manufacturer	NOUN
admet-437	253	25	of	of	ADP
admet-437	253	26	america	america	PROPN
admet-437	253	27	perspective	perspective	PROPN
admet-437	253	28	.	.	PUNCT
admet-437	254	1	drug	drug	NOUN
admet-437	254	2	metabolism	metabolism	NOUN
admet-437	254	3	and	and	CCONJ
admet-437	254	4	disposition	disposition	NOUN
admet-437	254	5	37	37	NUM
admet-437	254	6	(	(	PUNCT
admet-437	254	7	2009	2009	NUM
admet-437	254	8	)	)	PUNCT
admet-437	254	9	1350	1350	NUM
admet-437	254	10	-	-	SYM
admet-437	254	11	1359	1359	NUM
admet-437	254	12	.	.	PUNCT
admet-437	255	1	[	[	X
admet-437	255	2	15	15	X
admet-437	255	3	]	]	X
admet-437	255	4	t.w	t.w	PROPN
admet-437	255	5	.	.	PROPN
admet-437	255	6	harper	harper	PROPN
admet-437	255	7	,	,	PUNCT
admet-437	255	8	p.j	p.j	PROPN
admet-437	255	9	.	.	PROPN
admet-437	255	10	brassil	brassil	PROPN
admet-437	255	11	.	.	PUNCT
admet-437	256	1	reaction	reaction	NOUN
admet-437	256	2	phenotyping	phenotype	VERB
admet-437	256	3	:	:	PUNCT
admet-437	256	4	current	current	ADJ
admet-437	256	5	industry	industry	NOUN
admet-437	256	6	efforts	effort	NOUN
admet-437	256	7	to	to	PART
admet-437	256	8	identify	identify	VERB
admet-437	256	9	enzymes	enzyme	NOUN
admet-437	256	10	responsible	responsible	ADJ
admet-437	256	11	for	for	ADP
admet-437	256	12	metabolizing	metabolize	VERB
admet-437	256	13	drug	drug	NOUN
admet-437	256	14	candidates	candidate	NOUN
admet-437	256	15	.	.	PUNCT
admet-437	257	1	journal	journal	NOUN
admet-437	257	2	of	of	ADP
admet-437	257	3	aaps	aap	NOUN
admet-437	257	4	10	10	NUM
admet-437	257	5	(	(	PUNCT
admet-437	257	6	2008	2008	NUM
admet-437	257	7	)	)	PUNCT
admet-437	257	8	200	200	NUM
admet-437	257	9	-	-	SYM
admet-437	257	10	207	207	NUM
admet-437	257	11	.	.	PUNCT
admet-437	258	1	admet	admet	PROPN
admet-437	258	2	&	&	CCONJ
admet-437	258	3	dmpk	dmpk	PROPN
admet-437	258	4	5(4	5(4	NOUN
admet-437	258	5	)	)	PUNCT
admet-437	258	6	(	(	PUNCT
admet-437	258	7	2017	2017	NUM
admet-437	258	8	)	)	PUNCT
admet-437	258	9	212	212	NUM
admet-437	258	10	-	-	SYM
admet-437	258	11	223	223	NUM
admet-437	258	12	preclinical	preclinical	ADJ
admet-437	258	13	assessment	assessment	NOUN
admet-437	258	14	of	of	ADP
admet-437	258	15	ulixertinib	ulixertinib	PROPN
admet-437	258	16	doi	doi	PROPN
admet-437	258	17	:	:	PUNCT
admet-437	258	18	10.5599	10.5599	NUM
admet-437	258	19	/	/	SYM
admet-437	258	20	admet.5.4.437	admet.5.4.437	NUM
admet-437	258	21	223	223	NUM
admet-437	259	1	[	[	X
admet-437	259	2	16	16	NUM
admet-437	259	3	]	]	PUNCT
admet-437	259	4	r.	r.	PROPN
admet-437	259	5	kumar	kumar	PROPN
admet-437	259	6	,	,	PUNCT
admet-437	259	7	p.s	p.s	PROPN
admet-437	259	8	.	.	PROPN
admet-437	259	9	suresh	suresh	PROPN
admet-437	259	10	,	,	PUNCT
admet-437	259	11	g.	g.	PROPN
admet-437	259	12	rudresh	rudresh	PROPN
admet-437	259	13	,	,	PUNCT
admet-437	259	14	m.	m.	NOUN
admet-437	259	15	zainuddin	zainuddin	PROPN
admet-437	259	16	,	,	PUNCT
admet-437	259	17	p.	p.	PROPN
admet-437	259	18	dewang	dewang	PROPN
admet-437	259	19	,	,	PUNCT
admet-437	259	20	r.r	r.r	PROPN
admet-437	259	21	.	.	PROPN
admet-437	259	22	kethiri	kethiri	PROPN
admet-437	259	23	,	,	PUNCT
admet-437	259	24	s.	s.	PROPN
admet-437	259	25	rajagopal	rajagopal	PROPN
admet-437	259	26	,	,	PUNCT
admet-437	259	27	r.	r.	PROPN
admet-437	259	28	mullangi	mullangi	PROPN
admet-437	259	29	.	.	PUNCT
admet-437	260	1	determination	determination	NOUN
admet-437	260	2	of	of	ADP
admet-437	260	3	ulixertinib	ulixertinib	NOUN
admet-437	260	4	in	in	ADP
admet-437	260	5	mice	mice	NOUN
admet-437	260	6	plasma	plasma	NOUN
admet-437	260	7	by	by	ADP
admet-437	260	8	lc	lc	PROPN
admet-437	260	9	-	-	PUNCT
admet-437	260	10	ms	ms	PROPN
admet-437	260	11	/	/	SYM
admet-437	260	12	ms	ms	PROPN
admet-437	260	13	and	and	CCONJ
admet-437	260	14	its	its	PRON
admet-437	260	15	application	application	NOUN
admet-437	260	16	to	to	ADP
admet-437	260	17	a	a	DET
admet-437	260	18	pharmacokinetic	pharmacokinetic	ADJ
admet-437	260	19	study	study	NOUN
admet-437	260	20	in	in	ADP
admet-437	260	21	mice	mouse	NOUN
admet-437	260	22	.	.	PUNCT
admet-437	261	1	journal	journal	PROPN
admet-437	261	2	of	of	ADP
admet-437	261	3	pharmaceutical	pharmaceutical	NOUN
admet-437	261	4	biomedical	biomedical	ADJ
admet-437	261	5	analysis	analysis	NOUN
admet-437	261	6	125	125	NUM
admet-437	261	7	(	(	PUNCT
admet-437	261	8	2016	2016	NUM
admet-437	261	9	)	)	PUNCT
admet-437	261	10	140	140	NUM
admet-437	261	11	-	-	SYM
admet-437	261	12	144	144	NUM
admet-437	261	13	.	.	PUNCT
admet-437	262	1	[	[	X
admet-437	262	2	17	17	NUM
admet-437	262	3	]	]	X
admet-437	262	4	b.	b.	PROPN
admet-437	262	5	davies	davy	NOUN
admet-437	262	6	,	,	PUNCT
admet-437	262	7	t.	t.	PROPN
admet-437	262	8	morris	morris	PROPN
admet-437	262	9	.	.	PROPN
admet-437	262	10	physiological	physiological	ADJ
admet-437	262	11	parameters	parameter	NOUN
admet-437	262	12	in	in	ADP
admet-437	262	13	laboratory	laboratory	NOUN
admet-437	262	14	animals	animal	NOUN
admet-437	262	15	and	and	CCONJ
admet-437	262	16	humans	human	NOUN
admet-437	262	17	.	.	PUNCT
admet-437	263	1	pharmaceutical	pharmaceutical	ADJ
admet-437	263	2	research	research	NOUN
admet-437	263	3	10	10	NUM
admet-437	263	4	(	(	PUNCT
admet-437	263	5	1993	1993	NUM
admet-437	263	6	)	)	PUNCT
admet-437	263	7	1093	1093	NUM
admet-437	263	8	-	-	SYM
admet-437	263	9	1094	1094	NUM
admet-437	263	10	.	.	PUNCT
admet-437	264	1	[	[	X
admet-437	264	2	18	18	NUM
admet-437	264	3	]	]	X
admet-437	264	4	k.t	k.t	PROPN
admet-437	264	5	.	.	PROPN
admet-437	264	6	flaherty	flaherty	PROPN
admet-437	264	7	,	,	PUNCT
admet-437	264	8	j.r	j.r	PROPN
admet-437	264	9	.	.	PROPN
admet-437	264	10	infante	infante	PROPN
admet-437	264	11	,	,	PUNCT
admet-437	264	12	a.	a.	PROPN
admet-437	264	13	daud	daud	PROPN
admet-437	264	14	,	,	PUNCT
admet-437	264	15	r.	r.	PROPN
admet-437	264	16	gonzalez	gonzalez	PROPN
admet-437	264	17	,	,	PUNCT
admet-437	264	18	r.f	r.f	PROPN
admet-437	264	19	.	.	PROPN
admet-437	264	20	kefford	kefford	PROPN
admet-437	264	21	,	,	PUNCT
admet-437	264	22	j.	j.	PROPN
admet-437	264	23	sosman	sosman	PROPN
admet-437	264	24	,	,	PUNCT
admet-437	264	25	o.	o.	PROPN
admet-437	264	26	hamid	hamid	PROPN
admet-437	264	27	,	,	PUNCT
admet-437	264	28	l.	l.	PROPN
admet-437	264	29	schuchter	schuchter	PROPN
admet-437	264	30	,	,	PUNCT
admet-437	264	31	j.	j.	PROPN
admet-437	264	32	cebon	cebon	PROPN
admet-437	264	33	,	,	PUNCT
admet-437	264	34	n.	n.	PROPN
admet-437	264	35	ibrahim	ibrahim	PROPN
admet-437	264	36	,	,	PUNCT
admet-437	264	37	r.	r.	PROPN
admet-437	264	38	kudchadkar	kudchadkar	PROPN
admet-437	264	39	,	,	PUNCT
admet-437	264	40	h.a	h.a	PROPN
admet-437	264	41	.	.	PROPN
admet-437	264	42	burris	burris	PROPN
admet-437	264	43	3rd	3rd	PROPN
admet-437	264	44	,	,	PUNCT
admet-437	264	45	g.	g.	PROPN
admet-437	264	46	falchook	falchook	PROPN
admet-437	264	47	,	,	PUNCT
admet-437	264	48	a.	a.	NOUN
admet-437	264	49	algazi	algazi	PROPN
admet-437	264	50	,	,	PUNCT
admet-437	264	51	k.	k.	PROPN
admet-437	264	52	lewis	lewis	PROPN
admet-437	264	53	,	,	PUNCT
admet-437	264	54	g.v	g.v	PROPN
admet-437	264	55	.	.	PROPN
admet-437	264	56	long	long	PROPN
admet-437	264	57	,	,	PUNCT
admet-437	264	58	i.	i.	PROPN
admet-437	264	59	puzanov	puzanov	PROPN
admet-437	264	60	,	,	PUNCT
admet-437	264	61	p.	p.	PROPN
admet-437	264	62	lebowitz	lebowitz	PROPN
admet-437	264	63	,	,	PUNCT
admet-437	264	64	a.	a.	PROPN
admet-437	264	65	singh	singh	PROPN
admet-437	264	66	,	,	PUNCT
admet-437	264	67	s.	s.	PROPN
admet-437	264	68	little	little	PROPN
admet-437	264	69	,	,	PUNCT
admet-437	264	70	p.	p.	PROPN
admet-437	264	71	sun	sun	PROPN
admet-437	264	72	,	,	PUNCT
admet-437	264	73	a.	a.	NOUN
admet-437	264	74	allred	allred	PROPN
admet-437	264	75	,	,	PUNCT
admet-437	264	76	d.	d.	PROPN
admet-437	264	77	ouellet	ouellet	PROPN
admet-437	264	78	,	,	PUNCT
admet-437	264	79	k.b	k.b	PROPN
admet-437	264	80	.	.	PUNCT
admet-437	264	81	kim	kim	PROPN
admet-437	264	82	,	,	PUNCT
admet-437	264	83	k.	k.	PROPN
admet-437	264	84	patel	patel	PROPN
admet-437	264	85	,	,	PUNCT
admet-437	264	86	j.	j.	PROPN
admet-437	264	87	weber	weber	PROPN
admet-437	264	88	.	.	PUNCT
admet-437	264	89	combined	combine	VERB
admet-437	264	90	braf	braf	NOUN
admet-437	264	91	and	and	CCONJ
admet-437	264	92	mek	mek	PROPN
admet-437	264	93	inhibition	inhibition	NOUN
admet-437	264	94	in	in	ADP
admet-437	264	95	melanoma	melanoma	NOUN
admet-437	264	96	with	with	ADP
admet-437	264	97	braf	braf	NOUN
admet-437	264	98	v600	v600	PROPN
admet-437	264	99	mutations	mutation	NOUN
admet-437	264	100	.	.	PUNCT
admet-437	265	1	new	new	PROPN
admet-437	265	2	england	england	PROPN
admet-437	265	3	journal	journal	PROPN
admet-437	265	4	medicine	medicine	PROPN
admet-437	265	5	367	367	NUM
admet-437	265	6	(	(	PUNCT
admet-437	265	7	2012	2012	NUM
admet-437	265	8	)	)	PUNCT
admet-437	265	9	1694	1694	NUM
admet-437	265	10	-	-	SYM
admet-437	265	11	1703	1703	NUM
admet-437	265	12	.	.	PUNCT
admet-437	266	1	[	[	X
admet-437	266	2	19	19	NUM
admet-437	266	3	]	]	X
admet-437	266	4	l.m	l.m	PROPN
admet-437	266	5	.	.	PROPN
admet-437	266	6	chan	chan	PROPN
admet-437	266	7	,	,	PUNCT
admet-437	266	8	s.	s.	PROPN
admet-437	266	9	lowes	lowes	PROPN
admet-437	266	10	,	,	PUNCT
admet-437	266	11	b.h	b.h	PROPN
admet-437	266	12	.	.	PROPN
admet-437	266	13	hirst	hirst	PROPN
admet-437	266	14	.	.	PUNCT
admet-437	267	1	the	the	DET
admet-437	267	2	abcs	abc	NOUN
admet-437	267	3	of	of	ADP
admet-437	267	4	drug	drug	NOUN
admet-437	267	5	transport	transport	NOUN
admet-437	267	6	in	in	ADP
admet-437	267	7	intestine	intestine	NOUN
admet-437	267	8	and	and	CCONJ
admet-437	267	9	liver	liver	NOUN
admet-437	267	10	:	:	PUNCT
admet-437	267	11	efflux	efflux	NOUN
admet-437	267	12	proteins	protein	NOUN
admet-437	267	13	limiting	limit	VERB
admet-437	267	14	drug	drug	NOUN
admet-437	267	15	absorption	absorption	NOUN
admet-437	267	16	and	and	CCONJ
admet-437	267	17	bioavailability	bioavailability	NOUN
admet-437	267	18	.	.	PUNCT
admet-437	268	1	european	european	PROPN
admet-437	268	2	journal	journal	PROPN
admet-437	268	3	of	of	ADP
admet-437	268	4	pharmaceutical	pharmaceutical	PROPN
admet-437	268	5	sciences	science	NOUN
admet-437	268	6	21	21	NUM
admet-437	268	7	(	(	PUNCT
admet-437	268	8	2004	2004	NUM
admet-437	268	9	)	)	PUNCT
admet-437	268	10	25	25	NUM
admet-437	268	11	-	-	SYM
admet-437	268	12	51	51	NUM
admet-437	268	13	.	.	PUNCT
admet-437	269	1	©	©	PROPN
admet-437	269	2	2017	2017	NUM
admet-437	269	3	by	by	ADP
admet-437	269	4	the	the	DET
admet-437	269	5	authors	author	NOUN
admet-437	269	6	;	;	PUNCT
admet-437	269	7	licensee	licensee	PROPN
admet-437	269	8	iapc	iapc	PROPN
admet-437	269	9	,	,	PUNCT
admet-437	269	10	zagreb	zagreb	PROPN
admet-437	269	11	,	,	PUNCT
admet-437	269	12	croatia	croatia	PROPN
admet-437	269	13	.	.	PUNCT
admet-437	270	1	this	this	DET
admet-437	270	2	article	article	NOUN
admet-437	270	3	is	be	AUX
admet-437	270	4	an	an	DET
admet-437	270	5	open	open	ADJ
admet-437	270	6	-	-	PUNCT
admet-437	270	7	access	access	NOUN
admet-437	270	8	article	article	NOUN
admet-437	270	9	distributed	distribute	VERB
admet-437	270	10	under	under	ADP
admet-437	270	11	the	the	DET
admet-437	270	12	terms	term	NOUN
admet-437	270	13	and	and	CCONJ
admet-437	270	14	conditions	condition	NOUN
admet-437	270	15	of	of	ADP
admet-437	270	16	the	the	DET
admet-437	270	17	creative	creative	ADJ
admet-437	270	18	commons	common	NOUN
admet-437	270	19	attribution	attribution	NOUN
admet-437	270	20	license	license	NOUN
admet-437	270	21	(	(	PUNCT
admet-437	270	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-437	270	23	)	)	PUNCT
admet-437	270	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN